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Background and Aims: The inflammatory bowel diseases (IBD) are chronic diseases that affect 
populations worldwide and impart considerable morbidity to those affected. Immunosuppression 
in IBD is effective but limited by side effects and non-response. We aimed to identify 
pharmacogenetic markers of response to commonly used immunosuppressive medication in these 
patients.  
 
Methods: The influence of MTHFR 677C>T, MTHFR 1298A>T, ATIC 347C>G, TSER *2/*3 
tandem repeat, TYMS 3’-UTR 6 bp insertion/deletion, SLC19A1 80G>A, AOX 3404A>G 
polymorphisms, 14bp ins/del polymorphism in the HLA-G gene and the IL-10 -1082A>G, -
819C>T and -592C>A promoter SNPs were investigated on clinical response and side effect rates 
in 201 patients with Inflammatory Bowel Disease (IBD) treated with methotrexate (MTX). The 
HLA-G 14 bp ins/del polymorphism was correlated with azathioprine (AZA) response in 97 IBD 
patients. The IL-10 -1082A>G, -819C>T and -592C>A promoter SNPs on chromosome 1 were 
examined for an influence on the effect of the 14bp ins/del polymorphism in this group. The 14bp 
ins/del polymorphism was examined for an influence on susceptibility to IBD in 3148 individuals 
compared with 1330 normal controls. Stimulated PBMC from 14 normal individuals were 
incubated with MTX and 6-MP and expression levels of soluble HLA-G and IL-10 were 
correlated with genotype.  
 
Results: A small positive correlation was seen for the MTHFR677TT genotype for clinical 
response and for the ATIC347GG for intolerance to MTX.  The 14bp ins/del polymorphism 
strongly predicted clinical response to MTX (p=0.0016). The same influence was seen in 97 IBD 
patients treated with azathioprine (AZA) (p=0.001) and neither of these effects were affected by 
variant IL-10 promoter haplotypes. The described polymorphism did not influence susceptibility 
to IBD. Individuals with the 14bp del/del polymorphism expressed more soluble HLA-G after 
incubation with 6-MP (p=0.02) and MTX than carriers of the insertion allele. A dose effect was 
evident and carriers of the high producer IL-10 GCC promoter haplotype expressed significantly 
more IL-10 when incubated with 6-MP (p=0.04).   This provides functional correlation of the 
genetic effect.  
 
Conclusion: HLA-G genotype maybe a strong and predictor of response to MTX and AZA in 
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TLR Toll-like receptor 
TNF Tumour necrosis factor 
TPMT Thiopurine methyl transferase 
TR1 T regulatory cell 1 
Treg T regulatory cell 
TS Thymidylate synthase 
TSER Thymidylate synthase enhancer region 
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Pharmacogenetics or the study of the influence of individual genetic variation on drug effects has 
evolved considerably over the past 40 years. From a niche discipline in the 1950s, it has now 
found extensive application in many clinical trials. Whilst therapeutic practice has not yet been 
changed significantly by advances in the field, much is expected for the future. 
 
It was a century ago that alkaptonuria and how it was affected by individual metabolic variation 
was described.  Much of subsequent pharmacogenetics was often the reporting of extreme variant 
phenotypes. The serendipitous observation of the inter-ethnic variation in the side effect profile of 
primaquine during World War ІІ is often regarded the first major pharmacogenetic influence on 
scientific investigation. A number of other observations followed in its wake during the 1950s. 
 
The initially intriguing and seemingly inexplicable primaquine associated haemolysis seen in 
African American soldiers but not in their White American counterparts  [1] was found to be due 
to genetic variation of the enzyme glucose -6-phosphate dehydrogenase (G-6-PD) [2]. Primaquine 
was an antimalarial drug given during World War II to American soldiers. Many African-
American soldiers treated developed a haemolytic disease whilst white Americans were relatively 
unaffected.  This deficiency is more prevalent in populations originating from areas with a high 
malarial infestation load and appears to provide a degree of protection against infection [3].  After 
the initial description many more polymorphisms have been described but like other 
pharmacogenetic markers, a functional assay of enzyme effect is preferred in the diagnosis [4]. 
 
Shortly after this, a pseudocholinesterase variant called butyryl- cholinesterase was discovered 
and credited with a prolonged duration of action of succinylcholine; a drug often used in general 
anaesthesia and was rarely (1:1000) complicated by a profound apnoea [5].  
 
Similarly, on the theme of inter-ethnic variation in drug response, a description of a defect in the 
metabolism of isoniazid [6] followed. This was attributed to variation in the acetylation of INH 
by arylamine N-acetylytransferase-2 [7]. Two distinct metabolic phenotypes (rapid acetylators 
and slow acetylators) have been described worldwide with significant variation in frequencies 
among populations (50% among Caucasians, Asians and Africans; 20 % Amerinds) [8]. The 
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polymorphisms that lead to diminished enzyme activity are relatively recent discoveries [9]. 
Another important observation was the difference in metabolism of barbiturates (amobarbital) 
amongst Caucasians and Chinese individuals [10]. 
 
The antihypertensive debrisoquine [11] and anti arrhythmic sparteine [12] were found to have 
severe toxicity in certain patients and these effects were attributed to the already recognized lack 
of activity of the cytochrome P450 2D6. Subsequently, differences in the efficiency of 
metabolism of various medications dependent on genotype were noted and could be classified 
into poor metabolism, intermediate metabolism, rapid metabolism and ultra rapid metabolism [4, 
13]. A variety of drugs are metabolized by these pathways and the effects of the various 
phenotypes on drug response or toxicity differ according to whether the drugs are activated or 
inactivated (4). 
 
The traditional approach to pharmacogenetics has been based on clinical observations in affected 
families or in the general population that then leads to an identification of variation in single 
genes coding for drug metabolism enzymes. Advances in genetics have revealed the potential of 
the newer field named Pharmacogenomics.  With high-throughput technology, large numbers of 
genetic polymorphisms can now be detected accurately and rapidly. In a wide ranging model, that 
includes many genes and their interactions, Pharmacogenomics is now a field that encompasses 
genetics, pharmacodynamics and pharmacokinetics. These are now frequently a part of large 
clinical trials and important genetic associations with individual drug response may be 
forthcoming [14]. 
 
Despite all of these discoveries and of many genetic influences on drug metabolism, true clinical 
application has been rare and this is unlikely to change in the immediate future. However, one of 
the best examples of successful translation of pharmacogenetics to clinical practice is the impact 
of genetic variation in the activity of thiopurine-s-methyl transferase (TPMT). This is a central 
enzyme in the metabolism of azathioprine/6-mercaptopurine, two drugs used commonly in cancer 
chemotherapy and inflammatory diseases. However, even here it is the phenotypic assay of 
activity that has found widespread use rather than genetic testing. A more detailed review of this 






1.2 Inflammatory Bowel Disease 
 
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. 
The two main clinical subtypes are Crohn’s Disease (CD) and ulcerative colitis (UC). Although 
similar in many respects, significant differences exist in the cytokine milieu at the mucosal level 
between these diseases which are conventionally divided along Th1, Th2 and the emerging Th17 
lines. Modern genetic association studies have identified various single nucleotide genetic 
polymorphisms probably responsible for important changes in the interactions between bacteria 
and host innate immune mechanisms [15]. Despite impressive strides in unravelling the genetic 
basis for CD and to a lesser extent UC, the direct clinical applications of these advances have 
been slow. The investigation of pharmacogenetic markers allowing for optimal therapy of these 
diseases remains an important but largely unfulfilled ideal. 
 
It is likely that the diseases are the consequence of a complex interaction between the intestinal 
bacterial flora and the innate immunity, influenced by the host genotype. In effect; a 
dysfunctional immune response, by a genetically predisposed individual to what would, otherwise 
have been a normal bacterial challenge. 
 
Samuel Wilks described UC in 1859 [16] and it was not until 1932 when Burrell Bernard Crohn 
gave us a remarkably accurate description of what he and his colleagues termed “regional 
enteritis”, that Crohn’s disease was recognised. Much of the anatomical and pathological features 
noted at the time are familiar to us in current practice. It is encouraging that we have moved on 
from the palliative and supportive management that was the fate of patients not suited to surgical 
resection [17].  It would appear that CD is relatively new. The diseases are common and 1.4 
million people in the US and 2.2 million people in Europe are affected. Since its first description, 
the incidence has been rising in the western world although some suggest that these rates are 
starting to stabilise [18]. However, there has been no such effect in Southern Europe, Africa or 







1.2.1 The Etiopathogenesis of IBD 
 
1.2.1.1 Ethnicity and geographic differences 
 
There are clear differences in the racial predilection to the inflammatory bowel diseases. The 
augmented risk among the Ashkenazi Jewish population in Europe, USA and Cape Town is well 
known [19]. However, clearly there are also other influences. Migrant populations gradually take 
on the disease predilection of the pre-existing residents but it remains less prevalent. This effect 
has been seen in all high prevalence areas and include the Hispanic and Asian populations in the 
United States [20], The Bangladeshi population in East London, UK [21],  the Chinese population 
in mainland China [22] and the more recently immigrant of the  Jewish population in Israel [23, 
24]. Being a first-generation Canadian is protective against the development of CD [25] and 
immigrants from the UK in New Zealand have a greater risk of both UC and CD than the longer 




In 1982, Harries et al. first noted that smoking was rarely reported among sufferers of UC [27]. 
Some time later the opposite effect was noted among CD patients and this remains the current 
view on the effect of tobacco on the natural history of IBD. However, the pathophysiological 
basis for these differences remains obscure. The odds ratio for developing UC is lower in a 
current smoker compared with lifetime non-smokers (OR= 2.41, CI 0.34 to 0.48) [28]. Smoking 
cessation is associated with more relapses, hospital admissions, oral steroids and 
immunosuppressants among sufferers of UC. The risk of surgery was not different [29]. The 
opposite is true in CD, where the odds ratio is 2 (CI 1.65- 2.47) when current smokers are 
compared to those who have never smoked [28]. In a similar vein, the risk of clinical and surgical 
recurrence was lower in non-smokers than in smokers and the risk is dose-dependent [30]. 
Smoking cessation diminishes the need for immunosuppression and other medical intervention to 
levels similar to those enjoyed by lifelong non-smokers [31]. The fascinating report that smoking 
appears to influence disease concordance in siblings of affected individuals, deserves mention. 






1.2.1.3 Other aspects of the environment 
 
There has been a rapid increase in the inflammatory bowel diseases around the world; and 
previously low risk populations are displaying increasing disease incidence and prevalence.  
 
1.2.1.4 Hygiene hypothesis 
 
Increasing environmental hygiene is associated with increasing predispositions to autoimmune 
and inflammatory conditions. It is recognized that most autoimmune conditions are associated 
with imbalances between Th1 and Th2 related cytokines. These have reciprocal effects on each 
other and are influenced by infections. The ensuing production of regulatory T-cells (Treg) leads to 
“bystander suppression”. It is likely that this is mediated by Interleukin-10 (IL-10) and 
Transforming growth factor-β (TGF-β) from CD25+ T-cells [33]. In a similar fashion, allergies 
and autoimmune conditions appear to be associated [34].  
 
Environmental factors that may favour a high infectious burden such as crowded living 
conditions, and consumption of contaminated foods and a lack of potable water may confer low 
risk of IBD. This is particularly true for CD. It is proposed that limited exposure to environmental 
antigens impairs immune maturation and results in a dysfunctional immune response on exposure 





The human intestine is sterile at birth but then very rapidly becomes colonized by bacteria from 
the mother’s intestinal and vaginal flora [37].  The ecosystem of the intestine is very dynamic but 
some microbial members are long-term “residents”.  Despite the large environmental species 
diversity among microbes, the intestinal environment clearly mandates a more restricted 
population. Selection pressures reduce the bacterial diversity of the planet (over 55 divisions) to 
just the Bacteroidetes, Firmicutes and one member of Archaea [38].  
 
However, there is considerable strain variation; and is reminiscent of patterns seen where a few 
successful early colonists give rise to a variety of descendants. This is evident in instances of 
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extreme selection pressure and as been noted in Helicobacter pylori populations around the world 
[39], and in current theories about the origin of human populations [40].  
 
Commensal bacteria clearly influence absorption, mucosal integrity and angiogenesis [41]. The 
microbial population in the gut can provoke IBD but probably not due to direct pathogenicity 
[42]. Immune deficient mice do not have a different intestinal bacterial population to 
immunocompetent animals [43]. An inadequate or inappropriate immune response to commensal 
bacteria can drive the inflammatory cascade in IBD. In immune competent mice, antibiotics can 
control colitis and transfer of activated CD4+ T-cells into immune deficient mice causes colitis. 
This is not seen in germfree subjects [44]. IBD patients have an enhanced immune responsiveness 
to bacterial antigens, with a concurrent loss of tolerance. It is likely that this is influenced by 




Family members of a patient affected by IBD have a higher risk than that of the background 
population of being affected as well. Indeed, a positive family history is the greatest risk factor 
for developing IBD (both UC and CD) [46]. The genetics of IBD are complex and cannot be 
approached with simple Mendelian concerts of monogenic inheritance. They are polygenic 
diseases, affected by several gene mutations that interact with each other and influence a number 
of phenotypes [47]. 
 
Valuable information has been gleaned from twin studies that by their very nature, overcome 
important difficulties in adjusting for the contribution of environmental factors to the estimation 
of congenital risk. These studies that cumulatively report on 322 patients have estimated that 
monozygotic twins have a concordance rate of 37% for CD and 10% for UC [48-50]. These 
observations also demonstrate the important role that environment has in modifying the genetic 
risk, as otherwise, the concordance among twins may have approached 100%.  
 
There have been numerous attempts to quantify this risk in more detail. Unfortunately these 
classical large-scale referral hospital and population-based studies are limited by inconsistencies 
in phenotypic description, the lack of adequate age adjustment, the contribution of high risk  
populations (such as Jewish people), variation in the time point of assessment of what is a 
dynamic disease, and the chances of dual reporting of disease location [51]. 
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However, the risk of both CD and UC is higher than that of the background population. There 
does not appear to be greater concordance for disease location or disease nature among twins 
compared with other, non-twin siblings [52]. Across all studies, the estimate of s (the risk to 
siblings of a patient developing the disease compared with a member from the general population) 
is 20–35 for CD and 8–15 for UC [53].  
 
Major advances in techniques that have found application in large-scale population genetic 
studies have paid off handsomely in identifying genetic differences between populations with CD, 
and those who don't. Whilst the polygenic basis of the disease has limited the application of these 
findings in clinical diagnosis or monitoring of the disease state; they have led to an explosion of 
knowledge in the immune pathogenesis of disease [51].  
 
 Early investigators used candidate gene studies, looking at polymorphisms within genes of 
known function that were likely to be important in IBD. Since 1996, a number of ‘hypothesis-
free’ genome scans have been performed in IBD to identify regions of the genome likely to 
contain disease susceptibility genes. A systematic screen of genetic markers distributed across the 
human genome is made in a large number of affected individuals. This technique is more 
powerful when related individuals similarly affected by a disease are included. When affected 
siblings demonstrate more shared alleles than expected by chance, linkage is identified. Where 
such regions are replicable in independent family panels they merit further investigation, fine 
mapping by association study or positional candidate gene analysis. 
 
In a number of  full genome scans published for IBD,  9 strong candidate regions designated IBD 
1-9 have been identified. A recent meta-analysis of 10 GWAS studies has demonstrated linkage 
on chromosomes 1, 2, 3, 5, 6, 7, 16, 17 and 19 [54]. An excellent example of the candidate gene 
approach in IBD has been the studies of the HLA complex on the short arm of chromosome 6. 
More recently much attention has focused on genome scanning studies, but the process is 
beginning to come full circle with the acceptance that a powerful strategy for disease gene 
identification is to combine both approaches. Such genes are implicated both because they map to 








(Adapted from Budarf et al 2009 ) 
Figure 1-1  The influence of GWAS on the success of susceptibility genetics studies in IBD 
 
 
1.2.1.6.1   IBD1  (Chromosome 16) NOD2/CARD15  
 
The IBD1 locus on chromosome 16 has been extensively replicated and mutations in the NOD2 
gene influence some aspects of the pathogenesis of CD but not UC. NOD2 was reported 
simultaneously by Hugot et al [55] and Hampe et al [56] who applied classic techniques of LD 
mapping and identified one frameshift and two missense mutations, and Ogura et al [57] who 
used a candidate gene approach. Average relative risks for CD in genotypes containing zero, one 
or two of the variants were 1, 3 and 38 respectively in the French study. This finding has now 
been replicated in many panels around the world, with recent data suggesting that NOD2 
mutations are only associated with ileal inflammation, and not CD where the colon alone is 
inflamed [58]. Double dose mutations (homozygous or compound heterozygous) particularly 
increase the risk of early onset, penetrating disease of the ileum. Although over 30 
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polymorphisms are present within this gene, three single nucleotide polymorphisms (SNP) form 
80% of the mutated alleles [59].  There is variation among populations in the contribution these 
polymorphisms make to susceptibility to, and the phenotype of CD. In high prevalence areas such 
as the UK and USA, up to 40% of patients have these mutations [59].  This effect is absent 
amongst East Asian populations [60] and is less evident in Scotland and Ireland [61]. 
 
The protein encoded by this gene is present in Paneth cells [62], monocytes and tissue 
macrophages [63] and intestinal epithelial cells. Its primary role is in the recognition of bacterial 
pathogens [64], and a rare autosomal dominant  disorder called Blau syndrome affecting NOD2 is 
manifest as familial granulomatous arthritis, iritis and skin granulomas in the affected individuals. 
The parallels with IBD are obvious.  
 
The mutations identified affect the leucine rich repeat domain (LRR), which plays a role in 
sensing bacterial muramyldipeptide (MDP) lipopolysaccharide and regulating NF-κB. Unlike in 
vivo findings in inflammatory bowel disease, the mutant NOD2 gene appears to correlate to low 
levels of NF-κB [64] in knockout mouse models.  A recent knock in mouse model study of the 





1.2.1.6.2  IBD3 (Chromosome 6)   
 
Attention to the significance of the HLA region in IBD was first drawn by Japanese studies in 
which HLA-DR2 was associated with UC [66]. However this allele does not appear to be 
associated with IBD in Caucasian populations.  
 
In a Caucasian panel, Satsangi et al [67] identified association between HLA-DR3, DQ2 and 
extensive UC particularly in females, and DRB1*0103 in both severe disease requiring surgery 
and extra-intestinal manifestations. This is a rare mutation occurring in 0.2% to 3.2% of the 
population. In CD, the HLA-DRB1*0701, a common allele has been associated with ileal disease 
particularly in individuals who were unaffected by CARD mutations [58, 68]. The HLA region 
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clearly influences extra intestinal disease in IBD.  There is a large joint inflammatory oligo-
arthropathy associated with the DRB1*0103 allele, and a small joint arthropathy, associated with 




REGIONS WITHIN THE HUMAN MHC 
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(Adapted from Ranganathan, 2005) 
 
Figure 1-2  A diagrammatic representation of the gene map of the extended Major 





Although original association data for CD overall was inconsistent at the HLA locus, attention 
has recently been re-focused by the results of linkage studies. These strongly suggest a role for 
this region in CD as well as UC, and there is consistency now both for particular HLA alleles and 
TNF promoter polymorphisms [58]. The latter have shown replicable association in Japanese and 
Caucasian populations. In a recent study van Heel et al demonstrated association between IBD 
and a functionally significant TNF promoter polymorphism which appears to enhance binding of 
NF-κB [70]. 
 
Despite the replication, it is still unclear exactly which gene or genes on chromosome 6p 
contribute to IBD. This is because numerous immuno-active genes map here and there is 
extensive linkage disequilibrium (LD) in this region. Strong LD means that this is an area where 
few cross-overs tend to occur at meiosis, and thus association will be seen with ‘hitchhiking’ 







1.2.1.6.3   IL23R 
 
Original evidence for linkage between 1p and CD came from Chicago and John’s Hopkins, USA 
[71]. Individual variation in the IL23R gene is associated with a variation in susceptibility to both 
CD and UC [72]. These findings have been extensively replicated [73, 74]. A rare variant in this 
gene appears to offer protection against IBD and functional data has since then demonstrated the 
importance of the IL-23/Th-17 pathway in IBD pathogenesis. Other variants are also present but 
the effects are less obvious. The IL-23/Th-17 pathway has been described in greater detail 
elsewhere in this document. 
 
 
1.2.1.6.4  The genetics of susceptibility to UC 
 
Most initial studies were focused on CD due to the greater degree of heritability that has been 
attributed to it. As GWAS have become more widely available, the techniques have found 
application in UC.  The results are intriguing and the two diseases are becoming increasingly 
separated at the genomic level [75]. A number of loci have been identified, of which the most 
interesting would be the ECM1 locus [72] and the IL-10 [76] and IL-10 R genes [77]. 
It is also of particular interest that the genes influencing the innate immune pathway are not 
implicated in UC, in particular, NOD2, ATG6L1, and IRGM.  It is possible that the pathogenic 
mechanism in UC does not involve as large a bacterial contribution as in CD [78]. 
Substantial progress has been made in the past 10 years in understanding the genetic basis of IBD 
and genetic studies may yet, provide a quantum leap forward in understanding the pathogenesis of 










1.2.1.7   Immunology 
 
1.2.1.7.1 The normal Intestine and Innate Immunity 
 
The antigenic diversity of the human intestine is vast, and by far the largest contribution to this 
comes from the resident and occasionally transient bacterial flora.  There are over 100 trillion 
microbes and the vast majority reside in the colon. The density of the microbial population here is 
the highest recorded for any microbial habitat [79]. There has been increasing recognition that the 
intestinal microbiota plays a critical role in the maintenance of immunological homoeostasis in 
the gut.  CD4+ T-cells maintain the peripheral immune surveillance of antigens. Following 
selection in the thymus, effector and regulatory CD4+ T-cells (Tregs) specific to bacterial antigens 
are focussed in gut associated lymphoid tissues (GALT) in the small and large intestines [80].  
 
The system is predominantly one of immune tolerance and regulation. One only needs to consider 
the effect of bacterial capsular lipopolysaccharide A (LPS A) that is a component of over 5% of 
the bacterial population of the human intestine. It can stimulate a large fraction of the T- cell 
population [81]. Indeed, if these bacteria were presented in a parenteral manner, a catastrophic 
inflammatory response would ensue. Instead, in the healthy intestine, CD4+T helper cell and Treg 
mediated tolerance predominates [82].  
 
The epithelium separates the intestinal lumen from the immunologically active lamina propria. 
The secretion of antimicrobial defensins by Paneth cells [83]; and mucus perpetuate this barrier. 
The intestinal epithelial cells (IECs) produce anti-inflammatory cytokines like IL- 25, IL-10 and 
TGF β. Their downstream effects lead to sequestration of mucosal antigen presenting cells 
(APC), and the down-regulation of MHC ІІ, adhesion molecules and pro-inflammatory cytokine 
such as IL-6, IL-23, or IL-12 [80, 84].  
 
Despite this, the peripheral Treg population is influenced by the intestinal bacterial environment 
[85]. Clearly the intestinal epithelium is not impermeable not least because it provides a route for 
nutrient absorption. There are two routes; one, a transcellular route with specific membrane 
pumps and channels and a separate para cellular route that is policed by tight junctions, occludin 
and claudin proteins [86].  
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Epithelial pattern recognition receptors that identify microbial components like LPS, RNA, and 
methylated DNA. Fifteen toll like receptors (TLRs) taken together are capable of recognizing 
most microbial molecular patterns including commensal bacteria [87].  When they do, they 
trigger an intracellular immunological response [88]. They can increase or decrease the function 
of Treg cells [89] and lead to enhanced survival and accelerated induction of T effector cell 
responses. TLRs are also expressed on CD4+T cells (effector and regulatory) and stimulate 
adaptative immunity.  
 
Cytoplasmic NOD 1 and 2 proteins are expressed in APC and in small intestinal Paneth cells [62] 
and may provide an additional defence mechanism.  It is activated by bacterial peptidoglycan 
through MDP [90]. Expression is augmented by inflammatory cytokines [91] and NOD 2 
mutation increases NF-κB and IL-1 β activity [65].  
 
Dendritic cells (DC) sample bacteria by dispatching probes into the intestinal lumen through tight 
junctions between epithelial cells.  When DCs detect pathogenic bacteria, they mature, and induce 
immunity. DCs are important in balancing immune responses against pathogenic bacteria and 
tolerance towards commensal bacteria. They achieve this by expressing the entire spectrum of 
TLRs and NODs [84, 92].   
 
 
1.2.1.7.2  Adaptative Immunity 
 
The gut mucosa is home to a large lymphocytic population.  These include T-cells, B cells and 
natural killer (NK) cells. Villous microfold cells transmit antigenic material to Peyer’s patches in 
the small intestine as one of the key elements in the adaptative immune system. This is comprised 
of two populations of lymphocytes: the B lymphocytes and the T lymphocytes.  
 
All lymphocytes originate in the bone marrow. Subsequent T-lymphocyte maturation occurs in 
the thymus and B lymphocyte maturation in the bone marrow. In the periphery, lymphocytes are 
localised in mucosa associated lymphoid tissue (MALT) and to smaller extent in the 
lymphoreticular system. B lymphocytes possess immunoglobulin receptors that recognize intact 
antigens and by the secretion of immunoglobulins, activate the humoral arm of immunity. They 
act against extracellular pathogens in correlation with the complement system and phagocytes.  
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The T-lymphocyte is responsible for the cell mediated arm of immunity that responds to 
intracellular pathogen such as viruses.  The T-lymphocytes also regulate B-cell responses. The T-
lymphocytes possess T-cell receptors (TCR) that recognize antigen bound to the major 
histocompatibility complex (MHC) and APCs.  The effective activation of T cells requires 
specific mature APC s (dendritic cells or macrophages with high levels of MHC class ІІ 
molecules and co-stimulatory molecules). If any other APCs are the presenting cells, anergy or 
tolerance may result [93].  
 
 
These populations of T-cells are recognized.  
 
• Effector CD4+T cells 
o Type 1 helper T-cell (Th-1 cells) 
o Type 2 helper T-cell (Th-2 cells)  
o Th-17 cells  
o T regulatory cells(Tregs) (CD4+ CD25+ FOXP3+) 
 
• Cytotoxic CD8+T cells 
o Cytotoxic T-lymphocyte (CTLs) 
 
 
CD4+ T cells 
 
These T-cell subsets have distinctive cytokine expression profiles and responses to specific 
transcription factors. The uncommitted CD4 + T cell (Th-0) cell is influenced by a locally existing 
pattern of cytokines that steers the T cell population towards a Th -1 or Th- 2 phenotype. These 
secrete individual and exclusive cytokine profiles and mediate distinct effects. The Th-1 cellular 
population promotes cell mediated immunity by macrophages and antibody dependent cell 
mediated cytolysis.  The Th-2 population provides mucosal immunity by stimulation of mast 
cells, eosinophil differentiation, IgA synthesis (antibody and allergic responses). The two cellular 
populations influence each other by important feedback mechanisms. Monocytes secrete IL-12 
which stimulates the secretion of IFNγ by Th-1 cells. This upregulates IL-12 receptors (IL-12R) 
inhibits Th-2 and further augments the inflammatory response.  An early secretion of IL-4 favours 
a Th-2 profile characterised by the secretion of IL-10. This inhibits IL-12 secretion by monocytes 
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and augments IL-4 production by Th-2 cells. The IL-4 inhibits the expression of IL-12R and 
shifts the balance towards a Th-2 phenotype (Figure 1-3).  
 
Other T cells 
 
These phenotypically distinct cells can be cytotoxic (CTL: cytotoxic T lymphocyte) or 
suppressive CD8+ T regs. The cytokine profiles secreted can be very similar to those of the CD4+ T 
cells. A number of other T cells are recognised and include Natural Killer cells (NK). These are 
capable of initiating T cell responses by secreting IFN-γ and IL-4 and regulating dendritic cell 








Identifying markers: Red font, secreted cytokines: Bold black font, influencing cytokines: normal 
black font 
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T regulatory Cells (Tregs) and Tolerance 
 
The activated inflammatory cascade has the potential for unchecked destruction and mechanisms 
are in place to limit this. A subset of T cells is CD4+CD25+ and is regulatory or suppressive in 
function. Precise characterisation of these cells has been difficult as they do not express 
distinctive cell surface markers. However, their discovery has developed the concept of tolerance.  
 
Two mechanisms of tolerance have been proposed and “recessive” tolerance is a means of 
inducing apoptosis of self reactive thymocytes that escape clonal deletion. These cells become 
anergic. In the periphery, a similar mechanism exists and appears to be mediated by natural 
regulatory T cells. Simultaneous engagement ( by cell to cell contact ) of the T cell receptor and 
CTLA4  by CD80 and CD86 ligands on antigen presenting cells (APC) such as dendritic cells 
(DC) [94] reduces proliferation of naïve and activated T-cells.  
 
This process of “recessive” tolerance is augmented by specialised cells that suppress self 
reactivity and this is “dominant " tolerance. These induced T regulatory cells may be antigen 
specific or non-specific and express the CD4+ CD25+ phenotype typical of all active T 
lymphocytes. Importantly, they differ from others in their unique cytokine-expression profile.  
 
Non-antigen specific T cells are CD8 + T Cells, γδ T Cells and CD4 + T cells. Of these,             
CD4+ T regs secrete IL-10 or TGF-β and this differential expression allows their classification into 
two cell populations. TR 1 cells produce high levels of IL-10 [95], TH 3 cells produce large 
quantities of TGF-β [96] and, without cellular contact dependent mechanisms; these cytokines 
mediate their suppressor effects. The TR 1 cells suppress Th -1 cell responses and Th -1 cell 
mediated auto immune diseases. IL-10 inhibits the production of TNF and IL-12 by DCs and 
macrophages and the addition of IL-10 antibodies can reverse the suppression [97]. TGF-β 
secreted by TH 3 cells also inhibits Th 1 cell responses by inhibiting T-bet transcription and IL-12 
receptor expression [98]. Furthermore, TGF-beta1 induces Smad4, which then binds to and 
activates the IL-10 promoter and subsequently increases IL-10 expression [99]. Clearly the TR 1/ 











CD4+CD25+FOXP3+ (forkhead box P3) natural regulatory T cells (TReg cells) inhibit the proliferation of 
CD25- T cells by cell–cell contact. These then  express cytotoxic T-lymphocyte antigen 4 (CTLA4), which 
interacts with CD80 and/or CD86 on the surface of antigen-presenting cells (APCs) such as dendritic cells 
(DCs), and this interaction delivers a negative signal for T-cell activation.  
T regulatory 1 (TR1) cells, T helper 3 (TH3) cells and CD8+ regulatory T cells, secrete IL-10 and/or TGF-  
which inhibit the proliferation and subsequent cytokine production by TH1 cells, TH2 cells and CD8+ 
cytotoxic T lymphocytes (CTLs) 
 
Figure 1-4  TR1 and Th-3 differentiation and the influence on tolerance 
 











Antigen specific Tregs include CD8+CD28- T cells that express Foxp3. They suppress the antigen –
specific response of CD4+T cells by cell to cell contact [100], reducing IL-2 secretion, down 
regulating co-stimulatory molecules such as CD80 and CD86 and up reregulating inhibitory 
receptors such as ILT3 and ILT4 on APCs [101].  
 
As briefly described before, the maturity of DC in their antigen presenting role to T cells 
influences the response. Immature DC s induces an anergic response. However mature DCs are 
also capable of inducing tolerance by increasing regulatory CD4+CD25+ T cells [102] 
 
 
1.2.1.7.3  The immuno-pathogenesis of inflammatory bowel disease 
 
It is likely that a predisposition to abnormal intestinal permeability exists in individuals with a 
family history of CD and in those with a CARD15 3020 ins C mutation [103]. There has been one 
report of an individual with abnormal intestinal permeability going on to develop CD [104] and 
these abnormalities have been noted in both in inflamed and non-inflamed  areas of the bowel, in 
CD and UC [105].  A co existing defect in the innate immunity is most likely to be the next step. 
It may involve the TLRs. TLR4 is significantly up-regulated in CD and UC and TLR3 is down 
regulated in CD but not in UC [106]. In the injured mucosa, TLR5, usually expressed 
basolaterally, is exposed to bacterial flagellin and subsequently activated [107].  DC’s respond 
inappropriately to commensal bacteria with a Th-1 response normally reserved for pathogenic 
bacteria. [108]. The DC’s have a mature, activated and pro-inflammatory phenotype [109] rather 
than the immature, tolerogenic phenotype [110].  
 
There is a persistent failure of apoptosis in activated, reactive, mucosal T-cell populations [111] 
and the repeated activation of memory T-cells that perpetuate inflammation. Furthermore, the 
intestinal epithelial cells themselves activate T-cells through a variety of pathways including 
increased MHC expression in the presence of inflammatory cytokines [112] and some others that 
arise in injured colonic mucosa [113]. 
 
However, major developments in the understanding of CD4+ T-cell and Treg cell function in IBD 
in recent years have further enhanced our understanding of pathogenesis.  CD4+ lymphocytes are 
key to the development of IBD. They are increased and activated in the intestinal lamina propria 
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[114] and are dependent on the presence of intestinal microflora to generate inflammation [115]. 
Until recently, CD was thought to manifest a predominantly Th-1 phenotype, mediated by the 
sequential activation of signal transduction cascadesin activated T-cells (STAT-1 and STAT-4 by 
IFN α, IFN β and IFN-γ followed by the induction of the T box transcription factor (T-bet) and 
IFN-γ [116]. Th-1 mediated immune responses are evoked on exposure to an intracellular 
pathogen, such as a virus or bacterium. The immune response localises the infectious agent and 
by the secretion of IFN-γ and TNF-α or the differentiation of cytotoxic T-lymphocyte leads to 
microbial killing. 
 
The evidence for this is powerful, and includes 
1. The increased numbers of CD4+ T-cells that express IFN-γ and T-bet in the inflamed 
colon [117, 118]. 
2. Increased serum IFN-γ in CD patients but not in normal controls [119]. 
3. Increased expression of IL-12 receptor and IL-18 receptor on lamina propria CD4+ T-
cells of CD patients and subsequent increased production of IFN-γ when activated with 
the corresponding cytokine [120]. 
4. Increased levels of IL-12 in the inflamed mucosa [121] and the efficacy of IL- 12 
antibody therapy in CD [122]. 
 
 
Since high levels of IL-17 were reported in IBD in 2003 [123], some of these concepts have been 
revised. They have been significantly influenced by recent studies on Th-17 CD4+ lymphocytes 
which are found in large numbers in intestinal mucosa of patients with CD and UC [124]. They 
are found in the lamina propria of patients with UC and throughout submucosa muscularis propria 
of patients with CD; namely areas that display characteristic pathological changes. Th-17 
cytokines up regulate inflammatory cytokines and matrix metalloproteinases (MMP). These 
amplify T-cell effector pathways and cause significant tissue damage [125, 126]. When Th-17 
cells reactive to intestinal bacteria are transferred into immuno-deficient mouse recipients, the 
colitis induced is of a comparably greater severity than transfers of Th-1 cells.  
 
Th-17 cells are typified by the expression of the transcription factor RORγt [127] which is, in 
turn, dependent upon STAT-3 expression. TGF-β and IL-6 commit naïve T cells to Th-17 cell 
differentiation. The stimulated cells secrete IL-17 and IL-22 [128] and IL-10 and mediate a 
homoeostatic intestine. As the Th-17 cells mature, they acquire responsiveness to IL-23 [129].  
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IL-23 receptor [130] stimulation with IL-23 promotes expression of IL-17 and pro-inflammatory 
cytokines, but not the anti inflammatory IL-10 [131]. IL23p19 monoclonal antibody inhibits 
colitis and causes depletion of the co- transferred Th-17 effector cells. [132]. The inflammatory 
effects of IL-17 are apparently critically influenced by IL-23 [133].  
 
In UC, in which IFN-γ levels are not increased, the situation is different. Based on this, a Th-2 
hypothesis was proposed.  However, there are significant departures from previously recognised 
patterns.  Th-2 cells are rarely seen in the normal intestine and have a role in coordinating the 
response to helminthic infections. In UC, IL-4 levels are lower than expected but IL-5 levels are   
heightened. Animal models are somewhat limited in their similarity to human UC but it is useful 
to note is that an IL-4 dependent early phase of intestinal inflammation is superseded by an IL-18 
dominated late phase.   
 
 
1.2.1.8  HLA-G 
 
Previous data have suggested strong roles for the highly polymorphic human leucocyte antigen 
(HLA) region, located on the short arm of chromosome 6 in   susceptibility to IBD and in disease 
phenotype. It is clear that the HLA region contains genes that determine susceptibility to IBD  
[134, 135], that there are differences in associations between these two diseases, that ethnic 
groups differ and that some of these markers may have clinical significance in predicting disease 
course and the development of complications [136].   
 
The primary role of the HLA molecules is to transport peptides to the T-cell antigen receptor and 
present these peptides for recognition and induction of T cell responses.  Three classes are 
recognised and differ in their roles. Class І antigens are the products of the HLA-A, B, C, E, F 
and G genes. They also include pseudogenes (HLA-H, J, K, L, P and V). Class ІІ antigens are the 
products of are HLA- DR, DQ, DP, DM and DO genes [137]. The Class ІІІ region is located 
between the other two and contains over 20 genes coding for a variety of peptides (Figure 1-2).  
The gene enjoys a wide range of genetic polymorphism and extended haplotypes are nearly 
unique for an individual. There is, on the other hand, very significant LD and the co existence of 




1.2.1.8.1  Biology 
 
 HLA-G is a non-classical class I antigen and that contrasts from classical HLA. The most 
remarkable of these is the extremely low level of genetic polymorphism (8 protein variants versus 
over 500 for HLA-A and HLA-B). The tissue distribution is highly restricted with only a few 
privileged sites demonstrating expression such as the human trophoblast, thymic medulla, cornea 
and pancreatic islets [138]. HLA-G expression is inducible in cancers, transplanted grafts, 
inflammatory diseases and viral infections [138]. The effects of the HLA-G molecule vary in 
these areas and whilst in the semi-allogeneic foetus, a survival benefit is evident, in malignant 
tissues, the protein expression leads to aggressive disease [165]. Unlike classical HLA, the 
molecule enjoys a profound deficiency in eliciting immune responses [140] and like classical 
HLA, a particular efficiency in suppressing them.  HLA-G is up-regulated in monocytes and T-
lymphocytes in HIV patients and in patients with CMV infections [141, 142] and may be a key 
defensive strategy for escape from immune surveillance.  
 
Like classical HLA, there is a primary transcript. Here, it has as stop at exon 6 after the coding 
sequence for the trans-membrane tail. On alternate splicing, 7 isoforms are generated. These are 
membrane-bound (HLA-G1, G2, G3, G4) and soluble (HLA- G5, G6, G7) [143]. HLA-G5 is 
considered the soluble form of HLA-G1 and the extracellular segments of the two are identical 
and very similar to classical HLA. There is a heavy chain with three globular proteins linked to 
β2-microglobulin. Truncated forms are created by the excision of exons coding for some of these 
proteins and soluble forms are created by the translation of intron 4 or 2 [138] (Figure 1-5).   
 
Of these forms, HLA-G1 may be the only one expressed at the cell surface [144].  However the 
molecule is not essential for maintenance of a viable pregnancy as homozygotes for this allele of 
the null HLA-G allele HLA-G *0105N, demonstrate [145]. They do not express HLA-G1, G5 or 
G4. Instead, HLA-G2 and G6 are seen [146] and appear to protect against NK cytolysis [147]. 
The soluble forms (sHLA) are detectable in body fluids [148] and decreased sHLA-G is observed 
in pre-eclampsia and preterm placental abruption [149]. Increased sHLA-G levels are associated 
with an improved pregnancy outcome after in vitro fertilisation (IVF) and improved graft 
acceptance after cardiac and liver-kidney transplantation [150, 151]. Membrane-bound and 
soluble forms of HLA-G inhibit Natural killer (NK) cells, cytotoxic T-lymphocytes [152-154], 
DC maturation and induce CD4+ T regulatory cells (Treg) differentiation. These mechanisms may 





Reproduced from Carosella et al [138] 
Figure 1-5  The HLA-G primary transcript and the effect of alternate splicing and 











Cells HLA-G functions ILT 2 ILT4 KIR2DL4 CD8 
NK CELLS 
Inhibit Cytotoxicity +  +  
Suppress proliferation +    
Apoptosis    + 
Inhibit trans endothelial 
migration +    
CD8+ T cells 
Inhibit Cytotoxicity     
Suppress proliferation +    
CD8+T reg differentiation     
Apoptosis    + 
CD4+ T-cells 
Inhibit alloreaction + +   
Suppress proliferation +    
Monocytes  + + - - 
DC Inhibit maturation and  induce T regs 
+ + - - 
 




HLA-G acts on a number of inhibitory receptors that have site and cell specificity. ILT2 is widely 
expressed but ILT4 is myeloid specific, expressed only by monocytes and dendritic cells. Since 
these receptors recognise β2- microglobulin, they are not specific for HLA-G and are also 
activated by classical HLA molecules. However, affinity for HLA-G is considerably greater [156, 
157]. The KIR2DL4 is of greater relevance in the uterine environment and inhibits local NK cell 
activity and the greatest significance of HLA-G may be at the foetal-maternal interface [158].  
Most of the significance of the HLA-G molecule in transplantation and cancer immunology 
comes from its suppressive effects on T cell biology and this is mediated by the HLA-G1 and G5 
isoforms [138](Table 1-1). Impaired sHLA-G secretion associated with reduced IL-10 levels has 
been reported in patients with UC, unlike healthy subjects and patients with CD [159]. 
 
The effects on the peripheral T cell populations have received particular attention in recent years 
and two “classical” effects are recognised. Naturally occurring CD4+ or CD8+ T cells expressing 
surface HLA-G arise in the thymus and are seen in the peripheral circulation of normal 
individuals. They do not express CD25 or FoxP3 and do not secrete IL-10 or TGF-β but are 
hypoproliferative and hyporesponsive to stimulation. Therefore they have regulatory functions 
but are distinct from TR1 andTh3 cells. The suppressive effects seem to be mediated by soluble 
factors such as HLA-G5 and are partially abolished by specific antibodies [160]. 
 
Membrane bound or soluble HLA-G down-regulates the expression of CD4 and CD8 on allo-
stimulated T cells. These CD3 (+) CD4 (low) and CD3 (+) CD8 (low) T-cell subsets are Foxp3-
negative suppressor T cells that secrete IL-10. Patients with high HLA-G plasma concentrations 
have higher numbers of these cells and after transplantation, had better graft survival compared 
with low HLA-G patients. These cells are similar to TR1 cells, are low producers of CD4 or CD8 
and have potent immunosuppressive properties [161]. When naïve T cells are sensitized with 
HLA-G5 through ILT-2 and ILT-4 receptors, they exert regulatory effects and become anergic 
[155]. 
 
In addition, HLA-G exerts effects on DC’s through ILT4 receptors and on APC [162]. DCs are 
rendered tolerogenic as they do not up regulate co stimulatory molecules (CD80 and CD86) and 
MHC class ІІ and instead, stimulate the expansion of CD4+CD25+CTLA4- and IL-10 producing 
CD8+CD28- Tregs [163]. A subset of DCs producing IL-10 (DC-10) is activated through an 
ILT4/HLA-G signaling pathway and induces antigen specific TR1 cell differentiation. 
Suppressive effects through IL-10 can be expected [164].   
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Although, many of these powerful suppressive effects have been examined in transplant biology 




1.2.1.8.2   Genetics  
 
Over 40 HLA-G DNA alleles and sixteen HLA-G protein alleles have been reported. The most 
common allele is HLAG*0101 and amino acid substitutions generate variants. A Thr31Ser creates 
the HLAG*0103 allele, Leu 110 Iso creates the *0104 allele, Thr258Met at position creates the 
*0106 allele. Further subdivisions of the *0101 and the *0104 alleles are created by silent 
polymorphisms in exon 2 and 3. There are 2 null alleles:  HLA-G*0105N where a deletion 
mutation in codon 130 in exon 3 creates a frameshift mutation and a premature stop at codon 171 
and G*0113N where a point mutation at  codon 54 in exon 2 creates a premature stop [165]. 
Subsequently, alternate isoforms are generated instead of the classical isoforms of HLA-G1 and 
HLA-G5 [166].  
 
Altered expression of HLA-G has been associated with polymorphisms in the 3′ untranslated 
region (3′ UTR) and 5′ upstream regulatory region (5′ URR) of the gene.  In the 5’URR,  -G725C 
or -G725T seems to result in relatively low HLA-G expression and higher miscarriage rates [167] 
and this appears to be in LD with the 14 bp ins/del polymorphism in the 3’UTR [168].   
 
A 14 base pair deletion/insertion polymorphism in the 3′ UTR region of exon 8 has been 
described and some transcripts associated with the insertion polymorphism undergo differential 
splicing to remove the first 92 base pairs of Exon 8 [169]. These shorter transcripts are stable, but 












 Reproduced from Larsen et al [165] 
 
Figure 1-6  A schematic diagram of the 3’UTR demonstrating the recognized 




Although other polymorphisms in the coding region of the HLA-G gene have been described 
[170-173], the 14bp ins/del polymorphism has been extensively studied and the insertion is 
associated with recurrent spontaneous abortion, miscarriages, sarcoidosis and pemphigus vulgaris 
[139, 174-176]. Furthermore, strong LD exists within SNPs in the promoter region and the 14bp 
polymorphism [177]. Some have suggested that the HLA-G*010101 with the 14bp del allele is 
associated with higher levels of sHLA-G expression when compared with the HLA-G *010102 
haplotype with the 14bp ins allele but this effect has not been consistently observed [178] (Figure 
1-6). 
 
There is significant LD between HLA-DR3 and HLA-G*010102 in control populations and those 
affected by recurrent spontaneous abortions. For all four HLA loci studied, the alleles in the 
haplotype HLA-DRB1*03.DQA1*05.DQB1*02.G*010102 were in clear LD [179]. LD has also 
been demonstrated for HLA-DR3 and HLA-G*010102 in individuals with RSA but not controls 
and HLA-A1 and HLA-G*010102 [173].  The HLA-A locus is close to the HLA-G locus on 
chromosome 6 and the HLA1-B8-DR3 haplotype has been associated with colonic CD [58]. The 
G*010102 allele includes the 14-bp sequence polymorphism in the 3' UTR of the gene and the 
14bp ins/ins genotype was seen more frequently in CD patients who required ileo-caecal resection 
[177]. The haplotypes with the strongest LD with HLA-G*010102 are not amongst those best 
associated with susceptibility or disease severity in IBD. Impaired sHLA-G expression has been 
reported in patients with UC, as compared to healthy subjects and those with CD. This difference 
was related to a reduction in IL-10 secretion in UC but not in CD [159]. HLA-G and IL-10 may 






IL-10 is an anti inflammatory cytokine and is produced by monocytes, macrophages and Treg 
cells. It can induce T-cell anergy, inhibit MHC class I expression and the synthesis of pro-
inflammatory cytokines by activated macrophages [181]. There is a compensatory increase of IL-
10 in patients with CD and a more direct increase in patients with UC [182].  A relative 
deficiency of IL-10 in patients with UC could contribute to persistence of the inflammatory state 
[183] and IL-10 deficient mice develop spontaneous intestinal inflammation reminiscent of IBD 
[184]. These observations led to controlled trials of recombinant IL-10 for refractory CD but the 
results were disappointing. Recent genome wide association studies (GWAS) in adult [76] and 
paediatric [185] IBD cohorts have shown an influence of genetic variation in the IL-10 promoter 
region on susceptibility to IBD.  IL-10 is clearly pivotal as a regulator of mucosal inflammation in 
IBD. However, the precise role awaits clarification.  Expression levels are influenced by genetic 
variation in the promoter haplotype [186]. In normal individuals, the expression of IL-10 by 
stimulated PBMCs is influenced by three polymorphisms in the IL-10 promoter (G/A at -1082, 
T/C at -819 and A/C at -592). Three haplotypes are described of which GCC/GCC is a high 
producer, GCC/ATA and GCC/ACC are intermediate producers and ATA/ATA, ATA/ACC and 
ACC/ACC are low producers of IL-10 [187, 188]. Although initial trials studying  the effect of 
systemic injection of recombinant IL-10 in IBD were only modestly effective in individuals with 
active CD [189, 190], more recent trials involving local delivery of IL-10 by  lactobacilli in 













1.2.2     The clinical aspects of Inflammatory Bowel Disease 
 
Whilst it is not always possible to successfully distinguish between the CD and UC, the 
distinction is often made on the basis of a discontinuous involvement of any part of the intestine 
from the mouth to the anus in CD as opposed to uninterrupted colonic inflammation, extending 
proximally from the rectum of varying extent in UC.  CD is defined as a transmural intestinal 
inflammation affecting any part of the bowel; but typically the ileum and the colon. In UC 
inflammation is restricted to the intestinal mucosa and affects contiguous segments of the large 
bowel from the anal verge.  
 
 




The symptoms of UC are generally those of bloody diarrhoea and urgency to stool, a small 
significant minority however, with rectal disease can present with constipation and rectal 
bleeding. The onset is usually sub-acute but can vary. The rectum alone is involved in 50% of 
cases. Of the rest, abdominal pain, cramping and fever are frequent. Increased stool frequency 
and noctural urgency to stool, systemic symptoms such as anorexia and weight loss suggest 
severe or extensive disease. Acute severe UC remains one of the main causes of potential 





The symptoms are influenced by the part of the bowel predominantly affected. A further sub-
classification is often used dividing patients into non-stenosing, non-penetrating, stenosing or 






Table 1-2  The influence of Crohn's disease phenotype on presenting symptoms 
 
 




Small Intestine (30%) 
Stenosing 
Abdominal pain , subacute 
intermittent intestinal 









fistula or abscesses) 
Abdominal pain, fever, 
anorexia, weight loss 
Colon (30%) Crohn’s colitis Severe Diarrhoea, rectal sparing 
Perianal Penetrating 
Fistulae (entero cutaneous, 
recto vaginal, colo vesical 
etc.) and perianal 
abscesses with perianal 




Classification of Crohn’s Disease 
 
The classification schemes have continued to evolve as we have seen earlier proposals on  
Phenotypic descriptions based on an anatomical location, give way to more modern concepts, 










1.2.2.2  The Course of Crohn’s disease 
 
The disease course is intermittent, remitting and progressive. Although some of the data 
demonstrating this comes from a time when surgery was the predominant therapy for severe CD, 
it is illuminating. At diagnosis, 35 % have pure ileitis, 36% have isolated colitis and 29% have 
ileocolitis [194]. Disease distribution usually remained stable and this distribution can provide an 
estimate of prognosis. An early onset of disease and ileal involvement predicted a penetrating 
course [195], and late-onset of disease was often limited to the colon [196].  A small number    
(1% ) of patients have a continuously active course, 10% experience prolonged clinical remission 
and 50% with active disease may remain in remission for up to a year within three years of 
diagnosis[197].  
 
A number of population-based studies have confirmed that disease course, over a period of 40 to 
50 years, is characterised by an evolution in the nature of the inflammatory changes. The progress 
is one from an inflammatory (non-stricturing, non-penetrating type) to either of the two 
complicated types and was first noted in 2001 [198]. Most patients (usually around 60%) progress 
and a significant minority have established complicated disease at diagnosis (30%). Since then 
other reports have confirmed this and this has been the subject of a comprehensive review [196]. 
 
The landmark IBSEN population based study from Norway of 200 patients with CD follow-up 
over five years, demonstrated that the previously recognized progression of disease from one of 
the relatively mild non stricturing non-penetrating state to more complicated disease was not 
influenced by tertiary hospital referral bias [199].  However, the data does demonstrate the 




Early Crohn’s Disease 
 
The availability of powerful, efficacious treatments in the secondary prevention of disease 
complications in “at risk” individuals mandates the description and the subsequent diagnosis of an 
early stage of disease. This is less easy to apply in CD particularly because of the frequent delay 
in diagnosis that many patients experience. Indeed, some authors suggest that 32% of individuals 
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may demonstrate evidence of established complications of disease at diagnosis. This includes 
stricturing or fistulisation [200]. It is also recognised that the disease often moves from a non-
stricturing non-penetrating phenotype to the more complicated presentation over time [195, 198].  
 
Such data coupled with the recognition of a guarded postoperative prognosis demonstrate the 
rationale of investigating a secondary prevention model. Unfortunately, this approach is limited 
by the diagnostic difficulty of a subclinical or mildly symptomatic state. Recent proposals have 
suggested a diagnostic algorithm based on clinical features, C reactive protein, endoscopic 
appearances, stool tests of inflammation and an early freedom from the need for steroids or 
immunomodulatory medication [201]. These efforts are clearly preliminary but accumulating 
evidence on the role of early immunomodulatory therapy such as AZA and Infliximab (INFX) 




1.2.3  Treatment of the Inflammatory Bowel Diseases 
 
On the whole, treatment regimens are relatively standard, but variations in clinical response and 
individual drug tolerance usually mean that the therapeutic approaches are individualised. The 
therapeutic approach is one of initial treatment to induce a clinical remission (induction phase) 
and then a subsequent maintenance phase to sustain this remission.  Management in the 
traditional manner is based on the supposition that the least efficacious and least toxic 
medications are best used early when the disease may be relatively mild. The more efficacious 
and possibly more toxic drugs are therefore reserved for when the first choices fail; usually later 
in the disease course.  This approach has undergone some modification with the recognition that 
certain disease groups are at greater risk of resistance to certain medications, aggressive disease 
behaviour and recourse to surgery.  Small differences occur, but these are generally consistent 








1.2.3.1  Ulcerative colitis 
 
1.2.3.1.1  Induction Therapy 
 
Initial therapy for patients with mild- moderate disease is 5- aminosalicylic acid. If this is 
unsuccessful, oral prednisolone in a dose of 40-60 mg a day, continued until clinical improvement 
occurs and then tapered over a period of time is beneficial and recommended.  The 60 mg dose is 
more effective and causes more side-effects [203]. Anti TNF therapy, specifically INFX has been 
evaluated in moderate or severe UC and is effective in a dose of 5 mg per kilogram administered 
in the standard induction scheduled at 0, 2 and 6 weeks. In this moderately affected group, 22% 
of patients were able to achieve a steroid free remission at one year [205]. 
 
1.2.3.1.2  Maintenance treatment 
 
Mesalamine suppositories [206] and enemas are effective in maintaining remission, when used 
regularly [207] or intermittently in a higher dose [208]. Steroids are not effective in the 
maintenance of remission [209] but the thiopurines, namely AZA and 6-MP; and INFX can be 
very effective. AZA and 6-MP are effective in maintaining remission in placebo-controlled 
maintenance trials [210].  Furthermore, it is generally well tolerated and could be considered in 
individuals who cannot tolerate mesalazine or sulphasalazine and subsequently require repeated 
doses of steroids [211]. INFX administered every eight weeks was effective in maintaining 
response in those in a remission at week 30 (30-50%) and week 54 (40%) [205]. 
 
1.2.3.2   Therapy of Crohn’s Disease 
 
The severity of disease activity and location of disease are proposed as aids to rational therapy. A 
variety of guidelines are in existence that enshrines these principles [204, 212].  
 
1.2.3.2.1 Induction  of  remission 
 
Prednisolone is highly effective regardless of disease location with remission rates between 60 to 
80% compared with placebo rates of 30 to 40% [213, 214].  Indeed, if the steroids are not tapered 
in the conventional fashion, remission rates of up to 92% are reported over seven weeks [215].   
Unfortunately, 50% of all patients on corticosteroids will experience side-effects.  Early effects 
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are predominantly cosmetic such as acne and moon facies. Subsequently, sleep and mood 
disturbances, and glucose intolerance may occur.  A prolonged use of greater than 12 weeks could 
result in posterior subcapsular cataracts, osteoporosis and osteonecrosis of the femoral head, 
myopathy and increased susceptibility to infection [203]. Corticosteroid therapy predisposes to 
adrenal insufficiency, particularly in individuals who have received more than 30 mg per day of 
hydrocortisone of 7.5 mg per day of prednisolone for more than three weeks [216]. Symptomatic 
insufficiency is evident as postural hypotension, nausea, vomiting, hyperkalaemia and 
hyponatraemia. Steroid use increases risk of all infections (Figure 1-7) in particular, post 
operative infectious complications [217] This is particularly relevant in those who come to 
unplanned surgery. 
 
Steroid usage is not uncommon and between 40 to 50% of all patients with CD will receive this 
treatment [218, 219]. Endoscopic mucosal healing is not usually evident [215] and should not 
guide decisions on treatment duration. Extending treatment duration, whilst reducing 
symptomatic relapse, does not increase time in remission after steroid withdraw [220]. Of those 
treated, 58% have a complete clinical remission at four weeks and 26% achieve a partial 
response. This “steroid free remission” is maintained in the minority (32%). 28% become steroid 




Above a total dose of 700mg the infection rates are significantly higher than placebo. 






Graph demonstrating that steroid use is initially effective but after a year is relatively 
inefficacious. Reproduced from Faubion et al. [218] 




A variety of steroid tapering techniques are used around the world, with the expectation that most 
patients would be off steroid treatment in 8- 16 weeks [212]. Standard induction therapy would 
subsequently involve the commencement of immunomodulatory medication such as AZA, 6-MP 
or MTX and an attempt at weaning and maintaining a steroid free remission. However, patients 
who require steroids for remission induction are at risk of aggressive disease and up to 40 % of 
these patients will come to surgery within that year [218].   
 
 
Steroid sparing Induction Regimen  
In individuals who are resistant to or intolerant of steroid therapy, the anti TNF group of drugs 
offer an important alternative [221].  After the endoscopic confirmation of disease activity, 
treatment with this group of drugs should be started. Should these drugs prove inefficacious or if 
the patient experiences a loss of response, surgery should be considered [222]. The anti TNF 
therapy should be combined with AZA/6-MP as the combination is superior in maintaining the 





Perianal and fistulising disease 
 
This is a particularly severe phenotype of CD and is at high risk of progressive complications 
over time.  It affects the large majority of those with CD affecting the colon, increasing in 
frequency in rectal disease [224].  Although much of the evidence regarding the use of 
metronidazole and ciprofloxacin is from uncontrolled trials, it is recommended in most 
guidelines, commonly used and is often effective [225]. AZA/6-MP are used as second line 
treatment of CD fistula and a meta-analysis favoured fistula healing [226].  When these two 
treatments fail, INFX should be used. It should be continued to maintain the response that is seen 
in 36% of those treated [227, 228]. Therapy is often combined with surgical drainage of perianal 
abscesses and the use of setons [229]. Newer guidelines suggest that INFX and surgical therapy 
should be used early, perhaps as first line therapy as the disease course is adverse and is not 




1.2.3.2.2   Maintenance of remission 
 
The long-term maintenance of a clinical remission is beneficial and reduces the risk of 
hospitalisation and surgery [231].  While corticosteroids are not intended to be maintenance 
therapy, it is likely that some individuals will find themselves dependent on steroid treatment.  
Smokers and those with colonic disease appeared to be at greater risk [232]. Patients needing 
corticosteroids for longer than 3 months are at particular risk of osteoporotic complications and 
recommendations exist for bone mineral density screening and replacement therapy with calcium, 
Vitamin D and bisphosphonates [203].  Neither sulphasalazine [213, 219] nor mesalazine [233] 
maintain a steroid induced remission. AZA and 6-MP are effective in maintaining steroid free 
remission [234], induced by steroid therapy for up to four years [235]. Weekly MTX in a dose of 
25 mg per week is steroid sparing and 15 mg intramuscular maintains a MTX induced remission 
[236]. Scheduled, eight weekly infusion of anti TNF therapy (Infliximab) maintains remission in 
luminal and fistulising CD.  Adalumimab and Certoluzimab are most likely equally effective 





1.2.3.2.3  Mucosal healing and top-down therapy 
 
It is now accepted that healing of colonic or ileal mucosa on therapy imparts a significant 
advantage to patients. In UC steroids, mesalamine, immunomodulators and biologics can induce 
mucosal healing but steroids cannot maintain the healed mucosa. In CD, a similar observation is 
true except that meslamine is ineffective. Mucosal healing in CD treated with AZA/6-MP varies 
from 15% after 26 weeks [223] to 58% at 1 year [237]. Although there are no randomised 
controlled trials to examine these as a primary endpoint, it appears that the effect takes time but is 
achievable.  
 
Much of the data supporting the benefits of mucosal healing come from sub-group analysis of 
studies of INFX use, however there is a valuable population cohort study of the prebiological era 
that demonstrates that mucosal healing reduces the need for surgery in both UC and CD with 
benefits seen for upto 10 years. Healing at 1 year in this study identifies a low risk group [238]. 
There is obviously no study of mucosal healing in biologicals of this magnitude as the experience 
has not built up as yet.  
 
MTX is also capable of mucosal healing in CD in up to 40-50% of individuals [239]. Although 
the studies supporting these observations are substantially smaller, they provide valuable support 
for the role of immunomodulation in IBD. It is important to highlight the further impact of the 
role that MTX currently occupies; namely that of second line immunomodulation after AZA 
failure or intolerance. These rates of mucosal healing under these limitations are impressive 
indeed.  
 
The recognition that  treatment efficacy varies with time, with both INFX and AZA  
demonstrating greater response rates, when used earlier has led to criticism of traditional 
treatment regimen. The knowledge that up to 30% of patients have a benign course of disease, not 






1.3  The immunomodulators 
  
1.3.1  Azathioprine 
 
Much like other drugs used in the treatment of autoimmune conditions, AZA was developed to 
treat childhood leukaemia. A decade after the discovery by Hitchings and Elion [241], the first 
report was published on the use of 6-MP in CD [242] and another 10 years on, the first clinical 
trial in IBD was reported [243]. These drugs are now standard therapy in UC and CD. 
  
1.3.1.1  Pharmacokinetics 
 
Mercaptopurine contributes to approximately 50% of the molecular weight of azathioprine and 
90% of azathioprine is converted to this form. The oral bioavailability of azathioprine is highly 
variable and ranges from 25%- 80% [244]. 6-MP has a short plasma half life of between one to 
two hours [245]. 
 
    
1.3.1.2   Metabolism  
 
AZA is a pro-drug of the thiopurines analogue, 6-MP.  Neither has intrinsic activity, and need to 
undergo enzymatic metabolism to generate active molecules.  AZA is undetectable in the 
bloodstream since methyl-nitrothioimidazole is rapidly cleaved probably within red blood cells 
[246] and hepatocytes [247]. This is predominantly enzymatic in the liver, mediated by 
glutathione S-transferase (GST). In the erythrocyte, it is non enzymatic and may be mediated by 
compounds such as glutathione or cysteine. The relative contribution of these individual sites is 
unknown but hepatic metabolism may be very relevant. 
 
Intracellularly, 6-MP is faced with three competing enzyme pathways (Figure 1-9). These are 
very similar to those used by endogenous purines [248]. 6-MP is metabolised by xanthine oxidase 
(XO) to 6-thiouric acid (6-TU); an inactive metabolite identifiable in plasma and urine [249]. The 
active compounds, 6-thiogunaine nucleotides (6-TGN) are formed from 6-MP by the action of 
hypoxanthine guanine phosphoribosyltransferase (HGPRT), inosine 5-monophosphate 
dehydrogenase (IMPDH) and guanidine 5- monophosphate synthetase (GMPS). One of the 
intermediaries in this pathway, thioinosine monophosphate (tIMP) is a substrate for TPMT, 
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leading to methylated thioIMP (MeTIMP) and also 6-thioxanthine monophosphate (6-TXMP) 
[250] which inhibit de novo purine synthesis [251]. The predominant inactivation pathway of 
thiopurines in haematopoietic cells is through the methylation of 6-MP by thiopurine-s-methyl 
transferase (TPMT) generating 6-methylmercaptopurine (6-MMP). TPMT is affected by genetic 
polymorphism and can manifest a 50 fold variation in enzyme activity between individuals [252]. 
Thus, if this inherited deficiency is present in an individual treated with 6-MP, they are likely to 
generate excessive concentrations of the active compound 6-TGN with a high likelihood of 
toxicity. Conversely, augmented enzymatic activity would lead to attenuated 6-TGN generation 
and a compromise in therapeutic efficacy.  
 
 
1.3.1.3 Mechanism of action  
 
Although, thiopurines have found widespread application in a variety of conditions, the exact 
mechanism of the immunosuppressive effect remains unclear. There are a number of contributory 
influences. These are as follows: 
 
1. 6-TGN may be incorporated into DNA and RNA resulting in inhibition of nucleotide 
protein synthesis and ultimately, lymphocyte proliferation [253]. 
2. 6-TGN accumulates in lymphocytes, and when T-cells are activated, it blocks expression 
of TRAIL, TNFR57 and α4 integrin and subsequent inflammation [254]. This may be 
relevant in lamina propria T-cells in IBD. 
3. AZA and its metabolites control T-cell apoptosis by modulation of Rac-1 activation 
converting a stimulatory signal into an apoptotic signal. 6-thio-GTP binds to Rac-1 
instead of GTP and genes such as MAP-Kinase, NF-κB, and bcl-xl are suppressed [255]. 
4. 6-MP impairs in vitro differentiation of dendritic cells (DC) and has an inhibitory effect 
during DC activation processes inducing a tolerogenic phenotype. 6-MP significantly 










AZA: azathioprine, 6-MP: 6-mercaptopurine, GST: Glutathione S Transferase, TPMT:Thiopurine 
methyl transferase, 6-TA: 6-Thiouric acid, XO:Xanthine Oxidase, 6-TIMP:6-thio ionosine 
monophosphate, 6-TXMP:6-thioxanthine monophosphate, 6-TGMP:6-thioguanine 
monophosphate, 6-TGDP: 6-thioguanine diphosphate, 6-TGTP: 6-thioguanine triphosphate, 6-
TITP: 6-thi inosine triphosphate, 6-MeMP: 6-methyl mercaptopurine, xo: Xanthine Oxidase, 
IMPDH: inosine monophosphate dehydrogenase, HGPRT: hypoxanthine phosphoribosyl 
transferase 
 









1.3.1.4  Pharmacogenetics and Metabolite monitoring    
 
1.3.1.4.1  TPMT 
 
The pharmacogenetic influence of TPMT on AZA metabolism remains one of the great success 
stories in this field. Although, it is clinical application has been indirect with TPMT phenotype 
rather than genotype finding widespread use, it is clear that the findings of the genetic influence 
was crucial. A number of single nucleotide polymorphisms (SNPs) for TPMT have been 
identified.  The nomenclature is defined and follows clear criterion for clarity. The gene and the 
allele are separated by an asterisk and the alleles are represented as Arabic numerals. Further 
nucleotide changes are assigned letters that follow the Arabic numeral. The nucleotide numbering 
starts at A in the ATG start codon and are designated +1 [482]. Most of these are rare other than 
the *3A/C alleles. The nucleotide changes for TPMT*3A are 460G>A and 719A>G, TPMT*3B is 
460G>A and TPMT*3C is 719A>G [482]. Nearly 90% of Caucasian people have a wild type 
genotype (*1/*1) and subsequently normal TPMT enzymatic activity.  10% of this population are 
heterozygous (*1/*3) and have reduced TPMT activity, which may be as low as 50% of wild type 
activity. One in 300 individuals are homozygous mutants or compound heterozygotes (*3/*3) and 
have no TPMT activity [257]. This usually correlates with enzyme assays performed by high 
performance liquid chromatography (HPLC) and the combination of the two identifies accurately 
the one in 300 individuals at risk of profound haematological toxicity when treated with 
thiopurines in the standard dose [258]. Heterozygous individuals with intermediate TPMT 
activity also have a high risk of haematological side-effects when treated with standard doses of 
AZA [259].  Myelosuppression on AZA therapy occurs in up to 5% of patients [260] and this is 
thought to be dose related effect due to a elevated 6-TGN. Gastrointestinal side effects were not 
influenced by TPMT activity and the majority of individuals with haematological toxicity do not 
have impaired TPMT [261]. TPMT heterozygosity can lead to GI intolerance if individuals are 
exposed to full dose AZA (2- 2.5 mg/kg). This often leads to withdraw from therapy [262, 263] 




Since the majority of drug side effects to AZA and 6-MP are not attributable to variation in 
TPMT activity, other genetic influences have been explored. The enzyme, Inosine triphosphate 
pyrophosphatase (ITPA), mediates a futile cycle in purine metabolism [265]. In an individual 
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with low ITPA activity, exposure to AZA leads to accumulation of the methylated thio-ITP which 
may be toxic [266]. The ITPA 94A>C mutation has been implicated in causing rash, flu like side 
effects and pancreatitis and haematological toxicity in some cohorts but not in others. The clinical 
application is therefore currently uncertain. 
 
1.3.1.4.3   Xanthine oxidase/dehydrogenase and Aldehyde oxidase 
 
A recent report has suggested that a polymorphism in XDH appeared protective against side 
effects on AZA or 6-MP and that an additional polymorphism in the AOX gene reduces response 
to AZA therapy [267]. These findings are preliminary and require replication. 
 
1.3.1.4.4 IMPDH and HGPRT 
 
The central role of IMPDH makes it a likely candidate for inter-individual variation in activity 
and hence pharmacogenetic influence. However this has not proved to be the case to date [268]. 
HGPRT deficiency or genetic variation reducing enzymatic activity would also be predicted to 
have pharmacogenetic influence. However, the deficient state is not consistent with significant 
survival and is therefore not clinically relevant [269]. 
 
1.3.1.4.5  Glutathione-S-transferase (GST) 
 
Glutathione-S-transferase (GST) activity also varies according to genetic polymorphism. 
Polymorphism in GST-M1 has been shown to increase risk of lymphopenia in patients on 
thiopurines [270] rather than the expected hepatotoxicity and pancreatitis. 
 
1.3.1.5   Adverse Effects 
 
As previously described, adverse effects rates range from 5-13 % and two categories are 
described. 
 
1. Idiosyncratic ( dose independent) 
Up to 6.5% of individuals have idiosyncratic side effects including nausea, fever, rash, flu like 
illness, pancreatitis, hepatitis and arthralgia. These symptoms often occur within 4 weeks of 
starting therapy and recur on re-challenge. In some cases, particularly nausea on AZA, side 
 57 
effects can be overcome by switching to 6-MP suggesting involvement of the nitro-imidazole 
moiety [271]. Switching to 6-MP is not advisable in those individuals who have experienced 
acute pancreatitis. 
 
2. Dose dependent 
Myelotoxicity is dose dependent and occurs in 1.4% – 5% of patients [260, 272]. It can be caused 
by TPMT deficiency, TGN excess, viral infections, co medication such as 5-ASA, aspirin, 
allopurinol, frusemide, MTX and potentially INFX. It can occur at any time from the start of 
treatment up to 11 years and [210] and is managed by dose reduction or withdrawal of therapy. 
Hepatotoxicity is well known but relatively infrequent occurring in around 5% of patients [273]. 
It is usually detected as an elevation in liver enzymes and the patients are often symptomatic with 
fatigue, nausea and headaches. Withdrawal or dose reduction leads to resolution of symptoms 
[272]. Other more unusual conditions due to veno occlusive disorders may be seen. 
 
 
1.3.1.6   Clinical applications of AZA/6-MP in IBD 
 
The hospitalization rates for patients with CD have declined [274] and may imply an 
improvement in the management of the chronic inflammatory state by immunomodulatory 
medication. It is recognized that 5 ASA medications is inefficacious in CD, and that steroids 
cause cumulative problems. It may be reasonable to attribute this is decline in hospitalisation rates 
to increases in the clinical use of AZA or 6-MP. 
 
AZA and probably the equivalent 6-MP are effective in the induction of a clinical remission in 
individuals with active CD. It is effective in 54% of treated patients as opposed to a 34% efficacy 
for placebo. This gives an OR (odds ratio) of 2.4 (95% CI 1.6- 3.6) and a number needed to treat 
(NNT) of 5 for clinical efficacy. However, the time to effect may be prolonged and use as the sole 
agent in therapy is not easy. Steroids are often required for symptom control and improve the OR 
for response to 2.6 (95%CI 1.6 – 4). A steroid sparing effect is prominent and the OR of 
achieving a reduction in steroid dosage but not necessarily complete withdrawal is 3.6 (95% CI 2- 
6.4) [203, 204]. 
 
AZA is effective in maintaining a remission that has been induced with or without steroids. The 
OR is 2.3 (95% CI 1.55 to 3.5) with an NNT of 6. 6-MP has a slightly higher OR (3.32, CI 1.4 to 
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7.8) on the back of a smaller group of patients. A dose response and a steroid sparing effect are 
seen. The OR for response increases from 1.2 to 4.13 as the dose increases from 1mg/kg to 2.5 
mg/kg per day. The risk of side effects increases on treatment when compared with placebo 
[203,204]. 
 
The evidence for AZA/6-MP in the maintenance of a remission in UC has been more uncertain 
but a recent meta analysis [210] and “second look” [275] have both found that it is effective in 




Duration of treatment with thiopurines in IBD 
 
An observational study by the GETAID group in patients with CD demonstrated that after four 
years of therapy, the longer the duration of remission on AZA therapy, the lower the risk of 
relapse [277]. A report from the Oxford group on a 30 year experience of the use of AZA 
demonstrated that prolonged use was safe and effective in the long term with 60% of individuals 
maintaining a remission up to 5 years [278]. However on subsequent investigation, in a placebo-
controlled trial it was evident that prolonged AZA administration maintained a greater proportion 
of patients in remission [235]. Similar findings were reported by the Oxford Group [278] and this, 
associated with the recognition of a low risk of cumulative side effect rates on prolonged 
treatment and, it is now conventional for patients with CD to maintain long-term therapy. 
 
The mechanism of action has always lent itself to anxieties about the risk of malignancy on long 
term therapy. As described, the details of the mechanisms involved are unclear but all the 
proposed options could increase risk of carcinogenesis. There have been concerns about risk of 
cervical cancer, colorectal carcinoma and lymphoma. On balance it appears that the 
lymphoma/leukaemia risk is the most significant but taken in light of the low risk of one extra 
lymphoma in 300- 1400 years of treatment, it seems reasonable to recommend continued therapy 
[279]. It may be beneficial to monitor metabolite levels in those on established therapy with a 
view to minimizing the risk of persistently supra-therapeutic TGN levels and subsequent DNA 
instability. This approach has not been evaluated and will be difficult to examine in light of the 




1.3.2    Methotrexate 
 
1.3.2.1    The Folate pathway  
 
Folates are water-soluble B vitamins required for normal cell growth and metabolism. They play 
an essential role in 1-carbon metabolism and the subsequent biosynthesis of purines, thymidylate 
and other amino acids [280]. Polyglutamated dietary folates undergo deconjugation by folyl 
polyglutamate hydrolase in the intestine cell wall to the monoglutamate form and are then 
transported to the liver.  
 
Cellular transport is mediated by the bi-directional, high-capacity pH transporter molecule; 
reduced folate carrier (RFC) [281, 282]. Within the cell, folylylpolyglutamate synthase (FGPS) 
mediates the sequential addition of glutamate residues onto the proximal glutamate of folic acid 
increasing the chain length. Increased polarity and cofactor affinity results [283] and keeps the 
molecule within the cell. Gammaglutamate hydrolase (GGH) mediates the removal of 
polyglutamate groups. This balance of polyglutamation and deglutamation maintains high 
intracellular folate levels; 1-10 μmol compared to 10nMol/L in the plasma [284]. These folates 
are reduced to dihydrofolate (DHF) and then to tetrahydrofolate (THF) by dihydrofolate reductase 
(DHFR). The addition of a hydroxy methyl group forms 5-10, methylene tetrahydrofolate (5, 10-
CH2-THF). Methylene tetrahydrofolate reductase (MTHFR) is a critical enzyme and mediates the 
irreversible donation of a methyl group from 5, 10-CH2-THF creating all the circulating folate or 
5-methyl THF. A methyl group is donated towards the remethylation of homocysteine from 
methionine. This is the precursor of S-adenosyl methionine (SAM), the universal methyl donor 
important in many reactions including DNA methylation [285]. In effect, MTHFR diverts DNA 
synthetic activity towards DNA methylation. 5, 10-CH2-THF is also a cofactor for the enzyme 
thymidylate synthase (TS) and transfers a one carbon unit from dUMP (deoxyuridine 
monophosphate) to dTMP (thymidine monophosphate) [286].  
 
Reduced folate derivatives including 10-formyl-THF provide one carbon units for de novo 
purines synthesis. Glycinamide ribonucleotide transformylase (GARTF) contributes to the 
imidazole ring of purines and 5-aminoimidazole-4- carboxamide ribonucleotide transformylase 







dTMP: deoxy thymidine monophosphate, dUMP: deoxy uridine monophosphate, TYMS: thymidylate 
synthase, DHFR: dihydrofolate reductase, ATIC : 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase, MTR: methionine synthase, MTHFD1: methylene tetrahydrofolate dehydrogenase, 
AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide, IMP: inosine monophosphate, AMP: adenosine 
monophosphate, AdoMet : S- adenosyl methioninse/SAM, AdoHcy : S adenosyl homocysteine /SAH 
 
Enzymes in red are inhibited by Methotrexate. Folate pathway enzymes not affected by MTX are 
coloured pink. Folates are coloured blue and the methionine /homocysteine pathway is coloured 
purple. 
 









1.3.2.2   A history of Methotrexate 
 
Following the discovery of antibiotics, a growth factor essential to the bacterium Lactobacillus 
casei was isolated and identified as folic acid. When administered to patients with leukemia, a 
symptomatic deterioration was observed [283].  The pursuit of a hypothesis that a folate 
antagonist would be a therapeutic option led to the synthesis of aminopterin. This was created by 
a substitution of the hydroxyl group at position 4 of a pteridine ring of folic acid for an amino 
[287].  This key change allows for the tight binding and inhibition of DHFR although this was not 
recognised initially.  
 
Aminopterin's toxicity led to a search for a superior alternative. Methotrexate (MTX), a 4-amino 
10-methyl substituted analogue, initially used in childhood acute lymphoblastic leukaemia, went 




Figure 1-11  Chemical structure of Methotrexate 
 
 
Interesting observations on the resistance of acute myeloid leukaemia to methotrexate and the 
sensitivity of acute lymphoblastic leukaemia to the same drug provided impetus to the study of 
resistance mechanisms. This intrinsic difference appeared to be due to defective polyglutamation 








1.3.2.3   The mechanism of action of Methotrexate  
 
After the development of MTX in 1948 by Farber et al, it quickly found clinical application in 
RA [288] albeit without any real understanding of mechanistic influences. Since then, 
considerable progress has been made.   Aldehyde oxidase (AOX) mediates the hepatic oxidation 
of MTX to its primary metabolite 7- hydroxy MTX (7-OH MTX) [289].  7 -OH MTX is the 
dominant anti folate 42 hours after administration. Like MTX, and with a similar affinity, 
SLC19A1 allows the cellular influx of 7-OH MTX [290]. Inside tumour cells, 7-OH MTX is a 
good substrate for FGPS allowing a high level of polyglutamation [291, 292].  However, the 
resulting 7-OH derivatives are inferior DHFR inhibitors diminishing the cytotoxic efficacy of 
MTX [293]. 
 
MTX competes with folates for active transport by the low capacity transporter [294] SLC19A1 
and the alternative folate transporters [295] into the cell.  Efflux is mediated by ATP-binding 
cassette (ABCC1-5, ABCG2) transporters and breast cancer receptor protein (BCRP) [296, 297]. 
Intracellularly, MTX tightly binds DHFR and subsequently dihydrofolate (DHF) accumulates. 
FGPS mediated polyglutamation increases the intracellular half life of MTX [298]. GGH 
sequentially removes the polyglutamate allowing efflux of MTX from the cell. When 
polyglutamates accumulate, DHFR, TS, AICARTF and ADA [299-301] inhibition is evident. 
 
DHFR is a key enzyme in the folate pathway and generates 5–methyl-THF. This donates a methyl 
group and allows for the conversion of homocysteine to methionine.  Methionine is required for 
the synthesis of SAM, which is further converted to s-adenosyl homocystine (SAH) [302].  In a 
normal cell, DHFR activity is higher than the activity of TS.  Therefore, DHF is present at low 
levels. Consequently, a small amount of DHFR activity fulfils the cellular need and DHFR 
inhibition leads to a profound failure of the regeneration of THF from the DHF. 
 
MTX affects TS in two ways.  There is a failure of downstream pathways dependent on 5-10-
methylene tetrahydrofolate as a substrate; particularly TS catalysed dTMP formation from dUMP 
[303, 304].  MTX also directly inhibits TS. The effects are profound with partial depletion in the 
TS substrate, 5-10- methylene tetrahydrofolate [305], deoxythymidylate monophosphate (dTMP) 
depletion, mis-incorporation of the uracil cell base into DNA, chromosomal damage and 
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subsequent cell death. Also known as thimydineless death, this term emphasises the importance 
of the effect on TS [306] 
 
Methotrexate does not directly affect MTHFR but variant enzymatic activity  along with the 
MTX induced folate pool depletion, leads to a profound loss of 5-methyl THF and subsequent 
vitamin B12 dependent remethylation of homocysteine to methionine [307]. The downstream loss 
of SAM is manifest in the defective methylation of nucleotides in DNA, RNA and proteins [308].   
 
However, some clinical experience and controlled randomised studies in RA demonstrate that 
oral folate supplementation does not modify response to low dose MTX therapy but instead 
reduces complications attributable to the antiproliferative effects of MTX and hepatotoxicity 
[309]. This suggests that folate independent mechanisms are at play. MTX also mediates 
important effects on purine metabolism. The polyglutamated form competitively inhibits 
AICARTASE/ATIC [310] and AICAR accumulates [311].  AICAR riboside inhibits the catalytic 
activity of adenosine deaminase (ADA) and AMP deaminase [301, 310]. ADA is also affected by 
competitive inhibition by MTX [312]. The resulting accumulation of adenine and adenosine 
nucleotides leads to extracellular release and subsequent conversion by extra cellular 5’ 
nucleotidase to adenosine [313]. Adenosine is difficult to investigate or measure due to a short 
half-life but elegant experiments have demonstrated that adenosine receptor antagonists and 
adenosine inactivators such as ADA reversed the effects of MTX on leucocyte accumulation in an 
animal model [314, 315]. Adenosine inhibitors such as theophylline and caffeine reverse the 
development of adjuvant arthritis in an animal model [316] and caffeine consumption reduces the 
efficacy of methotrexate in humans with RA [317]. In animal experiments, the anti-inflammatory 
effects of MTX appear to be mediated by adenosine receptors A2A and A3 [318]. Some conflicting 
evidence has been provided where in an animal model, the anti inflammatory effects of MTX 
were not abolished by adenosine receptor antagonists but instead by folic acid supplementation 
[319]. The doses of MTX used were considerably higher than in earlier experiments and is an 
illustration of the differences between low dose and high dose MTX therapy.  
 
 
The effect of MTX on Cytokines 
 
The normal cytokine production following T-cell activation in whole blood cultures is inhibited 
by methotrexate.  IL-4, IL-6, IL13, TNF- α, interferon-gamma (IFN-γ) and GM-CSF are reduced. 
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The addition of folic acid, hypoxanthine and thymidine, or adenosine reversed the inhibitory 
effects of methotrexate suggesting that the cytokine inhibition followed de novo synthesis of 
purines and pyrimidines.  Furthermore, cytokine production by monocytes is modest [312, 320-
323]. MTX did not affect LPS induced cytokine IL-1β or TNF-α alpha release in monocytes. 
[324]. A sex differential on the anti-inflammatory effect of MTX on monocytic cells has been 
suggested, which may explain an observed increase efficacy of MTX in male patients [325]. 
 
MTX affects the cytokines via the NF-κB signalling pathway. TNF alpha binding activates this 
pathway, which subsequently upregulates a variety of genes. MTX inhibits IκBα.  Consequently 
NF-κB stays in the cytoplasm and the signalling pathway is not activated [326]. 
 
Other possible mechanisms of therapeutic efficacy of low dose Methotrexate  
 
Another proposed mechanism is that MTX inhibits the generation of polyamines which in turn 
generate lymphotoxic NH3 and H2O2. This occurs as a consequence of the previously described 
decrease in SAM which in turn is required for the methylation and synthesis of spermine and 
spermidine as reviewed by Cronstein [327]. 
 
Other mechanisms have been explored and some evidence suggests that the effects of MTX in 
vivo may be due to T-cell apoptosis, modified cytokine production and reduced T cell 
proliferation. A role for intracellular reactive oxygen species (ROS) levels, inhibition of 
pyrimidine pathway enzymes and increasing CD95 sensitivity of CD 45+RO cells (activated T-
cells) has been demonstrated. The correlation between apoptosis and ROS generation was shown 
in lymphocytic cell lines but not in monocytes. This may be due to a higher level of antioxidants 
in monocytes preventing ROS induced apoptosis. MTX induces ROS in a time and concentration 
dependent manner [328, 329]. 
 
Further evidence for methotrexate induced apoptosis is seen on prolonged incubation of activated 
T-cells with MTX leading to a CD95 sensitive state.  CD95 is a member of the death receptor 
family.  This increased sensitivity was seen with CD 45+ plus RO cells [330]. 
 
Methotrexate may be more beneficial in active RA, rather than exhibiting a general 
antiproliferative state in RA.  This has been inferred from the reduction of the CD4+ CD28 + cell 
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population and the CD4+CD28- population in active RA.  In non-active RA, these cell 
populations were unaffected [329] 
 
 
1.3.2.4   Methotrexate Pharmacokinetics 
 
The dosage used is important and the route of administration may be too, although this is less 
certain. A distinct lack of consensus about the optimal mode of administration in IBD has 
contributed to the uncertainty regarding the place of MTX in the therapeutic strategy for CD 
[331]. Variability in bioavailability following oral administration (80-25%) has led to 
recommendations for parenteral administration. However, food does not modify absorption [332] 
and subcutaneous dosing is comparable to IM administration with a bioavailability of more than 
80% [333]. The drug is absorbed from the proximal intestine by relatively specific transport 
mechanisms and is not reduced in patients with small bowel CD. Bioavailability of the drug has 
been reported to drop on dose escalation [334], but the result is insignificant in the doses used for 
IBD [335].  
 
A report of the Edinburgh experience in the treatment of  39 CD patients where the excellent 
initial response to IM MTX (71%) was lost over 50 weeks with a probability of relapse of 78% 
appears to supports the preference for parenteral administration, but in fact there were a 
considerable number of steroid dependent patients in the oral conversion group. These individuals 
could be considered to be MTX treatment failures that were steroid dependent and relapsed when 
the steroids were tapered [336]. It could also be a result of the described effect of steroid use 
increasing intracellular polyglutamate levels [337] which then drop when the steroids are 
withdrawn. Furthermore, the impact of diminished adherence is difficult to estimate. There is 
considerable inter-individual variation in the intracellular levels of the polyglutamated form of 
MTX. These are proposed to correlate with clinical response to MTX in RA [338] but the 
variability makes clinical application difficult [339]. Notwithstanding this, the results of dosing 
studies on intracellular polyglutamation levels clearly demonstrate that higher levels are achieved 
with higher dosages [337] and possibly, parenteral dosing. The use of the parenteral route is 
recommended in practice guidelines but it is thought that a switch to oral therapy would be 
preferred by patients [222]. 
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The predominant renal clearance of the drug means that patients with renal impairment are at risk 
for toxicity [340]. Owing to its significant intrahepatic recirculation and the persistence of a 




1.3.2.5   The use of MTX in the Inflammatory Bowel Diseases 
 
Immunosuppressive medication is used in patients who are steroid responsive but dependent or 
those who are steroid refractory [204]. In CD, these are primarily the thiopurines (AZA/6-MP) 
and MTX and both are similar in efficacy and tolerability [342, 343]. However, clinical 
experience and the volume of trial evidence have made AZA/6-MP fist choice. MTX is an option 
for remission induction and maintenance of that remission in those resistant or intolerant to 
AZA/6-MP [203].  
 
MTX use was first described in the treatment of patients with IBD in a small, uncontrolled study 
of 21 patients (14 with CD and 7 with UC). Almost all patients had either failed to respond to or 
tolerate AZA/6-MP and were steroid dependent. After an initial induction dose of 25mg IM for 
12 weeks, a dose reduction to 15 mg orally was undertaken in responders. Sixteen patients (11/14 
CD and 5/7 UC) responded to treatment with significant improvement in CDAI and UC activity 
indices and a reduction in steroid usage. 30 % were able to withdraw from steroids. Mucosal 
healing was noted in 4/14 CD (4 of the 11 responders, 36%) and 0/7 UC patients. Side effects 
were minor (transaminitis in 2, nausea in 2, minor leucopenia in 1 and minor pneumonitis in 1). 
Folate supplementation was not used. [344]   
 
The much quoted study by Feagan et al reported in 1995 was a randomised, double-blind, placebo 
controlled, multicentre study of 141 patients with steroid dependent CD. Patients received weekly 
injections of MTX (25 mg/week IM) and a prednisolone taper from 20 mg/day was attempted. 
37/94 (39%) in the treatment group as opposed to 9/47 (19%) in the placebo group were free of 
steroids and in a clinical remission as per CDAI (p=0.026, RR 1.95, CI= 1.09 – 3.48). Steroid use 
and mean CDAI was lower in the MTX group. Sixteen patients (16/94, 17%) in the MTX group 
withdrew because of side effects versus 1/47 (2%) in the placebo group. The reasons for 
withdrawal were liver function test (LFT) abnormalities in 7, nausea in 6, skin rash in 1, 
pneumonia in 1 and optic neuritis in 1. The incidence of minor side effects allowing continuing 
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treatment was not significantly different between the study group and placebo patients. Folate 
supplementation was not used [345]. 
 
Another randomized double-blind placebo-controlled trial of MTX in 33 patients with steroid 
dependent CD was reported a year later.  One third of these had previously failed treatment with a 
thiopurine.  Patients were given placebo or oral MTX 15 mg per week, adjusted up to 22.5 mg per 
week for up to 12 months in responders. 28 patients completed the study 13 patients received 
MTX and 15 received placebo. 46% of MTX treated patients relapsed, as compared to 80% of 
placebo treated patients.  Due to the small numbers examined this did not reach statistical 
significance. There was a non significant trend towards increased number of significant side-
effects in the MTX group (3/13 or 23%) as compared to placebo group (0/15 or 0%). Folate 
supplementation was not offered [346].  
 
Feagan et al conducted another randomised, multicentre, placebo-controlled trial of 76 patients 
with chronic active CD, who had previously entered remission with 25 mg of methotrexate/week 
by IM injection for 16 weeks.  Remission was defined as a withdrawal of steroids and the 
maintenance of a score of 150 or less on CDAI. 40 patients received MTX and 36 received 
placebo. The methotrexate group received 15 mg/week, IM for 40 weeks, no other treatments 
were permitted. At the end of the study, significantly more patients in the MTX group remained 
in remission (26/40 or 65% versus 14/36 or 39%). Steroid usage was less in the MTX group (28% 
versus 58%).  Some of the patients who relapsed (n= 22) were re-induced with 25 mg/week MTX 
administered IM.  Of these, 12/22 (55%) regained their remission and successfully withdrew from 
steroid treatment.  Of those who did not receive methotrexate after relapse 2/14 (14%) were in 
remission at week 40. None of the patients in the methotrexate group had a severe adverse event.  
Symptoms attributable to active inflammatory bowel disease were more common in the placebo 
group (abdominal pain, fatigue, diarrhoea, joint pain).  Nausea and vomiting, was more common 
in the methotrexate group 16/40 (40%).  One patient in the MTX group withdrew from treatment 
because of nausea. No patients suffered significant haematological or pulmonary complications. 
Folate supplementation was not used [347]. 
 
In a double blinded, randomised study from Milan, 54 patients with steroid dependent CD were 
treated with IV Methotrexate 25 mg/week or 2 milligram/kg/day of AZA. A steroid taper was 
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attempted in all patients. After the first three months, IV methotrexate was changed to the oral 
formulation in the same dose. No significant difference was found between the two regimen to 
clinical response at three or six months (6 month response- methotrexate 56%, AZA 63%, p = 
0.39). 3/27 (11%) patients treated with methotrexate (thrombocytopenia-1, leuco 
thrombocytopenia-1, hepatitis-1) and the same number in the AZA group (fever/headache-1, 
pancreatitis-1, hepatitis-1) withdrew from the trial due to adverse events. One patient in each 
group required dose reduction for control of leucopenia and impaired LFT.  Toxicity such as 
nausea and vomiting, not requiring withdrawn from treatment were more commonly seen in the 
methotrexate group (44%) vs 7% in the AZA group. Folic acid was not administered [342]. 
 
 
Table 1-4   Effectiveness of Low Dose MTX in Induction (I) and Maintenance (M) of 









Control    
Feagan 
et al CD 37/94 4/47 0.016 2.741 [345] 
Oren et 
al UC 14/30 18/37 0.872 0.959 [350] 
Arora et 
al CD 6/13 3/15 0.147 3.429 [346] 
Feagan 
et al CD 26/40 14/36 0.024 2.918 [347] 
 
(Modified from Schroder et al. [348]) 
 
 
Methotrexate in Ulcerative colitis 
 
Another group investigated MTX use in both UC (n=8) and CD (n=11) in a non-randomised open 
labelled fashion. All patients were steroid dependent. The majority of CD patients (10/11) had 
failed AZA/6-MP treatment and 2/6 patients with UC had received prior AZA/6-MP. Treatment 
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was started in an escalating fashion from 2.5 mg up to 15 mg orally until completion at week 18. 
Steroid reduction was successful in all those with CD who completed the study (10/11) and 2 /10 
were free of steroids at the end of the study. No patients with UC had a complete response but a 
partial response was seen in 3/6 patients with evidence of endoscopic improvement. Side effects 
were mild. One patient developed headache leading to withdrawal from the study. 5 patients had 
mild stomatitis, 1 had mild alopecia, 1 had nausea/vomiting and 1 had cutaneous flushing. Folate 
supplementation was not used [349]. 
 
A trial on 72 steroid dependent IBD patients (UC n=34 and CD n=38) compared the efficacy of 
1.5 mg/KG/day of 6 -MP or 15 mg/week of MTX or 3 g/day of 5- ASA. No placebo group was 
included.  Folic acid was not used. In UC 6-MP (79% response) was superior to MTX (58% 
response) and 5- ASA (25 % response) in remission induction [343]. 
 
An Israeli group have performed a double-blind, randomised, and controlled trial of MTX in UC. 
30 patients with confirmed UC and moderate or severe disease were randomised to receive 
placebo or MTX at a dose of 12.5 mg taken orally per week. Folic acid was not prescribed. 
Patients were treated for nine months without any dose adjustment. No significant differences 
were noted between the two groups in steroid use, symptom scores or side effects. Significantly 
more patients in the placebo group withdrew from the study [350]. The dose of MTX used is 
thought to be sub therapeutic. The limitations in these studies have led to MTX not finding a 




1.3.2.6   Mucosal Healing with methotrexate 
 
In a letter to the editor, Manosa et al. have described their experience of serial colonoscopy in 
patients with CD treated with IM/SC MTX and initial dose of 25 mg per week 16 weeks followed 
by a dose reduction to 15 mg per week for long-term maintenance. All patients had previously 
received MTX, and either been intolerant (4) or unresponsive (4). All patients had been steroid 
dependent and all had achieved a steroid free remission. In this group, mucosal healing was seen 
in 5/8 patients (3 had complete healing and 2 had partial healing). All those with complete 
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mucosal healing had been individuals with isolated colonic disease [239]. Other data in abstract 
form is also referenced in their letter and may indicate a role in mucosal healing. This remains 
unproven at the current time. 
 
 
1.3.2.7  Methotrexate toxicity 
 
Significant toxicity leading to drug discontinuation can be limiting factor in RA therapy occurring 
in up to 30% of patients [351]. In IBD, side-effects appeared to be less common, leading to 
treatment withdrawal in 10 to 18 % [352].   
 







Leucopenia Pneumonitis LFT Abnormalities Reference 
69 weeks 67 0 1 0 [344] 
12 weeks 19 0 0 0 [349] 
16 weeks 94 0 0 7 [345] 
40 weeks 40 0 0 0 [347] 
9 months 26 0 0 0 [466] 
9 months 30 1 0 0 [350] 
6 months 20 0 0 3 [467] 
16 weeks 32 0 0 1 [468] 
16 weeks 9 0 0 3 [346] 
17 months 70 3 0 2 (1 steatosis, 1 normal) [278] 




Reproduced from Fraser et al. [352] 
 
 
Folate depletion mediated gastrointestinal toxicity such as nausea, vomiting, diarrhoea; 
abdominal pain and stomatitis are often the earliest features occurring in up to 60% [353, 354] 
and are manifestations of the antiproliferative effect of MTX. 
Folate supplementation relieves some of these side effects without an associated fall in 
therapeutic efficacy. Usually, nausea may be minimised by a change in time of administration or 
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the route of administration (from oral to parenteral). Pancytopenia is relatively rare effecting 1 to 
2% of patients and may be ameliorated by folate supplementation.   
A hepatitic LFT picture is not unusual, particularly in the early stages of treatment. These are 
usually self-limiting and require no intervention. Some abnormalities remain persistent and may 
require dose adjustment or drug withdrawal. Liver fibrosis has been observed in patients with 
psoriasis, when treated with methotrexate and 50% of baseline liver biopsies in patients with 
psoriasis are abnormal. This has been attributed to excessive alcohol intake, NSAID drug use, 
diabetes and obesity.   
 
Unlike psoriasis, where a cumulative MTX dosage greater than 4g contributes to irreversible 
hepatotoxicity [355], MTX is relatively less hepatotoxic in RA. MTX therapy in RA continued 
over a period of five years appears to increase the incidence of cirrhosis and liver failure with an 
incidence of 1: 1000.  [356]. Hepatoxicity appears even rarer in IBD. A retrospective analysis of 
liver biopsies in patients with IBD who received a cumulative does in excess of 1.5g MTX 
showed cirrhotic changes in 1 out of 20 patients. LFT surveillance did not prospectively identify 
this patient. Currently, surveillance liver biopsies are not recommended [286] by some but are by 
others [212, 222] in IBD patients. The protocol recommended is the same as in RA (liver biopsy 
if a majority of AST values over 1 year are elevated or hypoalbuminemia is present). Pulmonary 
pneumonitis has been reported in IBD with an estimated prevalence of two to three cases per 100 
case years.  Recovery appears to be usual although mortality rates of of up to 17% have been 
reported [357-360].  
 
Low dose MTX does not appear to increase the risk of malignancy and infections possibly as the 
drug is not incorporated into nucleic acids. [361-363]. Positive effects on homocystine 
metabolism [364] have been implicated in the reduced lower mortality hazard ratio (0.4) for RA 
patients treated with methotrexate. 
 
Furthermore, caution in the use of MTX is recommended in individuals at risk of toxicity. These 
are diabetes, obesity, excessive alcohol intake, elevated baseline transaminase levels, clinically 






1.3.2.8   Folate supplementation 
 
Oral folate supplementation seems to diminish intracellular polyglutamation of MTX in psoriasis 
[365] and RA [337]. The use of supplemental folates, including folic acid and folinic acid 
improves adherence to therapy by reducing LFT abnormalities and GI intolerance. Folate 
supplementation does not appear to reduce the effectiveness of MTX in the therapy of RA. It may 




Table 1-6 The suggested use for folates in patients taking MTX 
 
 




All patients on MTX 
5mg – 10 mg once a 
week by mouth the 
morning after MTX 
Reduction of side 










15 mg by mouth 







Reproduced from Whittle et al. [366] 
 
 
1.3.2.9  The application of Pharmacogenetics to Methotrexate use in inflammatory diseases  
 
1.3.2.9.1   MTHFR 
 
MTHFR is the most studied in this aspect. The gene is mapped to chromosome 1p36.3 and 15 
polymorphisms within the MTHFR gene have been described [307].  Of these, two non-
synonymous SNPs, 677C>T and 1298A>C are the most studied. The resulting MTHFR 
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thermolability due to the 677C>T allows for plasma homocysteinemia and low serum folate 
levels [370, 371].  
 
The MTHFR gene is mapped to chromosome 1p36.3 and 15 polymorphisms within the MTHFR 
gene have been described [307]. It consists of eleven exons. The 677 C>T and the 1298 A>C 
variants have been associated with decreased enzymatic activity. Other polymorphisms have been 
described and are associated with undetectable levels of enzymatic activity. 
 
 The resulting MTHFR thermolability due to the 677C>T allows for plasma homocysteinemia 
and low serum folate levels [370, 371]. At the 677 position 15% of Caucasians and Asians are 
homozygous for TT and 50% are heterozygous. With an allele frequency of 35 % in North 
America, this SNP causes an Alanine to valine substitution at codon 222 of the MTHFR gene 
[371]. At the 1298 position the mutant homozygote CC occurs in 12% of Caucasians and has an 
allele frequency of 33% in the same populations [372]. These mutations have important effects. 
The mutant homozygous MTHFR677TT carrier exhibits 30% of the activity of MTHFR expected 
of a wild type. The heterozygote genotype has 60% of wild type activity [370, 371]. The 
1298A>C SNP causes a glutamine to alanine substitution at codon 429 [373]. The resulting 
impaired activity is not due to thermolability, is relatively mild and does not influence plasma 
homocysteine levels in isolation. The MTHFR1298CC (homozygous mutant) exhibits 60% of the 
enzymatic activity of a wild type genotype and 60% as a heterozygote [373, 374]. High folate 
states as seen in folate supplementation influences the stability of the mutant thermolabile enzyme 
making it more stable [375]. In folate deficient states, the homozygous mutant MTHFR677TT 
carriers show deficient DNA methylation. Similar findings have been reported in vitro 
lymphocytes from MTHFR1298AA wild type which has been attributed to strong LD with 
MTHFR677TT in that study population [376, 377].   
 
The two polymorphisms are in strong LD and the genotype polymorphic at both loci is very rare 
(MTHFR677TT/1298CC) [378]. The compound hetrozygote of the two polymorphisms impart a 
greater reduction in the enzymatic activity than either of the two homozygous mutants on their 
own [373] and is relatively common in Caucasians with a prevalence of 15-23% [379].  The 
estimated haplotype frequencies, and the fractional contribution of each, were 677C/1298A, 0.37; 
677C/1298C, 0.31; 677T/1298A, 0.32; and 677T/1298C, 0.0023 to 0.0034. Thus, a vast majority 





1.3.2.9.2   Thymidylate synthase 
 
Thymidylate synthase is inhibited directly by polyglutamated MTX and indirectly by folate 
cofactor depletion induced by MTX. The inhibition causes deoxythymidylate monophosphate 
(dTMP) depletion, mis-incorporation of the uracil cell base into DNA, chromosomal damage and 
subsequent cell death [368]. Three important polymorphisms have been described. A tandem 
repeat sequence of 28 base pairs within the 5′ untranslated region (UTR) can contain a variable 
number of repeats; either 2 or 3. An increasing number of sequences are associated with 
increasing enzyme efficiency in vitro. Homozygosity for the triple repeat allele TSER *3R/*3R is 
associated with greater mRNA than the double repeat allele TSER*2R/*2R [380]. The *3R occurs 
in a frequency of 50% in Caucasians and 60-80% in Asians [381]. The enhanced transcriptional 
activity is attributed to an additional upstream stimulatory factor (USF) protein binding site in the 
3R variant. A G>C polymorphism at position 12 within the second 28bp repeat of the 3R allele 
gives it a transcriptional activity similar to that of the 2R allele due to interference with the 
function of this additional binding site [382].   
 
 A six bp deletion (TTAAAG) at position 1494 in the 3′ UTR of this gene is associated with 
decreased mRNA stability and lower mRNA levels are noted in homozygous carriers of the 
mutant deletion [383]. The polymorphism is found in frequencies of 26 % in Hispanics, 41% in 
Caucasians, 52% in African-Americans and 70% in Chinese [383].   
 
 
1.3.2.9.3   SLC19A1 
 
The SLC19A1 or Reduced folate carrier 1 (RFC-1) gene has been mapped to the long arm of 
chromosome 21 [384, 385].  The role of the reduced folate carrier in cellular transport has already 
been described. SLC19A1 is also responsible for the intestinal absorption of MTX and 
demonstrates saturation at doses of more than 15mg per day [385]. The mutant SLC19A180GG 
occurs in a frequency of 18-25% among Caucasians and Asians and is relatively rarer in Africans 
at 8-15%.  
A SNP in the SLC19A1 gene substitutes arginine with histidine at position 80 in Codon 27. This 






1.3.2.9.4   AICARTase/ATIC 
 
In animal experiments the anti-inflammatory effects of MTX appear to be mediated by adenosine 
receptors A2A and A3 [318]. Adenosine is difficult to investigate and estimate due to a short half-
life but elegant experiments have demonstrated that adenosine receptor antagonists and adenosine 
inactivators such as ADA reversed the effects of MTX on leucocyte accumulation in an animal 
model [314, 315]. Adenosine inhibitors such as theophylline and caffeine reverse the 
development of adjuvant arthritis in an animal model [316] and caffeine consumption reduces the 
efficacy of methotrexate in humans with RA [317]. 
 
Adenosine binds specific receptors A1, A2 a, A2 b, and A3 and knockout mice studies have 
implied a significant role for these receptors [318].  The A1 receptor leads to immune stimulation 
of neutrophils, whereas the A2 a receptor leads to immune suppression [388] and is possibly the 
chief modulator of the anti inflammatory effects.   
 
1.3.2.9.5    Aldehyde oxidase (AOX) 
 
The effect of hepatic AOX on MTX forms 7 -OH MTX. This is the dominant anti folate 42 hours 
after administration. Like MTX, and with a similar affinity, SLC19A1 allows the cellular influx 
of 7-OH MTX [290]. Inside tumour cells, 7-OH MTX is a good FGPS substrate allowing 
exuberant polyglutamation [291, 292].  However, the resulting 7-OH derivatives are inferior 
DHFR inhibitors diminishing the cytotoxic efficacy of MTX [293]. The mutant AOX 3404AG 










Table 1-7  Folate Pathway Pharmacogenetics in inflammatory diseases 
  
MTHFR Generation of 5-methyl THF 
677C>T 
Thermolabile MTHFR 
and decreased plasma 
activity 
1.MTX Toxicity [470] [414] [471, 472] 
2.MTX efficacy [410] 
3.No assoc. with 
toxicity/efficacy [472, 473] 
1298A>C Decreased activity of MTHFR 
1. MTX efficacy and 
toxicity [410] 
2.MTX efficacy [414] [413] 
3.MTX toxicity [392, 474] 
4. No assoc. with 
toxicity/efficacy [473] 
DHFR DHF to THF 473G>A, 35289G>A DNA alignment 
Not assocoiated with 






















repeat Increase TYMS activity 
1.MTX toxicity [389, 473] 
2. MTX poor 
efficacy [423, 473] 
3. No effect on 
toxicity or efficacy [412] 
TYMS 6bp deletion polymorphism 
Decrease TYMS 
stability and expression 
1.MTX Toxicity [473] 
2. No effect on 
toxicity or efficacy [412] 
3. Increased efficacy [473] 
 
 
Table 1-8  Methotrexate Transporter Pharmacogenetics 
 
 
Gene Role of Gene Product Polymorphism Effects on Gene product Clinical Effects Ref 
SLC19A1/ 
RFC-1 MTX influx 80G>A 
May affect 
transcriptional activity 
of gene and reduce 
MTX entry 
Not associated with 




ABCB1 MTX efflux 3435C>T May affect P-gp function  
1.MTX efficacy [475] 
2.Not associated 
with MTX toxicity [471] 
  [476] 
ABCC2 MTX efflux 
1249G>A May affect enzyme 
activity and MTX 
efflux 










Table 1-9  Adenosine pathway Pharmacogenetics 
 
 







activity 1. MTX toxicity [389, 392] 
increases 
adenosine release  
2. Efficacy and 
toxicity [390] 
  3.MTX efficacy [391] 
AMPD1 Converts AMP to IMP C34T Enzyme activity  MTX efficacy [390, 391] 
ITPA Converts ITP to IMP C94A Enzyme activity MTX efficacy [390, 391] 
 
 
















1.3.2.9.6  Pharmacogenetic and Toxicity Indices 
 
It is clear that a single SNP in the MTX metabolic pathway is not going to have sufficient 
penetrance to find application as a predictor of adverse side effects to drug therapy. Instead there 
is now evidence that a variety of genetic mutations can be combined to create an index with 
sufficient predictive power to be clinically significant. 
 
MTHFR, TYMS, ATIC & SHMT 
In a study of 214 patients with RA, 32 patients had side effects. The homozygote mutants 
MTHFR 677TT, TSER*2R/*2R, ATIC 347GG, and SHMT 1420CC were all significant associated 
with a variety of side effects. When combined together as an index, each homozygote genotype 
increased the chance of a side effect by 1.9 in an additive fashion [389]. 
 
AMPD1, ATIC, ITPA, MTR, MTRR & MTHFD1 
Polymorphisms of adenosine pathway enzymes were studied in 205 patients with RA. The ATIC 
347CC, ITPA 94CC and the AMPD134T allele when combined was favourable genotypes and 
increased the chances of a clinical response to MTX (OR 27.8). The ATIC 347C>G was an 
independent marker for toxicity [390]. In another study, 205 patients with RA were genotyped for 
17 polymorphisms in 13 genes and the results were correlated with clinical outcome. The results 
were then validated in a further 38 patients. MTHFD1 1958AA, AMPD1 34CC, ITPA 94A allele 
and ATIC 347G allele.  A scoring system was based on this model was effective in predicting 
60% of responders [391].   
 
GGH, ATIC, MTHFR, MTR, MTRR 
A prospective study of 48 patients and genetic polymorphisms in SLC19A1, GGH, ATIC, 
MTHFR, MTRR, MTR, TSER and SHMT and MTX RBC Polyglutamate levels were correlated 
with clinical response and toxicity. RBC Polyglutamate levels correlated well with drug efficacy 
and a toxigenic index comprised of GGH 401CC, ATIC 347GG, MTHFR 1298C allele, 
MTRR66GG and MTR 2756AA was predictive of toxicity [392]. 
 






1.4  Summary and Aims: 
 
The inflammatory bowel diseases impart a considerable health care burden and most affected 
individuals are in need of regular therapy.  A significant number will need steroids with all their 
attendant risks and side effects. The use of immunomodulatory therapy namely AZA/6-MP and 
MTX clearly reduce steroid requirements but are themselves somewhat limited by their side 
effect profiles and therapeutic ineffectiveness in a significant minority. Furthermore, there is a 
considerable “lag time” to clinical benefits. 
 
Alternatives are available and the newer therapies such as antiTNF drugs (Infliximab and 
Adalumimab) are very efficacious in a large number of patients. Importantly, they have a rapid 
onset of action. However, they too have a significant side effect profile and risk therapeutic 
failure or a loss of clinical effectiveness.  Many individuals will not need these therapies, but will 
instead respond to immunomodulation, given adequate time to respond. Furthermore, there is 
evidence that early healing of the inflamed colonic mucosa is associated with improved outcomes 
and a reduced risk of bowel resections. Equally, the biological therapies are not infrequently, 
compromised by a loss of the early response. Hence the timing of biological therapy is clearly 
important. 
 
As both the commonly used immunomodulatory drugs (AZA/6-MP and MTX) and the anti TNF 
drugs can achieve mucosal healing of the affected intestine, clearly it is important to identify 
those who are most likely to respond to a particular medication early so that time to mucosal 
healing may be minimized. However, currently available indicators do not allow a reliable 
identification of this group. Clinical markers of disease severity are primarily retrospective and it 
can be argued that it reflects existing problems and are not truly predictive. Serological markers, 
genetic markers and algorithms with a combination of these have been evaluated but are still of 
limited value.    
 
Currently, immunosuppressive therapy is instituted relatively inflexibly. The pole position in IBD 
immunomodulatory therapy is occupied by AZA/6-MP. Here, the success of pharmacogenetics 
thus far has been predominantly in finding markers of drug toxicity. Reliable markers of clinical 
efficacy have not been easy to find. Second line therapy is conventionally MTX. Clearly, there 
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will be individuals more likely to respond to MTX than to AZA, as well as those who will not 
respond to either. There are a number of reports of pharmacogenetic markers of MTX efficacy in 
RA and cancer chemotherapy. However, the single study that examined some of these effects in 
IBD was probably some what underpowered to identify the relevant associations. Furthermore the 
important potential of an effect of folate supplementation on the pharmacogenetic markers was 
not examined. Therefore, the primary aim of this thesis is to examine the influence of recognized 
polymorphisms in the Folate Pathway and MTX efflux enzymes and to co-relate these with the 
response to therapy with MTX in individuals with IBD. The moderating influence of oral Folate 
supplementation will also be examined. This is the focus of chapters 3 and 4.   
 
The traditional model of pharmacogenetic investigation has focused on genetic variation in 
metabolic enzymes. On the other hand, the effects of genetic polymorphism in innate and 
adaptative immunity and the influence these have on drug response are complex and obviously 
multifactorial. The HLA-G 14 bp ins/del polymorphisms may have an important influence on 
adaptative immunity and can also influence individual response to immunosuppressive therapy. 
This has not been examined in IBD and is the second main aim of this thesis. The effect of this 
polymorphism on response to MTX and AZA therapy in IBD, the examination of moderating and 





















2 Materials and Methods  
 
 
2.1  Materials 
 
DNA extraction and purification kits were from QIAGEN Ltd. (Crawley, West Sussex, and UK). 
Primers were from MWG-Biotech AG (Ebersberg, Germany). Taq DNA polymerase, agarose 
electrophoresis grade (standard), Agarose 1000 and low melting point agarose were obtained 
from Invitogen Ltd. (Paisley, UK). Restriction endonucleases and a 100bp DNA ladder were 
obtained from New England Biolabs Ltd. (Hitchin, Hertfordshire, UK). BigDye®terminator v3.1 
cycle sequencing kit from Applied Biosystems, Warrington, UK, Agencourt®CleanSeq® from 
Beckman Coulter (UK) Ltd-Biomedical Research, High Wycombe, UK). The TaqMan® SNP 
genotyping assays and Taqman® Universal PCR mastermix were from Applied Biosystems 
(Warrington, UK),  Lymphoprep from Axis-Shield PoC AS, Norway. FCS, Glutamine, RPMI & 
LPS from Sigma-Aldrich, UK. sHLA-G kit from Exbio, Prague, Czech Republic and IL-10 
ELISA from eBioscience Human IL-10 ELISA Ready-SET-Go. Flow CytomixTM Human basic 
kit; and the IL-8, IL-1β, TNF-α, IL-23, IL-6, IL-18 Simplex kits were obtained form Bender 
MedSystems®, Vienna, Austria. 
 
 
2.2  Patients 
 
A number of patients were recruited for these experiments. Ethical approval was obtained from 
the ethical committee of Guy’s and St Thomas’ NHS Foundation trust for the MTX and AZA 
cohorts. Ethical approval for the additional pharmacogenetic work and cell culture experiments 
was granted by Bexley and Greenwich LREC (06/Q0707/84).  
 
For the MTX pharmacogenetics experiments, patients were recruited retrospectively from three 
tertiary referral centres in the United Kingdom. These included Guy’s and St Thomas's Hospital 
in London, Addenbrooke's Hospital, Cambridge and the John Radcliffe Hospital, Oxford.  A 
significant proportion of these patients have formed part of two previously published studies 
concerning clinical outcome on MTX [398, 399]. Patient details were obtained from an IBD 
database and cases were selected on the basis of age more than 16 years. The cases were seen in 
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gastroenterology or surgical clinics. Clinical details were collected by case note review by four 
independent assessors. The author of this work reviewed all the patient data from the 
Addenbrooke’s cohort and the Guy’s and St Thomas’s cohort.  Details about the assessment of 
clinical response and side effects are available in chapter 3. 
 
Patients studied for the pharmacogenetic influences on AZA response formed part of a larger 
prospective multicentre study of AZA for the treatment of IBD. It was designed to assess the 
impact of pre-treatment TPMT genotype and activity and subsequent red cell TGN levels on 
clinical outcome. The initial study reported on 215 individuals and the experiments reported here 
have examined the individuals who tolerated medication for a minimum period of three months 
and those for whom DNA was still available. (n=99). Further details on this cohort are available 
in Chapter 5. 
 
Patients studied for the effect of the HLA-G polymorphism on susceptibility to IBD comprised of 
920 cases with CD, 654 with UC and 665 controls. The cohort has previously been reported in a 
CD susceptibility study [436]. A multicentre research ethics committee approved the study of 
IBD susceptibility genotype in this cohort and the patients were recruited from Guy’s and St. 
Thomas’s Hospital, London, St. Mark’s Hospital, London and the Royal Victoria Infirmary, 
Newcastle. Further details of this group are in Chapter 5. 
 
For the functional experiments, seventeen Caucasian, female volunteers, aged between 25 and 55 
years, were recruited.  None of the volunteers had co existing medical conditions or were on any 
medications. After informed consent, phenotype details and whole blood was obtained. Details of 
this group are in Chapter 6. 
 
Population controls were obtained from the 1958 British Birth Cohort, which includes all subjects 











2.3   Molecular Biology 
 
DNA sequences were obtained from GenBank. With the help of Copy-DNA (cDNA) the genomic 
sequence was examined for introns, exons and sequence variants. DAPSA software (DNA and 
Protein sequence Alignment Software, Dr E. Harley, University of Cape Town, South Africa) was 
used to search and edit the sequences before identifying potential restriction endonuclease sites 
for digestion. 
 
2.3.1  DNA Extraction from whole Blood 
 
DNA was extracted from whole blood using QIamp® DNA Mini Kit 250 (QIAGEN Ltd., 
Crawley, West Sussex, UK). From 200μl of whole blood, it provides 6μg of DNA of around 20- 
30kb in length. Blood samples were taken from consenting patients in an EDTA tube and frozen. 
After thawing, 200 μl of blood was lysed by 20μl QUIAGEN Protease enzyme and 200μl of 
Buffer AL. Following a brief vortex, protein denaturation was achieved by incubation for 10 
minutes at 56°C. 200μl of 100% v/v Ethanol was added and the sample was vortexed again. 
Following this, it was transferred to a spin column placed in a 2 ml collection tube. Centrifugation 
was performed at 6000×G for 1 minute.  This allows the adsorption of the DNA onto the silica-
gel QIAmp membrane which is not released during subsequent washing steps. The DNA is then 
eluted by centrifugation at 6000×G for 1 minute of the spin column with 200μl of AE Buffer into 
a 1.5ml collection tube. The final DNA product is mixed with 50μl of 1×TE buffer (10mM 
Tris.Cl, pH 8.0, 1mM EDTA, pH 8.0) to inhibit DNAases and stored at -20°C. 
 
 
2.3.2  Polymerase Chain Reaction 
 
The introduction of the concepts of the polymerase chain reaction (PCR) revolutionised 
molecular biology. It is an elegantly simple concept that allows the selective amplification of 
specific DNA sequences from the genome. This is done by targeting of the required sequence. 
Hence, prior knowledge of this required, which in most cases is obtained from GenBank. The 





Rules of Primer Design: 
• The fragment should be around 20- 30 base pairs long 
• Tandem repeats of one or more nucleotides should be avoided especially guanine for 
more than 4 bases. 
• Sequences prone to secondary structure formation such as hair pins must be avoided. 
• The two primers should not be complimentary at the 3′ end so that primer-dimers 
(complexes formed by the mutual binding of the two primers) may be avoided. 
• The Ideal G+C content should be around 40% and never more than 70%. 
Accidental matching by an unintended strand of DNA to the two primers chosen in keeping 
with the above guidance is unlikely and this technique is therefore extremely specific. 
 
When this reaction is provided with a heat stable DNA polymerase enzyme and precursors of 
DNA (dATP, dCTP, dGTP, dTTP), the target sequence that is flanked by the two primers is 
reproduced in reverse (complementary strand). These serve as templates for further DNA 
synthesis and after around 25 cycles of replication around 105 copies of the targeted sequence 
will be available.  
 
This reaction is usually divided into a number of steps. At the initialisation step, heat is 
applied to a temperature of 94 to 96°C and activates the Taq enzyme. This is followed by the 
denaturation Step where a temperature of 94 to 98°C is applied for 20 to 30 seconds to 
denature the hydrogen bonds and provides providing single DNA strands. These will provide 
the templates for replication. Then, in the annealing Step, the reaction is cooled to 50 to 65°C 
for 20 to 40 seconds. The primers pair with the single-stranded DNA template. If the primers 
are well selected, stable hydrogen bonds are formed between the primers and the template 
sequence.  In the next step, the extension/elongation occurs and the DNA polymerase creates 
a new complimentary DNA strand, in a 5′ to a 3′ direction. The final elongation step occurs at 
a temperature of 70 to 74°C and lasts for five to 15 minutes after the last PCR cycle to ensure 
complete extension of single-stranded DNA (Adapted from Strachan and Read, Human Mol 
Gen 2) [478] (Figure 2-1). 
 










Figure 2-1 The technique of PCR (reproduced from Strachan and Read, Human Molecular 








This project has used four PCR based methods to identify known Mutations. 
 
• Mutation Detection with TaqManTM allelic discrimination assay 
• Restriction Fragment Length Polymorphisms (RFLP) 
• Allelic Discrimination, Allele specific PCR 
• Sequencing using fluorescent labelling and automated detection 
 
2.3.3  The TaqMan® Assay 
Taqman assay is a process that allows for automated large volume genotyping. Standard PCR is 
used to amplify the product but for allelic discrimination, a Taqman probe is used. This is 
composed of two types of fluorophoric proteins. These are the reporter at the 5′ end and the 
quencher at the 3′ end. They are located close to each other on the probe and in their position of 
proximity; fluorescence resonance energy transfer (FRET) inhibits the activity of the reporter. 
Because the 3′ end is blocked, the probe cannot prime any new DNA synthesis. When the 
polymerisation chain reaction takes place, the sequential addition of nucleotides over the DNA 
template separates the quencher form the reporter and light is emitted. This is detected and 
analysed by the 7900HT Fast Real-Time PCR system (Applied Biosystems) (Figure 2-2). 
 
The assay reagents consist of a 40× or a 80× mix of un labelled PCR primers and Taqman® 
probes (FAMTM and VIC® dye labelled). They require the use of a mastermix that comprises of 
Taq polymerase, nucleotides and the required chemical conditions. We have used the Taqman® 




A 5μl reaction is formed of Taqman® Universal PCR mastermix 2.5 μl, 40 × Assay mix 0.125 μl, 
Genomic DNA diluted in dH2O to 2.375μl.  Based on previous RFLP, control samples of all 3 
genotypes were included on a 96 well plate. The annealing is at 50° C for 2 minutes followed by 
extension/elongation at 92° C for 15 sec, 60 C for 1 minute for 40 cycles. The final elongation is 
at 95° C for 10 minutes. The product is then loaded into the 7900HT Fast Real-Time PCR system 










This was obtained in IL-10- 1082A>G genotyping. The AA is demonstrated as blue dots, the AG 
heterozygote as green dots and the GG homozygotes as red dots. The two black “x” are blanks. 
One sample could not be assigned a genotype. On review by sequencing, it was GG. 
 





The following probes were used in the genotyping of the studied polymorphisms.  
 
Table 2-1 Taqman® Probes used in genotyping 
 
SNP RS Number Probes 
ATIC 347C>G rs2372536 
C allele 5′-FAM-TCCAGGTGTAACTGTT-MGB -3′ 
G allelet 5′-VIC-CCAGGTGTAAGTGTTG-MGB -3′ 
MTHFR677C>T rs1801133 
C Allele : 5′-VIC-ATGAAATCGGCTCCCGC′3 
T allele : 5′-6 FAM-ATGAAATCGACTCCCGC′3 
MTHFR1298A>C rs1801131 
A-allele : 5′-VIC-AGTGAAGAA AGT GTC TTT 
MGBNFQ-3′ 
C-allele : 5′-6-FAM-AGT GAA GCA AGT GTC TT 
MGBN FQ-3′ 
SLC19A1 80G>A rs1051266 
G allele:  5′ -VIC-CACGAGGCGCCGC - 3′ 
A allele:  5′ -6 FAM-CGAGGTGCCGCCAG- 3′ 
IL-10- 1082G>A rs1800896 
G allele : 5′VIC-TTCCCCCTCCCAAAG- - 3′ 
A allele : 5′- 6FAM-TTCCCCTTCCCAAAGA- 3′ 
AOX1 3404A>G rs55754655 
A allele : 5′VIC-AAGCATTATCCTTTCAG- - 3′ 
G allele :  5′- 6FAM-TGAAAGCATTACCCTTTCAG- 3′ 
 
The results were confirmed in a selection of 25 samples by RFLP. The techniques used for this 
are described below. All of the results were obtained by TaqMan assays were confirmed by RFLP 
in the 25 selected samples.  
 
 
2.3.4  Restriction Fragment Length Polymorphism (RFLP) 
 
RFLP is a technique wherein a restriction endonuclease specifically recognises and cleaves 
double stranded DNA at a sequence specific site. A sequence variant may create or destroy a 
restriction site. PCR is used to amplify the DNA fragment containing the altered site and 
digestion with the predetermined enzyme splits the product at the restriction site yielding smaller 
fragments of a predicted size. The resulting fragments are of varying length and discriminate on 
electrophoresis. This allows identification of the homozygous and heterozygous and wild type 
genotypes with great accuracy.  
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Incompatibility between the PCR buffer and the digestion enzyme buffer some times caused 
incomplete digests and poor discrimination on gel electrophoresis. This was resolved by a dialysis 
step on the PCR product before digestion. The process was performed on Millipore VSP filters 
(Millipore-Waters, Elstree, UK) floating in a water bath with deionised water. Passive dialysis 
was performed for 3 minutes followed by retrieval and subsequent digestion.  
Lambda (λ) DNA is an E.coli bacteriophage which has restriction sites that are recognized by a 
variety of restriction enzymes. It was used as digest control for the experiments.  Bovine serum 
albumin (BSA) was used in some digests according to the enzyme manufacturers’ 
recommendation to prevent enzyme adhesion to reaction tubes and pipette surfaces.  The 
processes described above are labour intensive and have been largely replaced by rapid 
throughput real-time methods. They were used in this project for confirmation of the results of 
TaqManTM SNP genotyping assays. 
 
Restriction enzymes were used in the below recipe to create a master mix with 10× supplied 
buffer 1.6μl, PCR product 14.4 μl and 5 U of the supplied Restriction Enzyme. A master mix was 
made in order to avoid working with small volumes. From this 2μl containing the required 5U 
was used. Samples were then incubated for the period suggested by the suppliers and then 





The PCR products were separated on 2% (w/v) standard agarose gel run in 1×TAE 
electrophoresis buffer containing 1μl ethidium bromide (EtBr at 1mg/ml). EtBr intercalates 
between the complementary strands of a DNA molecule and fluoresces under UV light.  The gel 
is poured into a casting tray with a comb and allowed to set for 20 minutes. The PCR product (10 
μl) is mixed with 4μl of a loading buffer and loaded into the well. A 100bp DNA ladder was used 
to estimate fragment sizes. Gels were run at a constant voltage and the results were examined 










(Reproduced from Strachan and Read, Human Molecular Genetics 2) [478] 
 
Figure 2-4  The technique of RFLP  
 
 
Table 2-2 Primers, PCR conditions and restriction enzymes used  for the amplification and detection of MTHFR, SLC19A1 and ATIC polymorphisms.  
Separation at 90V for 35 minutes for MTHFR and 100V for 60 minutes for the others 
 
 








CCCCTCAAC - 3′ 
94°C 2 min, 94°C  30 s, 48°C 30 s , 
72°C  30 s: 30 cycles 
and then 72°C for 10 min 
 
HinfІ 







GCCCTCTG - 3′ 
 
5’-CGAGAGGTAAAGAACA 
AAGACTTCAGCGACAC - 3′ 
 
94°C for 2 min, 94°C for 30 s, 50°C 
for 30 s, 72°C for 30 s: 35 cycles, 
















94°C for 2 min, 95°C for 20 s, 
64°C for 20 s, 72°C for 30 s: 35 cycles. 
72°C for 10 min 
 
Dra ІІІ. 











94°C for 1min and 94°C for 30s, 54°C 
for 30s, 72°C for 30 sec: 35 cycles and 
72°C for 10min. 
 
AlwNІ 
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2.3.4.1  MTHFR 677 C>T 
The 677 C>T mutation creates a HinfІ site. The restriction site is 5’…G×ANTC…3’ and 
3’…CTNA×G…5’. The 579 bp fragment includes a second non-polymorphic HinfI site creating 
an extra 72 bp control in all samples when digestion is complete at 37°C overnight. The fragment 
sizes are shown in (Table 2-3) and the photographic gel demonstrates the findings (Figure 2-5). 
 






HinfI Digestion has produced the above results. Lane 1: Wild type (677 CC), Lane 2: 
Homozygous (677TT), Lane 3: Heterozygous (677CT) 
 
Figure 2-5 Gel image of RFLP of the MTHFR 677 C>T mutation 
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2.3.4.2  MTHFR 1298A.>C 
This was more complex. It is uncertain if the silent polymorphism at 1307C>T is recognized by 
the well described restriction enzyme MboII at 37°C overnight that was used to identify the 
1298A>C mutation. This would create false positives. Hence a mismatch reverse primer was 
designed with the purpose of using MwoI.  A mismatch reverse primer was used that had a 
complementary sequence but differed at AA→GC. This allows digestion by Mwo І when the 
1298 A>C mutation is present.  The recognition site is: 5’…GCNNNNN*NNGC…3’ and 
3’…CGNN*NNNNNCG…5’.  
 




Lane 1 : Homozygous (1298CC), Lane 2: Heterozygous (1298AC), Lane 3: Wild type (1298AA) 
 




2.3.4.3  SLC19A1  80G>A 
 
Overnight Enzymatic digestion was performed with Dra ІІІ at 37ºC for 2 hours. It is created from 
an E.coli strain that carries the DraIII gene from Deinococcus radiophilus. The recognition site is 
5’…CAGNNN*GTG…3’ and 3’…GTG*NNNCAC…5’. 
 








Three fragments are produced 150, 109 and 67bp. 
Lane 1 and 5:  Homozygous (GG), Lane 2 and 3: Heterozygous (AG), Lane 4: Wild type (AA) 
and 100 bp ladder 
 







2.3.4.4  ATIC 347C>G 
 
Microdialysis was performed of the product and then digestion was performed with AlwNІ at 
37°C overnight.  The digestion site is 5’…CAGNNN*CTG…3’ and 3’…GTC*NNNGAC…5’. 
 









Three fragments are produced 207, 172 and 35bp. The 35 bp fragments are seen very faintly. 
Lane 1, Lane 3 and Lane 5: GG, Lane 2: CG, Lane 7: CC, Lane 4: control DNA. 
 
Figure 2-8  Gel electrophoresis image of the ATIC 347C>G polymorphism 
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2.3.5  Allelic Discrimination by sizing assay 
 
Small sequential insertions or deletions of nucleotides can be very simply detected by targeting 
primers to flanking regions of the polymorphism and then distinguishing the normal and mutant 
alleles by size on polyacrylamide or agarose gels.  
 
 
2.3.5.1  HLAG 14 bp insertion /deletion polymorphism  
 
The Forward Primer was RHG4 5′-GGAAGGAATGCAGTTCAGCATGA -3′ and the reverse 
Primer was GE14HLAG  5′-GTGATGGGCTGTTT AAAGTGTCACC -3′.   
Thermocycling conditions were 92°C for 5 minutes, and 30 cycles at 92°C for 30 
seconds, 64°C for 1 minute, and 72°C for 2 minutes, with a final elongation step of 72°C 
for 10 minutes. Reactions were set up in a 25μl mixture containing 100 ng of genomic 
DNA, 0.2 mmol/l NTPs, 1.5 mmol/l MgCl2, 10 pmol of each primer, and 1U of Taq 
polymerase.The amplified products were visualized by electrophoresis on a 2.5% agarose gel 
(Invitrogen, Paisley, Scotland, UK) containing ethidium bromide (0.5 µg/ml) and were run at 






Lane 1: 14bp ins/ins, Lane 2: 14bp del/del, Lane 3 : 14 bp ins/del, Lane 4: ins/ins, Lane 5: del/del 
 






2.3.5.2  Thymidylate synthase 3′ un-translated region 6 base pair insertion/deletion 
polymorphism (TYMS 3′ (UTR) 6bp ins/del) 
 
Samples were amplified twice. Both amplifications shared the same forward primer and differed 
in the reverse primer.  Forward Primer was 5’-ATTACAA CAGGTCGTACAATTATGGC-3’ 
The “positive” 5’- CTTTATTATAGCAACATATAAAACAACTATAACT-3’ primer was 
designed to anneal when the 6-bp sequence was present. The “negative” 5’-
TTTATTATAGCAACATATAAAACAACTATA AAGT-3’ reverse primer annealed specifically 
to the DNA sequence when the 6-bp fragment was absent. Thermocycler Profile was 94° C: 1 
min, 94° C: 45 s, 54° C 30 s, 72° C 30 s: 35 cycles and 72° C: 10 minutes, 1 cycle. The fragments 
amplified with each set of primers were approximately 673-bp long. Each sample was run on 
consecutive lanes on a 2% standard agarose gel and scored for the presence or absence of the 673-
bp band.  
 
Table 2-7  Fragment sizes for the TS 6bp ins/del mutation 
 
 Insertion/Insertion Insertion/Deletion Deletion/Deletion 
6bp Positive band + + - 




Lane 1 and 2: 6bp ins/del, Lane 3 and 4: del/del, Lane 5 and 6: ins/ins 





2.3.5.3  Thymidylate synthase enhancer region (TSER) 28 base pair tandem repeat TSER 
3R/2R 
 
PCR was performed on genomic DNA with forward primer: 5′ GTGGCTCCTGCGTTTCCCCC-
3′ and reverse primer:  5′ - GCTCCGAGCCGGCCACAGGCATGGCGCGG-3′. The 
thermocycler profile was 94° C: 1 m, 94° C: 1 min, 60° C 30 s, 72° C 30 s: 35 cycles 
72° C: 10 minutes, 1 cycle. The resulting fragments were separated on a 3% agarose gel and two 
products are seen. 
 
Table 2-8  Fragment sizes for the TSER 3*R/2*R mutation 
DNA fragment size TYMS 3R/3R TYMS 3R/2R TYMS 2R/2R 
220 bp Absent Present Present 













2.3.6  Sequencing 
 
The IL-10 promoter region containing the -1082 A>G (rs1800896), -819 C>T (rs1800871) and -
592 C>A (rs1800872) polymorphisms was amplified using MolTaq Thermostable DNA 
polymerase 5U/µl (Molzym GmBH&Co. KG, Bremen, Germany), in a total volume of 50 µl PCR 
reaction.  Primers were designed using the Primer3 v.0.4.0 website [393]. 
 
0.5 µM   forward primer 5’-CACAAATCCAAGACAACACTACTAAGG-3’ and 0.5 µM reverse 
primer 5’-ATCCTCAAAGTTCCCAAGCAGC-3’ was used in a  thermocycler profile of  94° C: 
1 minute, 94°C for 30 s, 54°C for 30 s, and 72° for 1 min 94: 35 cycles, 72° C: 30 sec, 72° C  and 
a  finally a  10 minutes cycle. The amplified PCR products were purified using QIAquick®PCR 
purification Kit (QIAGEN Ltd, Crawley, West Sussex, UK).  This is a simplified centrifuge 
assisted purification process using a bind- wash- elute procedure. It removes primers, nucleotides, 
enzymes, and other impurities. The binding buffer is added directly to the sample and the mixture 
is added to quick spin column. The high-salt conditions in the buffer causes nucleic acids to 
adsorb to the silica-gel membrane. After centrifugation, the DNA is eluted with the low-salt 
buffer provided in the kit. 
 
Automated DNA sequencing was performed on the amplified product of the PCR reaction. Four 
separate fluorescent dyes are used as labels for the base specific reactions. After annealing, the 
Taq polymerase elongates the fragment with dNTP. If the dye terminators that are also present are 
incorporated, they prevent further extension and leads to strands of varying length. During 
electrophoresis, a laser beam is focused on the gel and this causes the dyes to fluoresce at 
different wavelengths for the different dyes. This gives a series of fragments of differing bp 
lengths that are assembled by specialized software to provide the DNA sequence (Figure 2-12).  
 
Sequencing reactions were performed using the BigDye®terminator v3.1 cycle sequencing kit 
(Applied Biosystems, Warrington, UK) and run on an ABI PRISM 3130x1 Genetic analyser 
(Applied Biosystems, Warrington, UK).with an additional two nested primers. These were 
forward : 5’-GGGTGGAAGAAGTTGAAATAACAAGGAA-3’ and reverse 5’-
 100 
AAGTGCAGACTACTCTTACCCACTTC-3’. The kit contains the Ready Reaction Premix, and 
Big Dye sequencing Buffer.  
The Recipe used is of Ready reaction premix 2.5× 4μl, Bid Dye Sequencing Buffer 5× 2μl , 
Primer  3.2 pmol, Template DNA 2, The final volume was 20μl. 
 
Sequencing reactions were cleaned using Agencourt®CleanSeq® (Beckman Coulter (UK) Ltd-
Biomedical Research, High Wycombe, UK) 
 
The technique was as follows, Add Agencourt CleanSEQ reagent and ethanol to sequencing 
reaction, bind sequencing products to magnetic beads, separate sequencing products from 
contaminants with magnetic field, wash with ethanol, elute from magnetic particles and then 
transfer away from magnetic beads (Figure 2-13).  
Sequences were analysed by Mutation Surveyor Local v3.20 (Softgenetics LLC, State College, 





 (Reproduced from Strachan and Read, Human Molecular Genetics 2) [478] 
 









After binding with the magnetic beads separation is performed in a magnetic field. Subsequent 
ethanol washing cleanses and the beads are eluted and transferred out. 
 
Figure 2-13 :Cleansing technique for the Sequencing Reactions 
Reproduced from Agencourt®CleanSeq® (Beckman Coulter (UK) Ltd-Biomedical Research, 




2.4  Cell Culture Experiments 
 
Peripheral Blood Mononuclear cells 
 
PBMCs were selected as the cells of choice as the aim was to examine the effects of 
pharmacologically relevant doses of 6-MP and MTX on the innate immune response in cytokine 
expression (particularly, IL-10) and sHLA-G. Furthermore, certain cytokines may be very 
similarly expressed in PBMCs from patients with IBD and normal individuals.  PBMCs are a 
mixture of monocytes and lymphocytes and the effects of stimulation and drug exposure across 
the whole spectrum of cells implicated in HLA-G function could therefore be examined. This is, 
as described in the introduction, wide ranging. Furthermore, PBMCs are readily available from 
healthy donors. Lamina propria intestinal mononuclear cells are a very attractive option, however 
supply is unpredictable particularly as the aim was to study the effects in healthy individuals who 
were not known to have inflammatory disease, malignancy or known to be pregnant. Hence, 
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PBMCs were the preferred option. The report of IL-10 expression being similar between PBMCs 
from IBD patients and normal individuals [394] further supports the choice. 
 
Monocyte populations in individuals with CD differ from classical monocyte populations in that 
they have a mature and pro inflammatory phenotype characterized by high TNF-α and low IL-10 
levels.  They are characterized by cell surface markers CD14HIGH, CD16+, CD56+ [395].  Such 
characterization of subpopulations has not been performed in this study, but cytokine expression 
levels on LPS stimulation appear consistent with those seen in inflammatory conditions.  There 
are therefore differences between LPMCs and PBMCs in patients with IBD [396] and there are 
differences between PBMCs in individuals with IBD and those from individuals without 
inflammatory disease.  On LPS stimulation of normal PBMCs, many similarities between these 
populations emerge. In vitro, they are immunologically active and comprise of T lymphocytes, 
monocytes. Hence, the use of PBMCs from normal individuals stimulated with LPS, a bacterial 
wall component that is found in a number of pathological Gram negative bacteria as the 
populations of cells for the in vitro experiment appears reasonable.  
 
 Whole blood was collected from healthy Caucasian female volunteers, not taking any 
medication. As there is a considerable influence of soluble HLA-G in pregnancy, we specifically 
selected individuals who could be sure of a menstrual period within the last month. Men have 
lower sHLA-G levels than women and were therefore not recruited.  As previously described, a 
number of immunologically active drugs influence sHLA-G levels and so therefore, all 
individuals were not taking any medications. History of coexisting medical conditions was 
elicited and individuals with active inflammatory conditions and diabetes were not recruited.  
 
2.4.1  Preparation of PBMCs 
 
The blood samples were collected into lithium-heparin tubes and within 4 hours were diluted in 
an equal volume of Dulbecco’s Phosphate-Buffered Saline DPBS (GIBCO 14190, Invitrogen). 30 
ml of blood was layered onto 15ml of FICOLL-Hypaque. Centrifugation was performed at RCF 
800 G for 20 minutes at 20°C. The PBMCs at the interface between the serum and the blood was 
carefully aspirated. The rest was discarded. DPBS was then added to make up the volume to 45 
ml. Centrifugation was repeated at RCF 1400 G for 10 minutes at 20°C. The supernatant was then 
carefully aspirated and the cell pellet was re-suspended in 15ml dialysed fetal calf serum 10% + 






2.4.2  The Drug Dilutions 
 
Serial dilutions of both 6-MP and MTX were required. MTX has a molecular weight of 450 and 
6-MP a molecular weight of 170. The molecular weight was used to prepare drug concentrations 
of 1 μM, 0.5 μM, and 0.25 μM. The solutions were made in DMSO. Previous experiments have 
demonstrated that the 1μM concentration of 6-MP is most consistent with therapeutically 
significant concentration of 6-TGN levels in co-incubated PBMCs. Levels of 10 μM and greater 
are associated with apoptosis [254]. Hence 1 μM was the maximal dosage evaluated. FCS, 
glutamine, RPMI & lipopolysaccharide (LPS) were all from Sigma-Aldrich, UK. The LPS 
solution was made up to 50 μg/ml. 
 
 
2.4.3  Cell Culture 
 
Cell culture was performed on a 16 well plate each of which contained 1 ml of the cell culture 
solution and was incubated for 48 hours in a CO2 incubator at 37°C . All incubations were 
performed in duplicate. 
 
 
Table 2-9  A schematic of the plating technique used for the cell culture experiments 
Unstimulated cells Unstimulated cells 
+ 1 μM  6-MP 
Unstimulated cells 
+ 0.5 μM  6-MP 
Unstimulated cells 





+ 1 μM  MTX 
Unstimulated cells 
+ 0.5 μM  MTX 
Unstimulated cells 
+ 0.25 μM  MTX 
LPS Stimulated 
Cells 
Stimulated cells + 
1 μM  6-MP 
Stimulated cells + 
0.5 μM  6-MP 
Stimulated cells + 
0.25 μM  6-MP 
EMPTY Stimulated cells + 
1 μM  MTX 
Stimulated cells + 
0.5 μM  MTX 
Stimulated cells + 





After 24 h of incubation, the supernatant was removed and stored at -8°C in labeled eppendorf 
tubes. New culture medium was added. At the end of 48 h, the adherent cells were re suspended. 
Cell viability was checked by trypan blue staining and cell count was performed for each well. 
The cell count was approximately 1×106 cells per ml. As expected the cells were a mixture of 
monocytes and lymphocytes. 
 
The solution was then transferred to an eppendorf tube and centrifuged for 30 sat 12,000 rpm. 
The supernatant was divided into 4 eppendorf tubes so that repeated freeze thaw cycles could be 
avoided and the samples were frozen. 
 
2.4.4  Enzyme linked immunosorbent assay (ELISA) 
 
The antigen, in saline, is incubated on a plastic tray and a proportion adheres to the surface. This 
often requires overnight preparation. The free and surplus antigen is then washed away so that the 
surplus will not cause non specific binding. The test antibody is then added which will bind to the 
specific antigen and once again the unbound proteins are washed away. Subsequently, a ligand 
specific for the antibody attached to a peroxidase enzyme is added. After binding, the surplus is 
washed away and a chromogen is added that will provide a coloured product. The intensity of the 
colour is proportional to the amount of the antibody and relative differences are estimated by 
optical density scanning of the plate. 
 




2.4.4.1  Interleukin-10 ( IL-10 )  
 
The IL-10 assay was performed with Human IL-10 ELISA Ready-set-go from eBioscience. 
(Catalog no: 88-7106) Sensitivity 2pg/ml, Standard curve ranges 2-300 pg/ml. 
The kit contained: Pre titrated capture antibody (clone JES3-9D7), Pre titrated Biotin conjugated 
detection antibody (clone JES3-12GB), Standards (recombinant cytokine), ELISA coating Buffer 
powder, Assay Diluent: 5×concentration, Detection enzyme: pre titrated avidin-HRP, Substrate 
solution: Tetramethylbenzidine and a 96 Well Corning Costar 9018 plate.  
 
Procedure: The plate was coated with 100μl of capture antibody diluted in the coating buffer and 
incubated overnight at 4°C. After repeated washing (5 times) with a well wash buffer, it was 
blotted on absorbent paper. The wells were then blocked with 200μl /well of assay diluent, 
incubated for 1 hour and then washed again. The standards were made up as described in the 
enclosed certificate of analysis. The 100 μl of the samples in duplicate were added to each well 
and incubated for 2 hours. Following this, 5 washes were performed and 100μl of detection 
antibody was added. The plates were washed again and 100μl Avidin-HRP was added. After 
further washes, 100μl of the substrate solution was added to each well, incubated for 15 minutes 
followed by 50μl of the stop solution. The plate was read at 450nM. 
 
 
2.4.4.2  Soluble HLA-G (sHLA-G) 
 
The soluble HLA-G assay was performed with an assay kit from Exbio, Praha, a.s (product no: 
RD194070100R) and measures sHLA-G1 and HLA-G5. The detection limits were 3 U/ml. 
The kit contained Antibody coated microliter strips, Conjugate solution, Master calibrator, 
Dilution buffer, Wash solution (10×), Substrate solution and a Stop solution. 
 
Procedure: The standards and the samples were loaded into the wells in duplicate and incubated 
for 16 h. Following this, the wells were washed (5×) and blotted on absorbent paper. The 
conjugate solution was added (100μl) was added to each well and incubated at room temperature 
for 1 h on an orbital microplate shaker.  After further serial wash (5×) and drying by blotting, 
100μl of the substrate solution was added and incubated at room temperature for 25 min. This is 




2.4.5  Measurement of other cytokine levels 
 
Of the samples from individuals analysed in the previous study, 3 with a HLA-G del/del genotype 
and 3 with a HLA-G insertion allele were subsequently investigated for other cytokine levels. A 
dose effect was not being examined here; hence the doses of immunomodulators associated with 
the highest levels of sHLA-G were selected.  The samples were analysed by Flowcytomix assay 
as described below.  
 
2.4.5.1 Flow cytomixTM  assay  
 
Fluorescent polystyrol beads are coupled with antibodies specific to the antigens to be detected. 
The required antibody linked beads are incubated with the samples to be tested. Specific binding 
takes place to the antibodies coupled to the beads. Following this, a biotin conjugated antibody 
mix is added, which binds to the bound capture antibodies. Finally, Streptavidin-Phycoerythrin 
(PE) is added which binds to the biotin conjugates.  Two sets of beads with different sizes (4 μm 
& 5 μm) are used in the assay and each of the two sizes has different intensities of an internally 
fluorescent dye. The dye can be excited with a laser and the beads can be identified and 
quantified by flow cytometry. 
 
The assay was utilized for the quantification of IL-10, IL-23, IL-8, IL-6, IL-18, IL-1β and TNF-α.  
The kit includes 1 vial set up beads, 1 bottle (10×) assay buffer (PBS with 10% BSA), 1 bottle 
reagent dilution buffer, 1 vial (200μl) Streptavidin-Phycoerythrin (Strepatvidin-PE) and a 96 well 
plate. In addition, each individual bead assay comprised of 1 vial of fluorescent beads (20×) 
coated with a specific antibody, Vial of lyophilized standard and a 1,350μl vial of Biotin-
Conjugate (20×). 
The proprietary software programme FlowCytomix Pro software provides a calculation of the 
customized volumes based on the number of samples and the number of assays being performed. 
Following this, the standards are reconstituted with all the standards from the intended assays. A 









Figure reproduced from: [479] 
 
Figure 2-15  Diagrammatic representation of the Flowcytomix assay process 
 
The bead mixture is then prepared in a centrifugation tube. Each individual bead mix is vortexed, 
1/20 of the calculated final volume is transferred into a vial and the volume was made up with 
reagent dilution buffer. This was then centrifuged at 3000×g for 5 min.  All but 50μl of the buffer 
is removed and new buffer is added and the beads are resuspended by vortexing. The biotin-
conjugate mixture is prepared and made up to volume with the supplied reagent dilution buffer. 
The supplied filter plate was pre moistened with 50μl of the assay buffer and aspirated by the 
vacuum manifold. Then 25μl of the standards were added in duplicate. An extra standard of the 
top concentration was added as instructed. Subsequently, the following sequential steps were 
performed 25 μl assay buffer, 25 μl samples, 25 μl bead mixtures and 50 μl Biotin-Conjugate 
mixtures.  
 
The plate was protected from light by tin foil and incubated for 2 h on a microplate shaker at 500 
rpm. This was followed by vacuum filtration of all the contents. The vacuum filtration was 
repeated twice with 100μl of assay buffer. A further 100μl of assay buffer was added along with 
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50μl of streptavidin-PE. The light free incubation process was repeated for a further 1 h on a 
microplate shaker. The contents of the wells were emptied by vacuum filtration after the addition 
of 100μl of the assay Buffer. This was repeated and then finally 200μl was added to each well, the 
contents transferred into a sample acquisition tubes for flow cytometry. The flow cytometer was 
set up with the supplied flow cytometry beads in accordance with the enclosed instructions. 
 
The results were calculated with the proprietary Flowcytomix Pro 2.2 (Cat No BMS8400FF) 
software programme. 
 
2.5   Statistics 
 
Statistical analysis was performed with Prism 4 for Windows, version 4.03, GraphPad Software, 
San Diego California USA, www.graphpad.com.  
 
Clinical response was correlated to genotype and a two sided Fisher's exact test was used to test 
for statistical significance. Dominant and recessive models were studied. In the dominant model 
both the homozygous mutants and the heterozygous individuals are affected. In the recessive 
model, only the homozygotes show an effect.  
 
Statistical analysis for allele frequencies and haplotypes was performed using UNPHASED to test 
for association between clinical response / control status , side effects / control status, folate status 
and SNPs.  PLINK was used for quality control for SNPs. Markers were analysed as single 
polymorphisms and in two-locus haplotypes within each gene.   
 
The Chi-square test was used to calculate a deviation from Hardy-Weinberg equilibrium Hardy 
Weinberg equilibrium was calculated. The principle of the Hardy-Weinberg equilibrium describes 
the distribution of allele and genotype frequencies in a random population. It is expressed as p2 + 
2pq + q2= 1. Where p is allele 1 and q is allele 2.  
 
The frequency of allele 2 is  
 
2× (the no. of 2/2 homozygotes) + (the no. of ½ heterozygotes) 
             The total no. of genotyped individuals× 2 
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The frequency of allele 1 is p =1.0 - q 
 
This formula is used to calculate the expected distribution of genotypes and the difference 
between the observed frequency and the expected frequency can be calculated with the chi 2 test 
(χ 2 = [o-e]2 /e ). Deviation from this equilibrium is seen in abnormally distributed populations 
such has an inbred population, skewed allelic transmission or population stratification. However, 
the most common situation is genotyping error. The court lab HW calculator from www.tufts.edu 
was used for the calculations. 
 
Gaussian distribution could not be assumed, hence, the non-parametric Mann-Whitney U test was 
used to test for an effect by genotype on the median change in sHLA-G and IL-10 values after 
cell culture with the studied drug.   
 
The standard unpaired t test measures the difference between means in two populations if the 
variance is equal. If the variance (namely the standard Deviation) is significantly different 
(measured by the Welch test as reported as a p value), there are some options to be considered. 
• Reject the hypothesis and conclude the populations are different. 
• Ignore the result. If the sample sizes are equal or nearly equal, the assumption of 
equal standard deviations is not crucial and the t test is robust. This is not a reliable 
approach if sample sizes are very small. 
• Transform the data to log values. This should be planned in the study design. 
• Run the t test with Welch correction for unequal variance. This has to be specified as 
part of the experimental design, otherwise there is risk of a Type I error. This is the 
option chosen in this study.  
The Mann Whitney U test as a non parametric test does not provide a solution as it is also 
affected by unequal variance and does not test for variance 
 
The two way ANOVA for repeated measures was used to test for significance in differences in 
cytokine levels and sHLA-G expression between samples incubated with and without the drug.  
 
A p value less than 0.05 was taken to indicate statistical significance for all analysis. The 
contentious issue of how to adjust for multiple statistical tests is sometimes resolved by the 
application of the sequential Bonferroni correction. However, it is increasingly appreciated that 
there is a strong case for rejecting the use of this process when low p values are obtained. 
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Researchers could use the standard p<0.05 cutoff and make interpretations that would use 
principles recognized by reviewers such as study design, control groups selection, and basic logic. 
Relatively large p values in a large data table may not be relevant but would identify areas for 
examination. Clearly, truly negative results will not be replicated. Equally, small but significant 
effects will be identified [397]. Hence, the Bonferroni correction has not been applied in the 
statistical analyses reported in this work. 
 
This work has a pragmatic design to reflect “real-world” clinical practice. MTX by dint of its role 
as second line therapy in CD is not widely used and access to DNA form well defined patient 
groups is relatively difficult. Hence, a priori power calculations for the experiments were not 
performed. Instead all available DNA as long as the patient phenotype was well defined and 
clinical information was available, was included. Post hoc power is not often useful and was not 
calculated in this thesis. The confidence intervals are all small particularly in the negative results 
and this can help identify genuine effects. The results of these experiments can help inform future 





















3  Pharmacogenetic influence of polymorphisms in the MTHFR genes 
on clinical outcome of methotrexate therapy in patients with 
Inflammatory Bowel Disease 
 
 
3.1 Introduction   
 
A major focus of the work presented in this thesis is the examination of well recognised but 
inconsistent pharmacogenetic influences on methotrexate efficacy and toxicity in IBD patients. 
Of these, MTHFR polymorphisms are the most investigated in the folate metabolism pathway. 
 
3.2  Aims 
 
In this chapter, the influence of the two most frequent MTHFR genetic variants on individual 
response to therapy and the incidence of side effects are examined. Secondly, the effect of the 
effect of the MTHFR 677C>T and 1298A>C haplotypes on clinical response and side effects 
rates were studied. Thirdly, the influence of folate supplementation on these effects was studied. 
 
3.3  Methods 
 
3.3.1  Study design 
 
Patients were recruited retrospectively from three tertiary referral centres in the United Kingdom. 
These included Guys and St Thomas's Hospital in London, Addenbrooke's Hospital, Cambridge 
and the John Radcliffe Hospital, Oxford.  A significant proportion of these patients have formed 
part of two previously published studies concerning clinical outcome on MTX [398, 399].   
Clinical details were collected by case note review by four independent assessors. Response was 
defined by a physician’s clinical assessment as disease remission without concomitant steroid 
therapy after 3 months of treatment.  Where MTX was used for fistula healing, response was 
defined as complete healing without discharge. Recourse to steroid therapy, Infliximab or surgery 
was, by definition, considered therapeutic failure. Adverse effects were defined by symptoms 
reported to the treating physician at clinic visits and review of laboratory investigations. Data 
collection of adverse events was not standardised as would be in a prospective trial. In most 
instances, such information was obtained from notes maintained by IBD nurse specialists.  
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Collection of data on folate supplementation was not universal across the three sites. Where such 
detail was available, the 5mg per day dose was the one used. The practice at the three centres that 
provided patients for the study was to use oral folates on all days of the week other than the day 
on which MTX was taken.  
 
 
3.3.2  Laboratory methods  
 
All patients were genotyped by Taqman SNP assay. The assay reliability was confirmed by RFLP 
in 25 patients. The correlation was 100% (Sections: 2.3.3 and 2.3.4).  
 
 
3.3.3  Analysis 
 
Statistical analysis for allele frequencies and haplotype was performed using UNPHASED to test 
for association between clinical response / control status , side effects / control status, folate status 
and SNPs. PLINK was used for quality control for SNPs. Markers were analysed as single 
polymorphisms and in two-locus haplotypes within each gene.  Across genes, specific tests of 
association were performed. Statistical analysis of association between genotype frequencies and 
clinical response and side effects was performed with Prism 4 for Windows, version 4.03, 
GraphPad Software, San Diego California USA, www.graphpad.com. Clinical response was 
correlated to genotype and a two sided Fisher's exact test was used to test for statistical 
significance. Dominant and recessive models were studied. No correction for multiple testing 
within or across genes has been applied.    
 
  
3.4   Results 
 
A total of 201 patients were included in the study.  Of these, 116 were female (57%). CD affected 
145 (72%) patients and 38 (19%) had UC. 18 (8%) patients were classified as indeterminate 
colitis or data was unavailable. In the CD group, 40 (27%) had isolated colonic involvement, 75 
(52%) had ileo-colonic involvement, 20 (14%) had isolated ileal involvement and 10 (6 %) had 
upper intestinal involvement. Fistulising perianal disease affected 41 (29%) patients. In the UC 
group 18 (47%) had left-sided colitis, 15 (39%) had pan colitis and five (13%) had isolated 
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proctitis. The mean age at diagnosis in the CD group was 29 years (range 9 to 78 years). In the 
UC group, the average age was 38 years, with a range of 19 to 75.  
 
MTX was commenced as a steroid sparing agent in 111 (55%) of patients.  There were 75 
patients (44 %) who were not on steroids at the time of commencing MTX. Some of these 
individuals had received steroids in the past and had responded to treatment. A further 15 patients 
were resistant to steroids. MTX was used for failure of AZA to achieve a therapeutic response in 
90 (48 %) patients and for AZA intolerance in 74 (36%) patients. AZA was not used in 11 
patients and 10 patients decided to stop AZA for personal reasons. Data on prior AZA use was 
not available in the remainder. MTX was administered orally in 174 (86%) patients, 
subcutaneously in three patients and an initial intramuscular induction progressing to an oral 
regime in 22 (10%) patients. There was no difference in the response to treatment between the 
oral (87/179) and IM (9/22) regimes (p= 0.65 for response, OR = 1.366, CI= 0.5 – 3.3). A small 
number of patients (n=11) were treated with a combination of AZA and MTX of whom one 
patient had developed significant neutropenia, requiring cessation of MTX. 179 patients 
completed at least three months of MTX therapy and were included in the group for analysis of 
treatment efficacy.  Response, defined as successful withdrawal of steroids in the steroid 
dependent group or the clear documentation of treatment efficacy in those who were not on 
steroids was noted in 97 patients. The Crohn’s Disease Activity Index (CDAI) was not used and 
the Harvey Bradshaw Index (HBI) was not consistently documented.  The mean dosage of MTX 
used was 20.34 mg/week (range 7.5 to 25 mg/week). There was no significant effect on clinical 
response of dosage (p=0.57), mode of administration (p=0.65) or folate supplementation 
(p=0.1527). Surgery was required in 85 patients. This included 76 patients with CD, 1 with 
indeterminate colitis and 7 with UC.  
 
Side effects were noted in 49 patients. Gastrointestinal side effects were the most common with 
nausea or diarrhoea reported in 19 patients. Other side effects in decreasing order of frequency 
were transient LFT abnormalities in 12,  haematological abnormalities including neutropenia in 
four, muscle and joint pains in four, minor infections in four, skin rash in three, mucositis in two 
and alopecia in one. The side effects were severe enough to lead to drug withdrawal in 17 
patients. These included 5 for LFT abnormalities, 6 for GI intolerance, 1 for musculoskeletal 
symptoms, 1 for mucositis and 1 for impotence.  Information on concurrent folate 
supplementation was available in 181 patients. Of these 114 received folate supplements and 67 
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patients did not. Folate supplementation (p=1.0) and MTX dosage did not influence side effect 
rates (p=0.08). 
  
3.4.1   Genotyping results 
 
The frequencies of the distribution of the homozygous mutation are displayed (Table 3-1) 
The MTHFR677 and MTHFR1298 haplotype are in linkage disequilibrium (r^2= 0.05). The 
MTHFR 677T allele was more common among responders to MTX therapy. This finding just 
fails to meet statistical significance (p= 0.06, OR = 1.525, CI 0.912 - 2.394). Furthermore, we see 
that the major contribution to this effect comes from those who received oral folate (p= 0.01, OR 
= 2.241, CI = 1.19 – 4.2) and the effect was not seen in those individuals not receiving oral folate 
(p=0.924, OR = 1.038, CI = 0.478 – 2.251) (Table 3-2). More individuals with the MTHFR677TT 
genotype responded to therapy (14/19) and when compared with the wild-type MTHFR677CC 
genotype (40/86), this effect achieved significance for clinical response as a recessive effect 
(p=0.04, OR=3.2, CI= 1.06- 9.7) (Table 3-3) 
 
In contrast, the MTHFR 1298C allele was not distributed significantly differently between 
responders and non responders to MTX therapy (p= 0.95, OR=1.0, CI= 0.6 – 1.53). Folate 
supplementation did not influence this effect (p= 0.1 for non- folate supplemented and p= 0.69 for 
folate supplemented) (Table 3-2)  
 
Neither of the two polymorphisms influenced side effect rates and the mutant alleles were not 
distributed differently between those that experienced side effects and those that did not. The 
effects were also not influenced by folate supplementation (Table 3-4). 
 
Compound heterozygosity with or without oral folate supplementation did not influence clinical 
response or side effect rates. Common haplotypes did not influence clinical response rates or side 
effects but the 677TT/1298AA haplotype was seen more often in those who responded to therapy 
than in those who did not (p=0.03, OR= 1.6, CI = 1.2 – 2.3). The numbers in the groups were not 





Table 3-1 MTHFR SNP frequency information 
The frequencies reported are of the homozygous mutation. 
 
 
SNP rs no Frequency in this 
study 
MTHFR1298A>C 1801131 0.24 




Table 3-2 The allele frequencies of the examined MTHFR allelotypes and their distribution 
between clinical responders and non responders. 
In each case, the mutant allele is the allele for which the frequency, estimated Odds Ratio and p 
value refers.  Table A refers to all cases (n-179), Table B to those who did not have oral folate  
(n=58) and Table C to those who did (n=103). 
 
TABLE A 
Gene All patients  
 Response Non Response OR CI p value 
MTHFR 677 0.357 0.267 1.525 0.971-2.394 0.065 
MTHFR 1298 0.423 0.4205 1.011 0.664 - 1.538 0.959 
TABLE B 
Gene No folate supplements 
 Response Non response OR CI P value 
MTHFR 677 0.348 0.342 1.038 0.478 - 2.251 0.924 
MTHFR 1298 0.484 0.34 1.827 0.855 - 3.901 0.116 
TABLE C 
Gene Folate supplemented 
 Response Non response OR CI p value 
MTHFR 677 0.368 0.206 2.241 1.191 - 4.217 0.01 






Table 3-3 The Recessive influence of the polymorphisms on the response to MTX therapy in 





Non Response  
MTHFR 
1298A>C 
AA 30 26 
p=1, OR= 0.9 (0.4-2) AC 45 50 
CC 16 12 
MTHFR 
677C>T 
CC 40 46 
p=0.04, OR=3.2 
(1.06- 9.7) 
CT 37 37 
TT 14 5 
 
 
Table 3-4 The allele frequencies of the examined MTHFR allelotypes and their distribution 
between those that experienced side effects and those that did not 
In each case, the mutant allele is the allele for which the frequency, estimated Odds Ratio and p 
value refers.  Table A refers to all cases (n-201), Table B to those who did not have oral folate 
(n=66) and Table C to those who did (n=114). 
 
TABLE A 
Gene All Cases Side-effects No side effects OR CI p value 
MTHFR 677 0.316 0.332 0.932 0.570 - 1.515        0.77 
MTHFR 1298 0.438 0.427 1.046 0.663 - 1.654 0.846 
TABLE B 
Gene No folate supplementation Side-effects No side effects OR CI  p value 
MTHFR 677 0.366 0.372 0.975 0.419 - 2.268        0.953 
MTHFR 1298 0.5 0.421 1.372 0.606 - 3.104        0.447 
TABLE C 
Gene  Folate supplementation Side-effects No side effects OR CI p value 
MTHFR 677 0.296 0.314 0.935 0.4804 - 1.822  0.844 




Table 3-5 The prevalence of the various MTHFR haplotypes in the study population and the 














3.5  Discussion 
 
Following on from the experience in cancer pharmacogenetics, the pharmacogenetic model has 
been applied to the investigation of side effects and clinical response rates in methotrexate 
therapy in RA and was initially focussed on the recognised polymorphisms in MTHFR.  
 
As discussed earlier, the mutant homozygous MTHFR 677TT carriers exhibit 30% of the activity 
of MTHFR expected of a wild type and the heterozygote genotype is associated with 60% of wild 
type activity [370, 371] due to thermoloability. The 1298A>C SNP causes impaired activity that 
is relatively mild and does not influence plasma homocysteine levels in isolation. High folate 
states as seen in folate supplementation influences the stability of the mutant thermolabile enzyme 
making it more stable [375]. In folate deficient states, homozygous mutant MTHFR 677TT 
carriers show deficient DNA methylation.  
 
Interestingly, in this study, the 677C>T mutation did not influence side effects and folate 
supplementation did not appear to change this. This is not completely at odds with previous 
reports as has been described in my review of the literature. Although, it has been associated with 
increased side effect rates, a number of reports have not found any associations [400]. The 
MTHFR 
Haplotype  
677 1298 Total Clinical Response 
Non 
Response 
p (v/s all other 
haplotypes) RR CI 
CT AA 19 (10%) 12 7 0.2 NS  
TT AA 16 (8%) 12 4 0.03 1.6 1.2 - 2.3 
CC AC 39 (20%) 18 21 0.8 NS  
CC AA 25 (12%) 8 17 0.1 NS  
CC CC 27 (14%) 15 12 0.4 NS  
CT AC 69 (35%) 27 42 0.1 NS  
 118 
677C>T mutation causes homocysteinemia in some individuals exposed to MTX. There is 
relative depletion of the folate pool in the form of 5′- methyl THF that would otherwise have been 
generated from 5′, 10′ methylene THF. The subsequent remethylation of methionine from 
homocysteine is impaired and there is a relative homocysteinemia. Serum homocysteine levels 
rise in 24 hours after MTX administration and remain elevated for up to 7 days [401]. In MTX 
therapy of ovarian malignancies, the mutation has a dose effect with greater homocysteine levels 
seen in the MTHFR 677TT genotype when compared to heterozygotes that have higher levels 
than the wild type genotypes [402]. This may predispose to toxicity and associations have been 
made with hepatotoxicity, haematological toxicity, mucositis and neurotoxicity. The 
homocysteinemia is seen in both cancer chemotherapy [403] and anti inflammatory therapy [402]. 
However, in RA the effect although clear and very obviously abolished by oral folate 
supplementation, was not related to the 677C>T mutation [404].  This finding is predominantly 
described at higher MTX doses [405] and may explain the lack of an association in this study 
where much lower doses were used. 
 
This data shows that the MTHFR 677TT genotype is associated with a greater chance of clinical 
response to MTX therapy (p=0.04, OR=3.2 (1.06-9.7) as a recessive effect. Furthermore we note 
that folate supplementation appears to play a role. All those individuals with the MTHFR 677TT 
mutant genotype receiving oral folate, responded to therapy (n=10). Among those who did not 
receive oral folate supplements, 5/11 (45%) failed treatment (p=0.03, OR = 17). There are more 
individuals with the MTHFR1298AA genotype in this group and it is possible that the MTHFR 
677TT/1298AA haplotype is exerting a previously unrecognised influence (p=0.03, OR= 1.6, CI = 
1.2 – 2.3). As stated earlier the group was too small for sub group analysis into the effect of folate 
supplementation and a hypothesis to explain such an effect is lacking. A larger study population 
may throw up some answers. 
 
In cancer pharmacogenetics, there appears to be an effect specific to cell type for the 677C>T 
genotype on response to MTX. Breast cancer cell lines are less responsive in vitro than colon 
cancer cells. [406]. In Acute Lymphocytic Leukaemia (ALL) ex vivo studies have been 
contradictory with both positive and negative effects on drug response attributed to the 677C>T 
polymorphism [407, 408]. In clinical studies on leukaemia patients, 677C>T has a negative effect 
on clinical response in most reports [409]. In RA, once again results are conflicting. Two studies 
showed a negative effect of 677C>T polymorphism on response [392, 410] and one showed a 
positive response [411]. In IBD and Psoriatic arthritis, no effects of this polymorphism were 
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noted on clinical response [399, 412].  The higher plasma levels of MTX seen in patients with the 
MTHFR 677TT genotype in a report on Japanese patients with acute myeloid leukaemia (AML) 
may be very relevant to the findings.  In this small study, individuals with the MTHFR 677TT 
genotype had high serum MTX levels that were toxic enough for leucovorin rescue [405]. As 
described earlier concurrent folate therapy appears to reduce the homocysteinemia and certainly 
increases drug tolerance in the MTHFR 677TT group [375]. While a coherent reason for MTHFR 
influencing MTX serum levels cannot be made at this time, this observation may explain the 
effect of MTHFR 677TT on clinical response seen in this study. Other reasons for a similar effect 
may be that reduced methionine and s-adenosyl methionine lead to impaired availability of a 
methyl group for DNA methylation and may augment MTX immunosuppression. Furthermore, 
MTX induced inhibition of TS, when associated with impaired MTHFR activity reduces the 
availability of THF derivatives that may increase the effects of immunosuppression [411]. 
Importantly in the absence of folate supplementation, these effects would be expected to cause 
systemic toxicity [411]. The MTHFR 1298A>C polymorphism has been investigated in paediatric 
ALL and the mutant genotype appears to predispose to a poorer clinical response; one that is 
unusually not seen in either homozygote genotypes [408].  In RA, positive [413-415] and 
negative [410] effects of MTHFR 1298A>C on clinical response have been noted. No effects 
have been seen in IBD and psoriasis [399, 412].  This polymorphism has no effect on efficacy or 
side effects to MTX therapy and that folate supplementation does not appear to influence this 
effect. There is no influence of compound heterozygosity on clinical response or side effect rates 
of MTX. Hence the hypothesis that MTHFR 1298AC or the MTHFR 1298CC genotype would 
demonstrate a compromised clinical response in comparison to the wild type genotype or that this 
effect would be diminished by folate supplementation was not supported. The hypothesis that the 
MTHFR 677TT genotypes would have a poorer clinical response than the other genotypes was not 
supported but instead, the co-administration of oral folate appeared to improve the clinical 
response in this group. This effect could be attributed to the effects of high folate states on 
enzymatic stability. The hypothesis that the mutations would influence side effect rates or that the 
compound heterozygosity would influence clinical response or side effect rates were not 
supported by the data. Furthermore, oral folate supplementation did not influence these effects.  
 
Clearly the influence of pharmacogenetic variation on other folate pathway enzymes may be 
important and this is examined in the next chapter. 
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4 The effect of polymorphisms in the thymidylate synthase gene and 





4.1   Introduction: 
 
A number of other polymorphisms have been examined, predominantly in the analysis of clinical 
response and side effect rates of individuals receiving cancer chemotherapy. Replication has then 
been attempted in RA and psoriasis with limited and often variable success.  Thymidylate 
synthase is inhibited directly by polyglutamated MTX. A tandem repeat sequence of 28 base pairs 
within the 5′ untranslated region (UTR) of the TS gene can contain either 2 or 3 repeats. 
Homozygosity for the triple repeat allele (TSER *3R/*3R) is associated with greater mRNA 
transcriptional activity that is manifest as enhanced enzymatic activity. This may decrease clinical 
response and not influence side effect rates. This effect would be abolished by folate 
supplementation. A six bp deletion (TTAAAG) at position 1494 in the 3′ UTR of this gene is 
associated with decreased mRNA stability and lower mRNA levels are noted in the homozygote 
carriers of the mutant deletion. Carriers may experience an enhanced therapeutic benefit with 
MTX.  These two polymorphisms may be in LD. The 3*R with the 6bp insertion has greater 
transcriptional efficiency and more mRNA stability than the 2R with the 6 bp deletion. MTHFR 
and TS are closely related in the maintenance of THF and single carbon methyl groups which are 
essential for DNA methylation and possibly the epigenetic modification of cytokine genes. The 
MTHFR677TT mutation may impart reduced clinical efficacy on MTX therapy to individuals 
who possess the TS 2*R with the TS 6bp deletion.  
 
A single nucleotide polymorphism in the SLC19A1 gene appears to lead to loss of SLC19A1 
gene expression. SLC19A1 80GG may impair cellular influx of MTX preventing polyglutamation 
and impairing response to MTX therapy.  ATIC 347 GG has been correlated with a better clinical 
response than ATIC 347CC and ATIC 347CG. Another group has reported the opposite effect. 
AOX 3404AG and the rare AOX 3404GG polymorphism may improve clinical response by 






4.2   Aims:  
I. To correlate clinical response to MTX therapy with the TSER3*R/3*R and the TS6bp 
ins/ins genotypes and to examine the effect of folate supplementation on this correlation. 
The hypothesis is that the mutant homozygote polymorphisms would be associated with 
decreased clinical response and that oral folate supplements would abolish this effect. 
Either of these polymorphisms would not be expected to influence side effect rates and 
folate supplementation would not be expected to play a role. 
II. To examine the effect of the combined TSER 3*R and TS 6bp ins on clinical response. It 
is hypothesised to be higher than the adverse genotypes and that folate supplementation 
would not influence these results. Side effect rates will not be affected.  
III. To evaluate the effect of the MTHFR 677TT on individuals with the TSER2*R and the 
TS6bp del. It may be impaired and oral folate supplementation may reverse this effect. 
IV. To examine the effect of the SLC19A1 80GG mutation with on clinical response and side 
effect rates to MTX with and without folate supplementation. The polymorphisms may 
impair clinical response and folate supplements would have no effect.  
V. To study the influence of ATIC 347C>G polymorphisms on clinical response rates and 
side effect rates to MTX in the study group. Oral folate supplementation is unlikely to 
have an effect. 
VI. To examine the effect of the AOX 3404A>G polymorphisms on response to MTX 
therapy. Folate supplementation may play a role as the folate status can affect cellular 
efflux of MTX. As SLC19A1 is the major efflux channel, the SLC19A1 80GG mutation 
may abolish this effect. All  these influences will be evaluated 
 
 
4.3    Methods 
 
Criterion for assessment of clinical response and side effects as well as the population used in this 
chapter was the same as that selected for the MTHFR study in the preceding chapter. The 
demographic and phenotype of the study group is represented in the table (Table 4-1 and Table 
4-2).   
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A combination of allelic discrimination and Taqman SNP assay was used in this experiment. The 
SLC19A1 80A>G was genotyped by RFLP. The TS1494 6bp ins/del and the TSER 3*/2* repeat 
were genotyped by allelic discrimination by sizing assay. The AOX1 3404A>G, the MTHFR 
1298A>C and the MTHFR 677C>T were genotyped by Taqman SNP assay. The validity of the 
Taqman assay for AOX1 3404A>G was confirmed by direct sequencing in our lab (results not 
displayed) and the MTHFR 1298A>C and MTHFR 677C>T by RFLP in a selected group of 
patients.  Details of these techniques are available in Chapter 2 (page no 86 and 88). 
 
 
















Statistical analysis for allele frequencies and haplotypes was performed as described in Chapter 2. 
 
 
4.4   Results: 
 
A total of 201 patients were included in the side effects group and 179 patients who completed 
therapy for 3 months were included in the clinical response group. The frequencies of the mutant 
homozygotes are displayed in (Table 4-4).  
 
All the genotypes were in HWE. There were differences in the distribution of alleles between 
clinical responders and non responders when all patients were examined together.  Although, 
overall, there was no significant difference in clinical response rates between folate supplemented 
and un-supplemented individuals, it was possible to discern differences in clinical response rates 
between those individuals that received oral folates and those that did not when stratified for 
certain genotypes. 
 
The TSER 3* allele was present in 65 of 91 (71%) individuals who experienced a clinical 
response and in 68/88 (77%) of those who failed therapy (p=0.3, OR =1.3, CI 0.6 -2.6). The TS 
1494del6 allele was present in 62 of the 91 clinical responders (68%) as compared with 71/88 
(80%) non responders (p=0.06, OR =1.9, CI= 0.9 – 3.9).  
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In the recessive model, the TSER 3*/3* did not have a significant correlation with clinical 
response (p=0.68, OR= 1.2, CI= 0.5 – 2.6). Of those who possessed the TSER 3*/3* genotype, 
20/46 experienced a clinical response (43%).  In the recessive model, the homozygous TS 6bp 
del/del genotype was equally distributed among the clinical responders and non responders (49 % 
v/s 51%) (p=0.3, OR=0.6, CI= 0.2 – 1.3). (Table 4-6)  
 
The high producer TS haplotype (TSER 3*/ TS 6bp ins) was equally distributed between clinical 
responders (43/91, 47%) and non-responders (45/88, 51%), [p= 0.65, OR = 1.16, CI= 0.64 -2.1]. 
(Table 4-6) 
 
The SLC19A1 80G allele was present in 61% of clinical responders and 68% of non-responders 
(p=0.43, OR= 1.3, CI=0.7 – 2.48). The recessive effect of the SLC19A1 80GG was also not 
significant for clinical response (p=0.8 OR= 1.169, CI= 0.4-2.7).  
 
The ATIC 347G allele was more common among responders to MTX therapy (p= 0.03, OR = 
1.57, CI 1.02 -2.42). Furthermore, we see that the major contribution to this effect comes from 
those who did not receive oral folate. (p= 0.05, OR = 2.12, CI = 0.98 – 4.5) and the effect was not 
seen in those individuals receiving oral folate.  More individuals with the ATIC 347CC genotype 
failed therapy (18/27) and when compared with the wild-type ATIC 347GG genotype, this effect 
just failed to achieve significance for clinical response as a recessive effect (p=0.07, OR=2.5 
CI=1-6.458).  The AOX 3404A>G polymorphism did not influence clinical response rates either 
in a dominant (p= 0.75) or recessive model (p=0.6) and allele frequencies did not differ between 
the clinical responders and non responders and folate supplementation did not appear too play a 





Overall side effect rates were low and MTX was well tolerated. In this relatively small group 
subgroup analysis was not possible and hence, side effects are presented as whole Only ATIC 
347C>G correlated with side effect rates. Individuals with the C allele were more likely to be free 
of side effects if they were receiving folate supplementation (OR= 2.09, CI = 1.13 – 3.8, p = 






The two tested TS polymorphisms have been reported to be in LD [416] and some have described 
a co existence of the high TS activity TSER3*R allele and the low TS activity TS6bp del allele. 
Others have not found this effect. In this study, they are not in LD (D’ = 0.06).  The proposed 
high activity haplotype did not influence clinical response rates or side effect rates with or 
without oral folate supplementation. (Table 4-8, Table 4-9).  The MTHFR677/TS 3*R/TS6bp del 
haplotype did not influence side effects or clinical response and was not affected by folate 
supplementation. (Table 4-11)  
 
For these haplotype models, we need to focus on the global p-value. The model also tests the 
effects of individual haplotypes, but this is a secondary analysis, to explore haplotype effects 
when the overall effect is significant.  The only significant result comes from the clinical 
response, folate group (p=0.029), but this is driven by the MTHFR 677 variant which alone has a 
significant effect on clinical response in patients with folate.  Further sub-models, testing whether 
either or both TS variants had a significant effect in addition to the MTHFR 677 effect, showed 
that the haplotype signal seen here comes entirely from MTHFR 677.  No significant effects of 
the haplotype were seen in the non folate group or in the study cohort as a whole. The haplotype 



















Table 4-3 The allele frequencies of the examined TS, ATIC, SLC19A1 AND AOX 
allelotypes and their distribution between clinical responders and non responders. 
In each case, the mutant allele is the allele for which the frequency, estimated Odds Ratio and p value 
refers.  Table A refers to all cases (n=179), Table B to those who did not have oral folate (n=58) and Table 
C to those who did (n=103). 
 
TABLE A 
Gene All patients   
  Response Non Response OR CI  p value 
SLC19A1 80G 0.412 0.414 0.989 0.6493 - 1.506 0.958 
ATIC 347G 0.423 0.318 1.571 1.02 - 2.422 0.039 
AOX 3404G 0.159 0.159 1.002 0.568 - 1.765 0.994 
TS 3*R 0.5 0.477 1.095 0.7235 - 1.658 0.667 
TS 6bp Ins 0.511 0.448 1.283 0.8467 - 1.944 0.239 
TABLE B 
Gene No folate supplements 
  Response Non response OR CI p value 
SLC19A1 80G 0.53 0.38 1.842 0.871 - 3.893 0.106 
ATIC 347G 0.5 0.32 2.125 0.988 - 4.569 0.0505 
AOX 3404G 0.181 0.14 1.365 0.494 - 3.765 0.544 
TS 3*R 0.515 0.42 1.467 0.699 - 3.077 0.308 
TS 6bp Ins 0.4394 0.38 1.279 0.604 - 2.707 0.519 
TABLE C 
Gene Folate supplemented 
  Response Non response OR CI p value 
SLC19A1 80G 0.35 0.402 0.803 0.455 - 1.417 0.449 
ATIC 347G 0.386 0.357 1.124 0.636 - 1.985 0.687 
AOX 3404G 0.1491 0.163 0.899 0.422 - 1.916 0.784 
TS 3*R 0.4825 0.51 0,8925 0.515 - 1.546 0.685 
TS 6bp Ins 0.543 0.4239 1.62 0.931 - 2.819 0.086 
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Table 4-4 SNP frequency information for TS, ATIC, SLC19A1 and AOX 
The frequencies reported are of the homozygous mutation. 
 
SNP 




TSER3*/2* 0.49 0.23 
TS1494del6 0.52 1.94 
ATIC 347C>G 0.37 0.09 
SLC19A1-1 80A>G 0.42 0.06 
AOX1 3404A>G 0.009 1.89 
 
 
Table 4-5 The dominant effect of the studied TS, ATIC, SLC19A1 and AOX genotypes on 
response rated to MTX therapy 
 
SNP CR NR p OR CI 
TSER3*/2* 65/91 (71%) 64/88 (72%) 0.3 1.3 0.6 - 2.6 
TS1494del6 62/91 (68%) 71/88 (80%) 0.06 1.9 0.9 - 3.9 
SLC19A1-1 80A>G 56/91 (61%) 60/88 (68%) 0.43 1.3 0.7 - 2.48 
AOX1 3404A>G 29/91 (32%) 26/88 (30%) 0.75 1.11 0.5 - 2.1 
ATIC 347C>G 59/91 (65%) 47/88 (53%) 0.13 0.6 0.3 – 1.1 
 
CR- Clinical responders, NR- Non responders 
 
Table 4-6 The distribution of the TS, SLC19A1, ATIC and AOX genotypes between clinical 
responders (CR) and non responders (NR) and the recessive effects of these polymorphisms 
on response rates 
SNP p OR CI 
TSER3*/2* 0.3 0.73 0.37 - 1.4 
TS1494del6 1 0.9 0.5 - 1.8 
SLC19A1-1 
80A>G 0.3 0.67 0.31 - 1.46 
AOX1 3404A>G 0.75 1.11 0.5 - 2.1 






Table 4-7 Haplotype analysis of the effect of the TYMS 5’UTR and 3’UTR Polymorphisms 
on the clinical response of IBD patients to MTX therapy 
P=0.65, OR = 1.1, CI= 0.6 – 2.1 for the 3R/6bp ins haplotype compared with other genotypes for 
clinical response. 
 
 Therapeutic failure Clinical Response 
 6bp ins/ins 6bp ins/del 6bp del/del 6bp ins/ins 6bp ins/del 6bp del/del 
2R/2R 3 14 7 7 14 5 
2R/3R 11 20 13 16 11 12 





Table 4-8 Influence of the TS 3*R and TS 6bp haplotype on side effect rates 
 
 Side effects Tolerated 
 6bp ins/ins 6bp ins/del 
6bp 
del/del 
6bp ins/ins 6bp ins/del 
6bp 
del/del 
2R/2R 2 6 2 10 24 10 
2R/3R 8 12 10 22 26 18 











Table 4-9 The allele frequencies of the examined TS, SLC19A1, ATIC and AOX allelotypes 
and their distribution between those that experienced side effects and those that did not. 
Table A includes all the subjects (n=201), Table B are those that did not receive oral folate 
supplementation (n=66) and Table C are those that did (n=114). In each case, the mutant allele is 




Gene All Cases Side-effects No side effects OR CI P value 
SLC19A1 80A>G 0.438 0.411 1.121 0.706 - 1.773        0.63 
ATIC 347C>G 0.438 0.352 1.439 0.905 - 2.288        0.124 
AOX 3404A>G 0.163 0.144 1.153 0.617 - 2.151        0.657 
TSER3*/2* 0.489 0.486 1.012 0.641 - 1.596        0.959 
TS 6bp ins/del 0.458 0.486 0.891 0.562 - 1.413        0.625 
TABLE B 
Gene No folate supplementation Side-effects No side effects OR CI P value 
SLC19A1 80A>G 0.4 0.48 0.721 0.315 - 1.649        0.436 
ATIC 347C>G 0.3 0.441 0.542 0.226 - 1.3          0.161 
AOX 3404A>G 0.166 0.147 1.161 0.384 - 3.504        0.794 
TSER3*/2* 0.4 0.48 0.721 0.315 - 1.649        0.436 
TS 6bp ins/del 0.4 0.431 0.878 0.383 - 2.013        0.759 
TABLE C 
Gene  Folate supplementation Side-effects No side effects OR CI P value 
SLC19A1 80A>G 0.425 0.362 1.307 0.702 -  2.434        0.4
ATIC 347C>G 0.518 0.339 2.099 1.13 - 3.899        0.0189 
AOX 3404A>G 0.111 0.155 0.68 0.265 - 1.747        0.409 
TSER3*/2* 0.537 0.488 1.215 0.658 - 2.24         0.533 






Table 4-10  The effect of the MTHFR 677/TS 3*R/TS 6bp ins haplotype on clinical response rates and the effect of folate supplementation in this group. 
The variant allele is each instance is accorded the number 1 (MTHFR677T, TS 3*R, TS 6bp Del). The wild type allele in each instance is 2. The 
reference haplotype is 1-1-1 
 
All Cases 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 31.59 42.67 0.17 0.24 1.00 1 0.08 
Chi sq=4.789, 
df=3, p=0.187 
1-1-2 28.24 28.67 0.16 0.16 1.28 0.8 – 1.9 0.83 
1-2-1 26.31 29.85 0.14 0.17 1.08 0.7 – 1.6 0.46 
1-2-2 30.86 27.80 0.17 0.16 1.38 0.7 – 2.5 0.74 
2-1-1 8.89 6.67 0.05 0.04 1.51 0.9 - 2.3 0.52 
2-1-2 22.28 13.98 0.12 0.08 1.92 1 – 3.5 0.11 
2-2-1 22.21 17.81 0.12 0.10 1.63 0.8 - 3 0.47 
2-2-2 11.62 8.54 0.06 0.05 2.09 0.9 - 4 0.39 
Folate supplemented 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 13.48 20.35 0.12 0.22 1.00 1 0.03 
Chi sq=9.04, df=3, 
p=0.02 
1-1-2 22.64 14.71 0.20 0.16 1.58 0.8 – 2.8 0.41 
1-2-1 21.02 21.83 0.18 0.24 0.99 0.5 – 1.7 0.30 
1-2-2 14.86 16.1 0.13 0.18 1.57 0.6 – 3.5 0.32 
2-1-1 5.14 4.323 0.05 0.05 2.20 1 - 4 0.93 
2-1-2 17.75 5.614 0.16 0.06 3.46 1.4 - 8 0.01 
2-2-1 12.36 6.493 0.11 0.07 2.19 0.9 - 5 0.26 
2-2-2 6.75 2.571 0.06 0.03 3.44 1.2 - 9 0.13 
No Folate Supplementation 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 17.53 16.36 0.2655 0.3271 1 1 0.44 
Chi sq=1.29, df=3, 
p=0.73 
1-1-2 6.347 6.823 0.09617 0.1365 1.205 0.5 – 2.5 0.42 
1-2-1 5.338 4.89 0.08087 0.0978 1.448 0.6 - 3 0.72 
1-2-2 13.79 4.929 0.2089 0.09859 1.745 0.5 - 5 0.074 
2-1-1 3.867 2.589 0.05859 0.05179 0.9409 0.4 - 2 0.84 
2-1-2 4.26 3.23 0.06455 0.06461 1.134 0.3 – 3.4 0.99 
2-2-1 10.27 7.163 0.1556 0.1433 1.362 0.4 - 4 0.83 
2-2-2 4.603 4.017 0.06975 0.08034 1.642 0.4 - 6 0.77 
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Table 4-11  The effect of the MTHFR 677/TS 3*R/TS 6bp ins haplotype on side effect rates and the effect of folate supplementation in this group  
The variant allele is each instance is accorded the number 1 (MTHFR677T, TS 3*R, TS 6bp Del). The wild type allele in each instance is 2. The 
reference haplotype is 1-1-1. Ca- Freq (Frequency of cases), Co- freq (frequency of controls)  
 
All Cases 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 19.82 59.18 0.21 0.19 1.00 1.00 0.77 
Chi sq=0.26, df=3, p=0.96 
1-1-2 14.24 51.03 0.15 0.17 0.89 0.5- 1.42 0.60 
1-2-1 15.28 46.36 0.16 0.15 1.01 0.63 - 1.60 0.85 
1-2-2 15.65 46.43 0.16 0.15 0.90 0.4 - 1.73 0.78 
2-1-1 5.34 14.97 0.06 0.05 0.96 0.58 - 1.57 0.71 
2-1-2 9.60 30.83 0.10 0.10 0.86 0.43 - 1.68 0.96 
2-2-1 11.56 35.49 0.12 0.12 0.97 0.49 - 1.90 0.91 
2-2-2 4.51 19.72 0.05 0.06 0.86 0.38 - 1.95 0.38 
Folate supplemented 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 8.17 28.45 0.15 0.16 1.00 1 0.80 
Chi sq=0.46, df=3, p=0.92 
1-1-2 8.84 33.07 0.16 0.19 1.07 0.5 -  1.99 0.60 
1-2-1 12.19 33.84 0.23 0.19 1.23 0.6 -  2.29 0.55 
1-2-2 8.81 24.64 0.16 0.14 1.31 0.5 - 3.17 0.63 
2-1-1 2.09 7.844 0.04 0.05 0.93 0.4 - 1.82 0.73 
2-1-2 5.91 19.64 0.11 0.11 1.00 0.39 - 2.49 0.93 
2-2-1 4.55 17.87 0.08 0.10 1.15 0.4 - 2.87 0.62 
2-2-2 3.45 8.649 0.06 0.05 1.23 0.4 - 3.71 0.53 
No Folate Supplementation 
Haplotype Case Control Ca-Freq Co-Freq Odds-R CI P-value Likelihood ratio 
1-1-1 8.44 27.14 0.28 0.27 1.00 1 0.86 
Chi sq=0.65, df=3, p=0.88 
1-1-2 3.80 12.46 0.13 0.12 0.93 0.3 - 2.16 0.94 
1-2-1 2.54 8.588 0.08 0.08 0.72 0.3 - 1.71 0.99 
1-2-2 4.22 15.82 0.14 0.16 0.67 0.2 - 2.25 0.83 
2-1-1 3.03 7.813 0.10 0.08 1.05 0.4 - 2.51 0.60 
2-1-2 2.74 5.591 0.09 0.05 0.98 0.2 - 3.29 0.38 
2-2-1 3.99 14.46 0.13 0.14 0.76 0.2 - 2.59 0.89 
2-2-2 1.24 10.13 0.04 0.10 0.70 0.15 - 3.13 0.21 
 
4.5   Discussion: 
 
4.5.1 Thymidylate synthase enhancer region (TSER) tandem repeats, TS 6bp 
insertion/deletion and MTHFR677 Polymorphisms 
 
The hypothesis that the polymorphisms increasing TS function would correlate with an impaired 
response to MTX therapy is not supported by the evidence. Hence, predictably, folate 
supplementation does not have an effect on the association. TS competes with the methionine 
cycle for the substrate 5, 10-methylene tetrahydrofolate. When the TS activity is increased as may 
be seen in the case of the TSER 3*R and the TS 6bp insertion, the expected inhibition by 
antifolate therapy may not be seen. High folate states would supply both the methionine and the 
thymidylate pathways and homocysteine levels would be normal. Low folate states would 
demonstrate the opposite effect and the resulting homocysteinemia may influence side effect 
rates.  
 
MTX therapy induces homocysteinemia that is abolished by oral folate or folinic acid 
supplementation [417].  The two formulations do not differ in their effects and there is no 
influence of the MTHFR 677 genotype on this effect. Other groups have reported that folic acid 
and folinic acid supplementation did not affect the homocysteine levels seen in MTX treated 
patients implying that the DHFR inhibition seen with MTX therapy may not be relevant in the 
low anti inflammatory doses used in this study.  MTHFR is strategically positioned between the 
methionine and the thymidylate pathways. The methionine pathway as described earlier can be 
affected by variant MTHFR activity and may have some impact on the clinical efficacy of 
antifolate therapy such as MTX. This may explain the positive association of the MTHFR 677TT 
genotype on clinical response in Chapter 3 (page 114). The haplotype analyses here do not 
support an interaction between MTHFR and TS on clinical response to MTX.  
 
There could be a number of reasons for this. In addition to body folate levels, Vitamin B12 and 
Vitamin B6 are important co-factors and may have confounded the effect of the studied 
polymorphisms. Deficiencies of Vitamin B12 can result in increases in plasma homocysteine 
levels [418]. There is a G/C functional SNP in the second repeat of the 3*R allele that appears to 
influence clinical response to oral fluoropyrimidine adjuvant therapy. The G allele is proposed to 
decrease TS transcription and reduce clinical response to therapy [419] and the combination of 
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the three TS high activity polymorphisms are additive on serum homocysteine levels [420]. Data 
on this polymorphism are not available in this study.   
 
4.5.2 The Reduced Folate carrier (SLC19A1) 
 
The hypothesis that individuals with the SLC19A1 80AA genotype would be predisposed to an 
improved outcome from MTX therapy in this study of individuals with IBD could not be proven. 
We have also found that the polymorphism did not influence side effect rates. As was expected, 
oral folate supplementation did not affect these findings.  The elevated MTX levels seen in 
leukaemia in carriers of the SLC19A1 80AA genotype [421] and higher methotrexate 
polyglutamate levels and improved therapeutic benefit in RA [338, 422, 423] has been at odds 
with the results of a large prospective trial in RA  [422] and a retrospective study in IBD [399]. A 
retrospective study in psoriasis associated the SLC19A1 80A with side effects but not with 
response to medication. Importantly, in functional studies, no differences were noted in the 
uptake of MTX by leukaemic blast cells with the mutant SLC19A1 protein versus the wild type 
[424] and the role of this polymorphism in modifying MTX drug response remains controversial.  
 
SLC19A1 is considered to be a relatively low capacity transporter of folate and anti folates [294] 
in comparison to the folate binding protein (FBP) or the folate receptor (FR) which has higher 
affinity for reduced folate cofactors and folic acid relative to the antifolates. This mechanism 
maintains cellular folate levels [295]. While the low pH transporter, expressed independently of 
SLC19A1 transports reduced folates and anti folates such as MTX, its relevance as the transporter 
mechanism at physiological pH is questionable [425, 426]. Despite that, these alternative routes 
of folate transport may be critical in tissues with low SLC19A1 expression and may explain the 




That adenosine is an important mediator of the anti-inflammatory effects of MTX is not 
contested. MTX inhibits ATIC and this may lead to an intracellular accumulation of adenosine. 
This occurs by way of accumulation of AICAR. This compound inhibits the catabolism of both 
AMP and adenosine by the inhibition of the enzymes AMP deaminase and ADA. The 
intracellular adenosine accumulation is followed by extracellular efflux. These findings have not 
been restricted to RA. In IBD, a similarly pro-inflammatory state that is attenuated by ADA 
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inhibitors has been described in an animal model [427]. Adenosine inhibits neutrophilic 
recruitment, adhesion and the generation of superoxide anions [428]. In experimental colitis, it 
attenuates mucosal TNF-α, IFN-γ and plasma TNF-α, and IL-6 [427]. The anti-inflammatory IL-
10 and TGF-β are relatively unaffected [429]. In essence, there is a move form a Th-1 to a Th-2 
inflammatory profile [430] and not surprisingly, this effect has generated interest in the 
therapeutic potential of adenosine inhibitors in inflammatory diseases.  
 
There remains some uncertainty over the role of genetic variation in ATIC and the subsequent 
influence on MTX effects as has been reviewed in chapter 1 and there are no reports on the 
functional effects of this polymorphism. Like the results here, the first report of ATIC 347C>G 
on MTX response in RA showed that the minor allele correlated with clinical response [423]. 
However a subsequent larger study demonstrated the exact opposite, namely the major allele was 
associated with superior clinical response [390].  These contentious findings have had some 
clarification from a recent GWAS examination that was applied to MTX therapy in RA. This 
showed that an intronic marker rs4673993 that was in complete LD with the ATIC 347C>G 
polymorphism also showed an association for clinical response with the minor allele, hence 
consistent with the first reported observation [431] and the results in this study. It is important to 
note that this GWAS study did not follow a hypothesis free approach; nevertheless it was the only 
positive finding.  None of these studies have specifically reported on the influence of folate 
supplementation on these effects.  
 
The results in this study draw attention to another animal model where the anti inflammatory 
effects of MTX were not abolished by adenosine receptor antagonists but instead by high doses of 
folic acid supplementation [319]. The doses of MTX used were considerably higher than in 
earlier experiments and is consistent with a landmark double blinded clinical trial [432]. These 
data provide an elegant illustration of the differences between low dose and high dose MTX 
therapy. There may be a folate dependent mechanistic influence of ATIC on MTX response that 
is currently undefined. The findings in this experiment show that the clinical effects of MTX 
therapy in carriers of the major ATIC 347C allele are higher in those individuals receiving oral 
folate supplementation. Not taking oral folates appear to reduce response rates in carriers of this 
allele. Faced with this novel effect, one may also hypothesize that the ATIC 347C>G 
polymorphism is in LD with another functional variant that influences MTX response in a folate 
status dependent way. Clearly, these findings suggest a need for further investigation of these 




4.5.4 Aldehyde Oxidase (AOX-1) 
 
The expected effect of the polymorphism was not seen. The influence of Aldehyde oxidase on 7-
OH MTX levels are seen in cancer chemotherapy and the lower dosages of MTX used in IBD 
may not be adequate. The proposed influence of the SLC19A1-1 variant on clinical efficacy was 
also not seen. Both hypotheses were discarded 
 
4.5.5 Side effects  
 
Using the pharmacogenetic model to study the correlation of genetic variation on side effect rates 
is a major rationale for the approach. However the process is fraught with difficulty as a number 
of the side effects are not attributable to single patho physiological mechanisms. Previous studies 
have tried to introduce a classification to side effects namely hematological, hepatic, gastro 
intestinal, skin and mucosa, neurological etc. While this is reasonable for data collection, analysis 
of the small numbers in each of these groups is not without difficulty. One is left having to merge 
some of these groups to attain meaningful numbers. This erodes the rationale of the exercise. In 
this thesis, the approach is of reporting all side effects and subsequently examining those that led 
to cessation of therapy. It was hoped that this approach will avoid some of the pitfalls of other 
approaches.  
 
Individuals with the wild type ATIC 347G allele were more likely to be free of side effects if they 
were receiving folate supplementation. The ATIC 347GG genotype has been correlated with 
gastro intestinal intolerance in a study of patients treated with MTX for RA [389]. There was no 
stratification for folate status although 20% did not receive oral folates. In the data presented here, 
the numbers of affected individuals are small but there do not appear to be a particular 








4.6  Summary  
 
In IBD, particularly UC, immunomodulators are often used after aminosalicylates have failed. 
When used, MTX traditionally follows AZA failure or intolerance. In recent practice, biologics 
such as infliximab may replace MTX as second line therapy. Importance should be attached to 
evidence in RA where the early use of MTX is nearly as effective as biologics [433]. Efficacy 
rates of 40 -50% may reflect the role MTX currently plays i.e., a second line drug used in 
potentially advanced or complicated disease. The role of pharmacogenetics is particularly 
important in such a situation as potentially greater benefit could be obtained if MTX could be 
offered as second line therapy in a group more likely to respond and infliximab be preferred 
second line therapy in the group more likely to fail therapy. 
 
It is clear that MTX inhibits several key enzymes responsible for purine and pyrimidine synthesis. 
This affects DNA and RNA formation and is obviously cytotoxic. However, equally clearly, there 
is a difference between the effects of MTX as seen in cancer chemotherapy and those seen in the 
treatment of chronic inflammatory conditions such as RA, psoriasis and CD. Weekly low-dose 
MTX can suppress disease activity over a period of weeks and administration of folic acid every 
week does not affect clinical efficacy but reduces adverse drug events.  There is no evidence that 
systemic toxicity in individuals receiving antifolates correlates to homocysteine levels, however 
folate supplementation abolishes homocysteinemia and also prevents side effects.  These obvious 
discrepancies between what is expected and what was observed have been the subject of intense 
investigation.  
 
Comprehensive reviews have provided some insight into this but there remains a need for further 
clarity in this area [312, 434]. It is possible that the effects of MTX therapy in IBD are unrelated 
to the folate pathway and may explain why these polymorphisms, in contrast to cancer 
chemotherapy, are not particularly influential in inflammatory diseases. This has now been the 
experience in a number of reports. Other mechanisms have been explored in RA and some 
evidence suggests that the effects of MTX in vivo may be due to T-cell apoptosis, modified 
cytokine production and reduced T cell proliferation. A role for intracellular reactive oxygen 
species (ROS) levels, inhibition of pyrimidine pathway enzymes and increasing CD 95 sensitivity 
of CD45+RO cells (activated T-cells) has been demonstrated and these may be significant [327]. 
Some of these alternative mechanisms are explored in subsequent chapters in this thesis. 
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5 The influence of the HLA-G 14 bp insertion / deletion polymorphism 
and the IL-10 promoter haplotype on response to MTX and AZA in 
individuals with IBD 
 
 
5.1   Introduction 
 
HLA-G is a non classical class I antigen and is biologically active. It creates a truncated form by 
alternate splicing that appears to mediate an anti inflammatory or a tolerogenic state. There is 
evidence that some of these effects are associated with elevated IL-10 levels and there may be a 
close correlation between the two. There is also evidence that the molecule is very relevant in the 
maintenance of a viable foetus, transplant graft survival and tumour cell viability. Genetic 
polymorphism in the 3’ UTR, specifically a 14 base pair insertion destabilises the mRNA and 
may influence the effects of immunosuppressive medication [138].  
 
5.2    Hypotheses 
 
The hypotheses are:  
• The HLA-G 14bp del/del polymorphism by means of increasing tolerance in intestinal 
mucosa in individuals with IBD predisposed them to response to immunomodulatory 
medication.  
• High IL-10 producers (GCC haplotype) would be more likely to experience these anti 
inflammatory effects of the HLA-G 14bp ins/del polymorphism. There may in addition, 
be an independent effect of IL-10 on clinical response to immunosuppressive medication. 
 
5.3   Aims 
 
1. To examine the effects of he HLA-G 14bp ins/del polymorphism and the IL-10 haplotype 
on response to the study medication namely AZA and MTX in patients with IBD.  
2. The HLA-G region is in LD with other areas in the chromosome 6, some of which 
influence susceptibility to IBD and influence joint disease in these patients. Hence the 






5.4   Study Design 
 
Three groups of patients were included in these experiments.  
 
5.4.1  Methotrexate cohort 
 
The patient cohort characterised and studied in the previous chapters on folate pathway enzyme 
pharmacogenetics is used here. (Table 5-1) 
 
5.4.2  Azathioprine cohort 
 
Patients for the AZA part of the study formed part of a prospective multicentre study of AZA for 
the treatment of IBD. It was designed to assess the impact of pre-treatment TPMT genotype and 
activity and subsequent red cell TGN levels on clinical outcome. The initial study reported on 215 
individuals. All patients were aged between 16 and 80 years of age and had IBD diagnosed by 
standard criteria. After an initial TPMT assay to exclude low activity, patients were commenced 
on AZA 2mg/kg/day taken orally. The patients were followed up at weeks 4, 12 and 24 when they 
underwent an assessment of disease activity (Harvey Bradshaw Index for CD and Truelove and 
Witts for UC), side effects, TGN levels, full blood counts, liver function tests, ESR, CRP and a 
record of concomitant medication. Data was specifically collected on the use of steroids, 5-ASA. 
All those on steroids underwent a steroid taper over 12 weeks.  Clinical response was defined as 
the achievement of each patient’s stated treatment goal according to indication for treatment. 
Steroid withdrawal was defined as complete withdrawal of corticosteroids by 3 months and 
remaining off corticosteroids for a further 3 months. Maintenance of remission was defined as 
maintenance of normal inflammatory parameters and activity indices for 6 months. Remission of 
active disease was defined by normalization of disease activity indices at 6 months of treatment. 
Recourse to surgery, an alternative immunomodulator or a biologic agent was considered 
treatment failures. Adverse drug effects were recorded. The full protocol of this study has been 
reviewed and reported elsewhere [435].  
 
A total of 124 patients completed the intended 6 months of therapy. The rest withdrew from 
therapy, mainly due to gastrointestinal intolerance. There was a significant positive correlation of 
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drug intolerance with TPMT intermediate activity. In those that completed therapy, there was also 
a negative correlation of clinical response with TPMT high activity and a positive correlation 
with therapeutic TGN levels. DNA in sufficient quantities for the experiments reported here were 
available in 97 patients of the 124 that completed 6 months of treatment. As this is a study of the 
markers of response to therapy, all those who were unable to complete a minimum of 6 months of 
treatment were excluded. They and the subjects whose DNA samples were exhausted form no 
part of this study.  
 
The mean age was 36 years (range 18-80) and 43 were female. 48 (50%) patients were treated for 
CD of whom 11 (21 %) had ileal disease, 23 (44%) ileo-colonic and 14 (27%) colonic disease. Of 
the 49 patients with UC, 28 (55%) had pancolitis, and 21 (45%) had distal colitis. In the majority 
of patients (84/97, 85%), AZA was used as a steroid-sparing agent.  Induction of remission of 
active disease was the indication in 3 (3%) patients, maintenance of remission in 10 (10%) 
patients (Table 5-2). 
 
 
5.4.3  IBD susceptibility cohort 
 
This cohort comprised 920 cases with CD, 654 UC and 665 controls. The cohort has previously 
been reported in a CD susceptibility study [436]. A multicentre research ethics committee 
approved the study of IBD susceptibility genotype in this cohort and the patients were recruited 
from Guy’s and St. Thomas’ Hospital, London, St. Mark’s Hospital, London and the Royal 
Victoria Infirmary, Newcastle. All patients provided written informed consent. The diagnosis of 
IBD was established by standard clinical, radiological and endoscopic criteria. Phenotypic data 
was available on the majority of the individuals included (908 CD cases and 475 UC cases). This 
data is displayed in (Table 5-3). Matching of controls was not performed. 
The population controls were obtained from the 1958 birth control cohort. The ethnicity of both 



















Table 5-3 The demographics and clinical characteristics of 908 patients with CD and 475 







5.4.4   Genotyping  
 
The Forward Primer was RHG4 5′-GGAAGGAATGCAGTTCAGCATGA -3′ and the reverse 
Primer was GE14HLAG  5′-GTGATGGGCTGTTT AAAGTGTCACC -3′.   
Thermocycling conditions were 92°C for 5 minutes, and 30 cycles at 92°C for 30 
seconds, 64°C for 1 minute, and 72°C for 2 minutes, with a final elongation step of 72°C 
for 10 minutes. Reactions were set up in a 25μl mixture containing 100 ng of genomic 
DNA, 0.2 mmol/l NTPs, 1.5 mmol/l MgCl2, 10 pmol of each primer, and 1U of Taq 
polymerase.The amplified products were visualized by electrophoresis on a 2.5% agarose gel 
(Invitrogen, Paisley, Scotland, UK) containing ethidium bromide (0.5 µg/ml) and were run at 
100v for 120 minutes. 
 
 
5.4.5   Sequencing 
 
The IL-10 promoter region containing the -1082 A>G (rs1800896), -819 C>T (rs1800871) and -
592 C>A (rs1800872) polymorphisms was amplified using MolTaq Thermostable DNA 
polymerase 5 U/µl (Molzym GmBH&Co. KG, Bremen, Germany), in a total volume of 50 µl 
PCR reaction containing 0.5 µM of forward primer 5’-
CACAAATCCAAGACAACACTACTAAGG-3’, and reverse primer 5’-
ATCCTCAAAGTTCCCAAGCAGC-3’. Primers were designed using the Primer3 v.0.4.0 
website [393]. The thermocycler profile was 35 cycles of 94°C for 30 s, 54°C for 30 s, and 72° 
for 1 min. Amplified PCR products were purified using QIAquick®PCR purification Kit 
(QIAGEN Ltd., Crawley, West Sussex, UK). Sequencing reactions were performed using the 
BigDye®terminator v3.1 cycle sequencing kit (Applied Biosystems, Warrington, UK) with an 
additional two nested primers, forward 5’-GGGTGGAAGAAGTTGAAATAACAAGGAA-3’, 
and reverse 5’-AAGTGCAGACTACTCTTACCCACTTC-3’. Sequencing reactions were cleaned 
using Agencourt®CleanSeq® (Beckman Coulter (UK) Ltd-Biomedical Research, High 
Wycombe, UK), and run on an ABI PRISM 3130x1 Genetic analyser (Applied Biosystems, 
Warrington, UK). Sequences were analysed by Mutation Surveyor Local v3.20 (Softgenetics 




5.4.6   Statistical  analysis 
 
Statistical analysis was performed as described earlier. 
 
 
5.5   Results 
5.5.1  Methotrexate cohort 
5.5.1.1 HLA-G 14 bp insertion/deletion polymorphism 
 
All 201 patients were successfully genotyped. The genotype frequencies are comparable to 
control data in other independent studies [158,159]. Genotype frequencies were in Hardy-
Weinberg equilibrium (χ2 = 1.79) (Table 5-4). 
 
The insertion allele occurred significantly more commonly in patients who failed treatment 
compared to those who responded to treatment (80% vs. 54% respectively, p=0.0001, OR = 
3.580, 95% CI: 1.5 to 8) (Table 5-5). 
 
The variant HLA-G 14bp insertion allele had a frequency of 0.36 in those that responded to MTX 
therapy and 0.53 in those that did not (p=0.0007, OR= 0.48, CI 0.31 – 0.74) (Table  5-7). Folate 
supplementation did not influence this effect. There were no significant differences in the 
distribution of the IL10 -1082G allele between responders and non responders to therapy. Folate 
status did not have an effect.  The type of IBD (UC vs CD had no influence on this effect 
(p=0.56). The insertion allele did not identify those who had a higher likelihood of failing AZA 
therapy in the past (p=0.88).  UC and CD patients did not differ in genotype distribution or 
clinical response rates. 
 
 
5.5.1.2  IL-10 -1082 A>G polymorphism   
 
The mutation was present in 71 % of clinical responders and in 73% of non responders to MTX 
therapy. (p=0.86, OR = 1.06, CI= 0.5 – 2.05). Folate supplementation did not play a role in 




5.5.1.3  Interaction between the HLA-G 14bp genotype and the IL-10 1082A>G genotypes  
 
A conditional analysis was performed to assess the influence these two polymorphisms may have 
on each other and on the primary outcome of clinical response.  The results show a significant 
result for the haplotype of HLA-G14bp ins/del and IL10 -1082A>G (p=0.0036), but this is 
primarily from the HLA-G14bp ins/del contribution, as can be seen from the OR of 0.61 and 0.36 
for the IL-10 1082G allele at the first marker (HLAG 14 bp ins). There is some indication that the 
OR for (IL-10 1082G – IL-10 1082G)   is lower than for (IL-10  1082G – HLAG 14bp ins), 
which would indicate a role for IL-10 1082A>G in moderating the risk of HLA-G14bp ins/del. 
However, an analysis of IL-10 1082A>G conditional on HLA-G14bp ins/del) give no increase in 
fit (p-value = 0.34286) Fitting an additive model for risks across the two loci, (which reduces the 
degrees of freedom) does not help (p-value = 0.228543 for IL-10 1082A>G conditional on HLA-
G14bp ins/del). (Table 5-6) 
 
 
5.5.1.4  Side effects 
 
Neither the HLAG 14bp insertion allele nor the IL10 -1082G allele influenced side effect rates. 
Folate supplementation also had no influence on this effect (Table 5-8).  
 
5.5.2   Azathioprine cohort 
5.5.2.1  The HLA-G 14 bp insertion/deletion polymorphism 
 
All 97 patients were successfully genotyped and data are given in (Table 5-9) 
 The observed frequency of the deletion allele in the cohort was 54%. This is comparable to 
genotype frequencies in 665 population controls (55.3%) and control data in other independent 
studies [158,159]. Genotype frequencies were in Hardy-Weinberg equilibrium (χ2 = 0.4201). The 
homozygous del/del genotype frequency was significantly lower amongst patients who failed 
treatment compared to those who responded to treatment (12.5% vs. 44% respectively, p=0.001, 
OR = 5.469, 95% CI: 1.869 to 15.9). 
 
The same pattern was also seen when the data was stratified by type of IBD. In those receiving 
AZA for CD, 2 of 19 (10%) non-responders were del/del homozygotes compared to 15 of 29 
(52%) responders (OR = 9.107, 95% CI: 1.773 to 46). Similarly, 3 of 21 (14%) UC patients 
 145 
failing to respond to treatment were homozygous for the del/del genotype compared to 10 of 27 
(37%) of those who responded. UC and CD patients did not differ in genotype distribution 
(p=0.3851) or rate of clinical response (p=0.6).  No differences were noted in age, sex, steroid 
use, 5-ASA use, pre-treatment TPMT, AZA dose and 24 week 6-TGN levels between the HLA-G 
14bp del/del and insertion groups (Table 5-9). 
 
 
5.5.2.2  IL-10 promoter haplotype 
 
Genotyping was successful in all patients. All genotypes were in Hardy-Weinberg equilibrium. 
There were no significant differences in genotype distribution between clinical responders and 
patients who failed treatment or when divided into UC and CD subgroups. Although more 
patients with UC than CD had the -1082 G/G genotype [11/48 (23%) vs. 8/48 (17%)], this 
difference was not significant.  
 
However, interestingly, no patients with the combined favorable HLA-G 14bp del/del genotype 
and the IL-10 GCC/GCC haplotype failed treatment. Possession of the favorable HLA-G 14bp 
del/del genotype and the IL-10 GCC haplotype conferred a significant likelihood of clinical 
response [18/20 (82%)] compared to those who lacked this combination [18/20 (82%) versus 
39/76 (51%) respectively, p=0.001, OR = 8.4, 95% CI: 1.8 to 39) (Table 5-10). 
 
5.5.2.3 The influence of TPMT activity and TGN levels on clinical response to azathioprine 
 
As has been described previously, the HLA-G 14bp genotypes did not differ in the distribution of 
TPMT genotypes and the TGN levels at 24 weeks. It is recognised that TPMT levels correlate 
with clinical response and that TGN levels may do the same. As the findings of the study that 
forms the source of the patients in this experiment has found similar results, it is important to 
asses the influence of these variables on clinical response in this cohort. Exhaustion of DNA 
stocks led to the exclusion of 27 subjects who were suitable for inclusion (had completed 6 
months of treatment). 
 
TGN levels at 24 weeks were available in 76 individuals. A level of greater than 100pmol/ 8 × 
108 RBCs was taken as predictive of clinical response in the original publication. Hence that has 
been used here. 44 patients achieved levels greater than this cut off.  The TGN levels did not 
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correlate with clinical response in this group (p=0.23, OR= 1.891, CI = 0.7 -4.8). The high TGN 
patients were not different in distribution between the HLAG deletion individuals (High TGN 
levels in Response vs. treatment failure among HLA-G 14bp del carriers), p= 0.16, OR= 2.3, CI = 
0.7 – 7.3). 
TPMT levels correlated with therapeutic response in the study population.  A TPMT level of 
more than 35pmol/hr/mg of haemoglobin was more frequent among clinical non- responder than 
in responders to AZA (p=0.02, OR =2.7, CI = 1.18 – 6.2). The number of patients with high 
TPMT levels were more among those with a HLAG 14bp insertion than in those without the 
insertion, but this difference fails to achieve significance (p=0.07, OR = 2.3, CI = 0.9 – 6). 
 
 
5.6  IBD susceptibility cohort 
 
All the genotypes were in HWE. The 14 bp del allele was not distributed significantly differently 
among the individuals with UC (p= 0.97, OR=1, CI= 1- 1.7) or CD (P= 0.9, OR = 0.99, CI = 1 – 


















Table 5-4  SNP frequency information for HLA-G 14 bp ins/del and IL-10 -1082A>G in the MTX group 
From dBSNP.http://www.ncbi.nlm.nih.gov/projects/SNP/.  
The frequencies reported are of the homozygous mutation. 
 
 
Table 5-5 The dominant influence of the HLA-G 14bp insertion/deletion polymorphism and the IL-10 1082A>G polymorphisms on 
clinical response.  
 





Table 5-6  The influence of the haplotype of the HLAG 14bp insertion allele and the IL-10 1082 G allele on clinical response rates to MTX 






Table  5-7  The allele frequencies of the examined genotypes and their distribution between 
clinical responders and non responders 
Table A includes all the subjects, Table B are those that did not receive oral folate supplementation and 
Table C are those that did. In each case, the minor allele is the allele for which the frequency, estimated 
Odds Ratio and p value refers.  All patients n=179, Folate supplemented n=103, Folate not supplemented 






Figure 5-1 The effect of the HLA-G 14bp del/del genotype on the percentage of patients 
with IBD responding to treatment with AZA. 
 
Individuals with the insertion allele had a 48% chance of response to medication as opposed to 
the del/del genotypes that had an 83% chance of success. 
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Table 5-8  The influence of the HLAG 14bp insertion allele and the IL10-1082G allele on 
side effect rates.  





Table 5-9  Genotype frequencies of HLAG 14 bp Ins/del and the IL-10 promoter 







Table 5-10  The influence of the high producer HLAG1bp and IL10 promoter haplotypes on 
clinical response to AZA 
 
HLA-G 14bp ins/del (HLA-G 14 base pair insertion/deletion polymorphism), IBD (Inflammatory 
bowel disease), UC (Ulcerative colitis), CD (Crohn’s disease). The high producer promoter 












Table 5-12 Differences in the prevalence of the HLAG 14 bp ins/del polymorphism between 







5.7  Discussion:  
 
Previous studies in RA have shown that the HLA-G 14bp deletion polymorphism is associated 
with MTX response (p= 0.009; OR= 2.46, 95% CI 1.26 to 4.84 ) and the expression of sHLA-G 
in LPS stimulated PBMCs cultured with MTX in vitro is highest in subjects with the homozygous 
14bp deletion [437]. There is evidence that the HLA-G 14bp ins/del polymorphism influences the 
response to post-organ transplant immune suppression and that sHLA-G levels are up regulated 
by this treatment [438, 439].  
 
The MTX group have demonstrated a powerful influence of the studied polymorphism that is 
apparently folate independent. It is interesting that the genotype was not under represented in the 
MTX group as the majority of patients had arrived at MTX after AZA therapy. However, the bulk 
of these were intolerant to AZA rather than unresponsive to it and that may explain this finding. 
IL-10 promoter polymorphisms do not modify the influence and the dose of MTX used has not 
modified the effect.  
 
The study presented in this chapter has demonstrated an association with response to AZA and 
MTX treatment in patients with IBD. Presence of the HLA-G 14bp insertion polymorphism is 
associated with a significantly reduced likelihood of successful response to AZA treatment 
irrespective of disease type, but the influence appears stronger in CD compared to UC.  No such 
differences were seen in the MTX treated group but UC patients were not very many. 
 
The immunosuppressive effects of AZA may be due the integration of 6-TGN’s into DNA 
leading to DNA fragility, failure of repair mechanisms and inhibition of replication [440]. These 
effects are almost certainly less relevant at the lower dosages of the drug used in the treatment of 
inflammatory conditions such as IBD [441]. In this setting, more recent evidence suggests that the 
drug may act via 6-Thio-GTP and its inhibitory effects on Rac1 and subsequently on T cells 
leading to apoptosis [255, 442]. The 24 week TGN levels did not correlate with clinical response. 
Whilst as described earlier, the mechanism of action of thiopurine drugs is poorly understood, 
there is no doubt that the generation of high levels of 6-TGN predisposes to haematological 
toxicity [443] and that high levels of MeMP can predispose to hepatoxicity [273, 444]. 6-TGN 
levels above 450 pmol/8×108 are associated with leucopenia in TPMT deficient patients started 
on standard dosage therapy [445, 446]. However on dose escalation, WBC counts trends are 
relatively modest (8.6 down to 6.9 ×103) and patients experience significant benefits in reducing 
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disease activity indices and steroid requirements at TGN levels that do not cause leucopenia 
[447]. However, the application of TGN levels in targeted dose adjustment of AZA has been 
difficult to justify in light of significantly contradictory trials [212]. In light of the mechanism of 
the action of AZA that could include TGN mediated modulation of Rac-1, this is somewhat 
difficult to reconcile and may be the effect of small sample sizes and variable recruitment criteria. 
Furthermore, the technical aspects of TGN measurement are difficult and are not consistent 
across different laboratories [264].   A meta analysis has addressed some of these difficulties and 
demonstrated that TGN levels  more than 230 pmol/8×108 are more commonly found in 
individuals responding to AZA/6-MP (p= 0.006 for clinical response , 95%CI) [448].  This is not 
the experience with the limited data available in this group,  
 
At first glance the TPMT levels appear to contribute significantly to clinical response in this study 
and may be a confounding influence. An important consideration is that the TPMT heterozygotes 
were in effect excluded form this study group due to the design of therapeutic intervention. A 
large number of heterozygotic individuals were intolerant of the fixed full dosing used and 
withdrew before the conclusion of the trial. Also, although the p values denote significance, the 
confidence intervals are wide. These limitations make further analysis of this observation 
difficult. Importantly, the TPMT levels or genotypes were not distributed differently between the 
HLA-G 14bp genotypes and conditional analysis suggests that the major contribution to clinical 
response is from the HLA-G genotype.  
 
Intestinal epithelial cells (IECs) are important in innate and adaptative immunity and HLA-G may 
protect IECs from NK-mediated cell lysis [449]. PBMCs that express HLA-G, influence decidual 
cells in vitro leading to a shift from Th1 to Th2 cytokine expression (reduced TNF-α and IFN-γ 
and increased IL- 4 [450]. IBD has traditionally been considered a consequence of an imbalance 
in the interaction between Th1 (via secretion of IFN-γ, TNF-α, IL-2) and Th2 (via IL-10 and IL-
4) mechanisms [451]. An HLA-G mediated shift from Th1 to Th2 expression and the implied 
resolution of an acute inflammatory state may explain the correlation with response to anti-
inflammatory or immuno-modulatory therapy.   It has been postulated that HLA-G, through the 
expression of IL-10, or sHLA-G, mediates a protective effect at the mucosal interface in the gut 
[449]. Enhancement of this effect may therefore be another potential mechanism of action of 
AZA and MTX. 
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IL-10 production in PBMC cultures has previously been noted to be highest in individuals with 
the HLA-G 14bp ins/ins genotype [180] and serum IL-10 levels have been implicated in 
modifying response to immunomodulators in RA [452]. HLA-G and IL-10 appear to be closely 
interrelated in their immunological influence [180].  Hence, it is possible that the HLA-G 14bp 
insertion destabilises mRNA and impairs sHLA-G production. When this is associated with 
impaired IL-10 secretion, the response to immunomodulatory drug therapy may be diminished.  
Although limited by small numbers in sub-group analysis, the data in this study appears to 
support this hypothesis. The combination of the favourable HLA-G 14 bp deletion and the IL-10 
GCC promoter haplotype favoured a clinical response to AZA therapy in IBD patients. 
 
Interestingly, this study revealed that the influence of HLA-G 14bp ins/del polymorphism on 
response to AZA medication was less significant for UC than for CD. LPS-stimulated PBMCs 
from patients with UC express more sHLA-G in association with lower IL-10 production than 
those from individuals with CD [159]. No correlations with genotype were made. 
Immunohistochemical studies of gut mucosa have shown that all patients with UC express HLA-
G and IL-10 at the apical surface of intestinal epithelial cells (IEC) and the crypts of Lieberkuhn 
in both non-inflamed and inflamed areas. This was not seen in patients with CD [451]. Hence, 
there is clearly a difference in the expression of HLA-G both in vivo and in vitro however 
mechanistic inferences are difficult to make currently. 
 
In light of extensive LD across the HLA region and the known association of this area with 
susceptibility to colonic CD and joint disease in IBD patients, it is reassuring that the 14 bp 
ins/del polymorphism is not increased in frequency amongst those with CD, UC or IBD (UC 
+CD) when compared with controls. This is particularly relevant because of the previously 
reported association of the 14 bp ins/ins genotype with ileo-caecal resection in individuals with 
CD [177].  
 
In conclusion, the 14bp insertion/deletion polymorphism in HLA-G influences individual 
response to AZA and MTX in IBD. The polymorphism does not influence susceptibility to UC or 
CD and does not correlate with disease location in CD. Possession of the insertion allele 
significantly reduces the likelihood of successful clinical response. The hypothesis that there is a 
further independent correlation between AZA response and IL-10 promoter haplotype is not 
supported by our data but IL-10 and HLA-G genotypes may act together to influence response. 
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Further investigation of these immunomodulatory effects is likely to improve our understanding 


































6 IL-10 and soluble HLA-G expression in vitro is influenced by 
genotype/haplotype and is different between samples co-incubated 
with 6-mercaptopurine and methotrexate  
 
 
6.1   Introduction 
 
Like other HLA molecules, soluble HLA-G (sHLA-G) is detectable in body fluids [148] and 
decreased sHLA-G correlates with adverse foetal outcomes [453]. Conversely, increased sHLA-G 
levels are associated with an improved pregnancy outcome and improved graft acceptance after 
cardiac and liver-kidney transplantation [150, 151]. Expression of sHLA-G in transplant 
recipients is induced by therapy with steroids, tacrolimus and ciclosporin and correlates with 
improved graft survival [439].  In vitro experiments on peripheral blood mononuclear cells 
(PBMCs) have shown a similar effect of MTX in RA [437]. The reduced sHLA-G expression 
reported in patients with UC, as compared to healthy subjects and those with CD was related to a 
reduction in IL-10 secretion [159]. Hence although, an influence of the interaction between the 
genotypes investigated in the previous chapter could not be found on clinical response to 
immunomodulatory medication, HLA-G and IL-10 may be closely interrelated [180].  
 
  
6.2   Hypotheses 
 
The hypotheses examined in this chapter are 
1.  The expression of sHLA-G would be diminished in individuals possessing the 14 bp 
insertion. 
2. The expression of IL-10 would be influenced by the promoter haplotypes examined and 
the high producer GCC would express the highest levels. 
3. The expression of IL-10 would be higher in individuals with the HLA-G 14bp del/del 
genotype than in those with the other genotypes. 
4. The expression of sHLA-G and IL-10 from immune cells would be influenced by 
exposure to MTX and 6-MP and differences would be seen between the high producer 
and low producer HLA-G and IL-10 genotypes or haplotypes. A dose effect would be 
evident.  
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5.  There would be an increase in IL-10 and a decrease in pro inflammatory cytokines such 
as TNF-α and IL-1β among those individuals who expressed the highest sHLA-G levels 
when compared with those who expressed the lowest levels. 
 
6.3  Aims 
 
1. To asses the level of IL-10 expression in LPS stimulated PBMCs at 24 Hours and 48 
hours after incubation with varying concentrations of AZA and 6-MP.  
2. To assess the level of sHLA-G expression in LPS stimulated PBMC cultures incubated 
with varying concentrations with AZA and 6-MP. 
3. To assess the differences in the levels of TNF-α, IL-23, IL-6, IL-1β, IL-18 and IL-8 in the 




6.4  Study design and methods 
 
Seventeen Caucasian, female volunteers, aged between 25 and 55 years, were recruited for 
PBMC experiments. IL-10 haplotyping failed in one individual. This sample has been used for 
analysis involving the HLA-G14bp ins/del genotypes which was successful.  Hence IL-10 
analysis is performed on 16 individuals and sHLA-G on 17 individuals. None of the volunteers 
had co existing medical conditions or were on any medications.  Written informed consent was 
obtained from all participants.  Ethical approval for the additional pharmacogenetic work and cell 
culture experiments was granted by Bexley and Greenwich LREC (06/Q0707/84).  
 
The monocytes were isolated and expression of sHLA-G and IL-10 was compared between 
cultures with and without MTX alone or 6-MP alone after LPS challenge and incubated for 48 h.  
MTX and 6-MP in concentrations of 0.25, 0.5 and 1 μM were studied. HLA-G 14bp ins/del 
genotyping was performed as described (page no: 96). Sequencing of the IL-10 promoter region 
containing the -1082 A>G (rs1800896), -819 C>T (rs1800871) and -592 C>A (rs1800872) 
polymorphisms was performed. For the assay of other cytokines, of the samples already collected, 
the 3 individuals with the highest baseline sHLA-G levels were selected from amongst the high 
producer genotypes and those with the lowest sHLA-G levels from the low producer genotypes.  
The low producer genotypes were those with the 14bp insertion allele.  Samples from these six 
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individuals were used for this experiment.  The samples analysed were as described before. Only 
samples incubated for 48 hours were used. The samples were analyzed by Flowcytomix assay. 




The values for the different samples that were analysed in duplicate were used and means were 
calculated. The mean values were used for all calculations. The non-parametric Mann-Whitney U 
test was used to test for an effect by genotype on the median change in sHLA-G and IL-10 values 
after cell culture with 6-MP.  The two-way ANOVA for repeated measures was used to test for 
significance in differences in IL-10 expression between samples incubated with and without 6-
MP and MTX. A p value less than 0.05 was taken to indicate statistical significance for all 
analysis. 
 
The t Test with Welch’s correction was used for assessment of the significance of the effect of 





















6.5  Results  
 




6.5.1   Interleukin-10 (IL-10) 
 
As described earlier, IL-10 haplotyping failed in 1 of the 17 individuals recruited. Hence data is 
presented for 16 individuals. No significant IL-10 expression was seen in un-stimulated samples. 
LPS stimulation increased IL-10 levels and levels at 24 hours were significantly higher than un-
stimulated samples.  (p=<0.0001, Mann Whitney U for un-stimulated v/s 24 hour samples). 
(Figure 6-1)  However all the levels were increased and differences were difficult to elicit. Over 
the second 24 hours, the IL-10 levels were lower (p=0.0017, MWU for means 24 hrs vs. 48 hrs). 
The IL-10 levels in 48 hour samples were also significantly greater than un-stimulated samples 
(p=<0.0001, MWU for unstimulated vs. 48 hour incubation) and hence 48 hour samples were 
used in all the analysis. 
  
No significant differences were seen in the baseline and 48 hour levels of expression between the 
high producer and the low producer IL-10 promoter haplotypes after LPS stimulation. The IL-10 
levels were 20% higher in the high producer haplotypes (p=0.7 MWU for means, IL10 GCC vs 
non GCC haplotype (Figure 6-2). 
 
6.5.1.1  The effects of 6-mercaptopurine on IL-10 expression 
 
No differences are seen between the IL-10 levels in the low producer and high producer 
haplotypes when 6-MP at 0.25 μM is used. This increases to 20% higher IL-10 levels in the high 
producer haplotypes when 0.5 μM 6-MP is used. A further increase is seen when 1 μM 6-MP is 
used and the levels are 50% higher in the high producer haplotypes. Hence, the levels over the 
second 24 hours of cell culture are apparently influenced by drug dosages. Lower expression 
levels are seen in the 6-MP dose of 0.25 μM when compared with the dose of 1 μM   However, 
this finding does not reach significance (p=0.7, with the parametric t Test with Welch correction 
for variance for comparison of means). There is also an apparent influence of the promoter 
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haplotypes. It is possible that small sample sizes have not allowed significance to be evident 
(p=0.2, unpaired two tailed T test for comparison of the difference in means of IL-10 expression 
between the 6 MP doses 0.25Mm and 1 μM in GCC and non GCC) , nevertheless a trend is hinted 
at in this graph (Figure 6-4). This experiment may indicate that IL-10 levels are influenced by 6-
MP in PBMCs more so in   individuals with the high producer GCC haplotype of the promoter 
region. 
 
6.5.1.2  Methotrexate 
 
The results vary from those seen with 6-MP and similarly, significance is not achieved. After 48 
hours of culture, the high producer haplotypes express more IL-10 but a dose effect is not as 
evident as in 6-MP with increasing drug concentrations. The low producer haplotypes exposed to 
the study medication in vitro over 48 hours express 40% lower IL-10 levels than the high 
producer haplotypes with 0.25 μM MTX, 52% lower with 0.5 μM MTX and 1 μM MTX (Figure 
6-5) (p= 0.4, Unpaired t Test for High producer vs. low producers for difference in IL-10 between 
dose 0.25 μM MTX and 0.5 μM MTX) (Table 6-2). 
Although, this effect did not reach statistical significance these experiments suggest that there 
may be a pharmacogenetic influence of the IL-10 haplotypes on the dose response seen in the use 
of 6-MP and MTX for inflammatory conditions. IL-10 expression levels appear different between 
PBMC cultures with 0.25 μM MTX and 1 μM MTX when stratified for IL-10 promoter 




6.5.1.3   The influence of the HLA-G 14 bp insertion/deletion genotype on IL-10 expression 
and differences between the two studied pharmacological agents. 
 
This hypothesis was examined in both the study groups detailed above. These experiments have 
not demonstrated a significant influence of these genotypes on baseline IL-10 expression after 
LPS stimulation at 24 hours or 48 hours in neither the 6-MP group nor the MTX group. Also, no 







This graph shows that levels decline over 48 hours and significantly lower levels that those at 24 
hours are seen (p=0.0017). Levels are in pg/ml. 
 
Figure 6-1 IL-10 expression levels are significantly increased after LPS stimulation.  
 
 
Figure 6-2 The IL-10 expression levels were not significantly different between GCC and 






The cell cultures were stimulated with LPS and incubated without immunomodulatory 
medication. Levels are in pg/ml. 
 
Figure 6-3  IL-10 levels expressed by PBMCs are apparently influenced by 6-MP after LPS 
stimulation. No drugs are used in this culture.  
 
 
Lower doses of 6-MP are associated with lower levels of detectable IL-10 (p=not significant). All 
levels in pg/ml. 
 
Figure 6-4 Expression of IL-10 are greater in individuals with the GCC promoter haplotype 






Figure 6-5 IL-10 levels after MTX incubation showing a dose effect in the high producer 




6.5.2  sHLA-G Expression  
 
 
6.5.2.1  6-mercaptopurine co incubation 
 
All cell cultures were viable at all drug concentrations used. No significant differences in sHLA-
G expression were noted between genotypes at baseline (p=0.6) and after LPS stimulation 
(p=0.4).  There were no significant differences between mean sHLA-G expression levels in the 
un-stimulated blank samples and those un-stimulated samples incubated with 6-MP. (Table 6-4) 
 
LPS stimulation increased sHLA-G levels in all genotypes. sHLA-G concentrations ranged from 
1-6.5ng/ml (Median = 3.065, Mean = 3.242, SEM=0.4) in LPS stimulated cultures and between 
0.2 -6.0ng/ml (Median = 3.8, Mean = 3.6, SEM = 0.39) after incubation with 1 μM 6-MP. 
Significant differences were noted in sHLA-G expression after 48 hours incubation with   1 μM 
6-MP between carriers of the 14bp del/del genotype and the insertion allele. The greatest 
increases were seen in those with the del/del genotype (mean increase = 1.63ng/ml). The increase 
was less marked in the ins/del genotype (mean increase = 0.06ng/ml) and a decrease was noted in 
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the ins/ins genotype (mean decrease = 0.46ng/ml) (Figure 6-6). These differences were 
statistically significant (p=0.02 , unpaired t Test  comparing mean difference in sHLA-G 






6.5.2.2  Methotrexate co-incubation 
 
Here concentrations of 0.5 μM and 1 μM of MTX were studied. No significant differences in 
sHLA-G expression were noted between genotypes at baseline (p=0.6) and after LPS stimulation 
(p=0.4).  LPS stimulation increased sHLA-G levels in all genotypes. sHLA-G concentrations 
ranged from 1-6.5ng/ml (Median = 3.065, Mean = 3.242, SEM=0.4) in LPS stimulated cultures 
and between 0.2 -6.0ng/ml (Median = 3.8, Mean = 3.6, SEM = 0.39) after incubation with 1 μM 
MTX. Significant differences were noted in sHLA-G expression after 48 hours incubation with   
1 μM MTX between carriers of the 14bp del/del genotype and the insertion allele (Table 6-4). 
The greatest increases were seen in those with the del/del genotype (mean increase = 2.53ng/ml). 
The levels dropped in the ins/del genotypes (mean decrease = 0.54 ng/ml) and a further decrease 
was noted in the ins/ins genotype (mean decrease = 1.96 ng/ml). These differences were 
statistically significant (p=0.01, unpaired t Test comparing all three genotypes) (Figure 6-7). 
 
Concentrations of 0.5 μM and 1 μM of MTX were studied and there appears to be a dose 
dependent increase in sHLA-G expression levels in the carriers of the del/del genotype that is not 
seen in the others. Indeed, in other individuals, the effect is one of a relative decline over the two 












Stimulated and co-incubated PBMCs from the high producer HLA-G 14bp del/del genotypes produced 
significantly more sHLA-G than the low producer ins/del genotype and the ins/ins genotype when exposed 
to 6-MP.   
 
Figure 6-6  Comparison of  the differences in mean increase in  sHLA-G expression (ng/ml)  
between the 14bp del/del, ins/del and ins/ins genotypes after incubation of LPS stimulated 
PBMCs with 1 μM 6-MP  
 
 
Figure 6-7  The effect of the HLA-G in/del genotype on the expression levels of sHLA –G in 








Figure 6-8  Demonstration of the effect of increasing MTX dosage on the expression levels of 




















6.5.3  Other Cytokines 
 
The samples were selected and analysed as described earlier. The data is displayed in tables Table 
6-5 and Table 6-6.  For statistical analysis, the data is displayed as the difference in cytokine 
expression between the un-stimulated and LPS stimulated samples. Subsequently the Mean and 
standard deviations of the cytokine levels in each of the sample groups for both the high s-HLA-
G producer and low s-HLAG producer groups were calculated. The data for all samples is 
displayed, and analysis of statistical significance has been performed on samples co-incubated 




The data demonstrates some clear trends in the levels of cytokines. LPS stimulation increased all 
the levels of the examined cytokines irrespective of low or high sHLA-G status. When the 
samples were co incubated with 1 μM 6-MP, some differences were seen between the high and 
low sHLA-G groups. When LPS stimulated samples are exposed to 6-MP for 48 hours, IL-23 
levels drop from the LPS stimulated baseline by 17% in the high sHLA-G group and are 
unchanged in the low sHLA-G group (p=0.2). The levels of TNF-α drop the low sHLA-G group 
by 14% and rise by 35% in the high sHLA-G group (p=0.39). No differences are seen between 
the low and high groups with IL-8 (p=0.2). IL-6 levels in the high sHLA-G group rise by 2% and 
drop in the low group by 7% (p=0.3).  IL-18 levels in the high sHLA-G group rise by 15% and in 
the low group drop by 15% (p=0.5).  IL-1β levels in the high sHLA-G group drop by 7% and in 




Here the data demonstrates some differences in trends in the levels of cytokines. LPS stimulation 
increased all the levels of the examined cytokines irrespective of low or high sHLA-G status. 
When the samples were co incubated with 1 μM MTX for 48 hours, IL-23 levels drop from the 
LPS stimulated baseline by 8% in the high sHLA-G group and by 10% in the low sHLA-G group 
(p=0.9). The levels of TNF-α drop in the high sHLA-G group by 15% and there is no change in 
the low sHLA-G group (p=0.6). No differences are seen between the low and high groups with 
IL-8 (p=0.4). IL-6 levels in the high sHLA-G group drop by 33% and are unchanged in the low 
group by (p=0.1).  IL-18 levels in the high sHLA-G group drop by 17% and in the low group 
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drop it is unchanged (p=0.5).  IL-1β levels in the high sHLA-G group drop by 35% and in the low 
sHLA-G group rise by 14% (p=0.2). 
 
Hence, these experiments demonstrate that the levels of cytokines seen in LPS stimulated samples 
are not different at baseline between the low and high sHLA-G groups. On the other hand 
although significance is not achieved, the exposure of these samples to MTX and to a lesser 
extent 6-MP appear to influence the cytokine levels differently between these two groups. The 
numbers of individuals in this experiment is small and that may have influenced the significance 
levels seen. Nevertheless, in the MTX group the group of individuals who express the higher 
levels of sHLA-G and may be a group who respond well to immunosuppression if they had IBD, 
appear to have lower levels of TNF-α, IL-6, IL-18 and IL-1β. It is tempting to hypothesise that 
these changes predispose to a resolution of the inflammatory state. Such changes are not seen in 
the 6-MP group and indeed TNF-α and IL-18 levels are higher in the high sHLA-G group. The 
similarity of the effect of the 14 bp ins/del polymorphism on response to immunosuppression 
































































IL-23 Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-18 Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-1β Expression differences between the high sHLA-G and low 
sHLA-G group 


























































TNF-α Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-8 Expression differences between the high sHLA-G and low sHLA-
G group 
IL-6 Expression differences between the high sHLA-G and low sHLA-
G group 
 
Figure 6-9   Differences in the expression levels of the examined cytokines IL-23, IL-18, IL-1β, TNF-α, IL-6 and IL-8 after co incubation 1 
μM 6-MP. 
The low sHLA-G and high sHLA-G groups are being compared. 6-MP ( 6-mercaptopurine), TNF-alpha (Tumour necrosis factor-alpha ), Interleukin 23 ( IL-23 ), Interleukin 6 ( IL-6), Interleukin 8 (IL-
8), Interleukin 18 ( IL-18), Interleukin 1 -beta ( IL-1B) 
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IL-23 Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-18 Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-1β Expression differences between the high sHLA-G and low 
sHLA-G group 
























































TNF-α Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-8 Expression differences between the high sHLA-G and low 
sHLA-G group 
IL-6 Expression differences between the high sHLA-G and low sHLA-
G group 
 
Figure 6-10 Differences in the expression levels of the examined cytokines IL-23, IL-18, IL-1β, TNF-α, IL-6 and IL-8 after co incubation 1 
μM MTX. 
The low sHLA-G and high sHLA-G groups are being compared. MTX (methotrexate), TNF-alpha (Tumour necrosis factor-alpha ), Interleukin 23 ( IL-23 ), Interleukin 6 ( IL-6), Interleukin 8 (IL-8), 





Table 6-1IL-10 expression in PBMC cultures incubated with 6-MP and the relationship with recognised high producer and low producer 
haplotypes of the IL-10 promoter.  
The IL-10 concentrations are reported in pg/ml. The values reported are all the mean of the duplicate values. Sixteen patients are included in this analysis. The 






Table 6-2 IL-10 expression in PBMC cultures incubated with methotrexate and the relationship with recognised high producer and low 
producer haplotypes of the IL-10 promoter.  
The IL-10 concentrations are reported in pg/ml. The values reported are all the mean of the duplicate values. Sixteen patients are included in this analysis. The 








Table 6-3  IL-10 expression in PBMC cultures incubated with 6-MP/MTX and the relationship with recognised HLA-G 14 bp ins/del 
genotypes.   
 
The IL-10 concentrations are reported in pg/ml. The values reported are all the means of the values. Sixteen patients are included in this analysis. The low 
producer genotype is HLAG 14bp ins/ins and ins/del. The high producer genotype is HLA-G 14bp del/del.  The p value reported is of the difference between the 
IL-10 expression levels between the 0.25 μM and the 1 μM concentration of the drug used.  
 
Table 6-4  The changes in sHLA-G levels between LPS stimulated PBMC samples with or without 6-MP or MTX.  








Table 6-5 : The expression levels of the studied cytokines divided into Low and High s HLA-G expressing individuals- 6-MP group.  
 
The drug used is 6-mercaptopurine. All values are expressed in ng/ml 
 
6-MP 
sHLA-G SAMPLE IL-23 IL-8 IL-6 IL-18 IL-1B TNF-A 
HIGH 
BLANK 77 280 10 46 30 27 
LPS 98 1192 1971 54 80 34 
0.5 μM 6MP 85 415 11 46 30 28 
LPS + 0.5 μM 6MP 100 1089 1994 45 74 30 
1 μM 6MP 76 239 10 45 30 27 
LPS + 1 μM 6MP 81 1191 2021 62 74 46 
  
LOW 
BLANK 78 69 10 44 30 27 
LPS 98 1192 1732 52 52 36 
0.5 μM 6MP 73 161 13 57 31 32 
LPS + 0.5 μM 6MP 79 795 907 33 31 23 
1 μM 6MP 75 127 10 44 30 27 
LPS + 1 μM 6MP 101 1192 1608 44 55 31 
 
All data displayed is for 48 hour incubation. 6-MP ( 6-mercaptopurine), TNF-alpha (Tumour necrosis factor-alpha ), Interleukin 23 ( IL-23 ), 









Table 6-6 The expression levels of the studied cytokines divided between the High and Low sHLA-G producers- MTX Group.  
 
The drug used is MTX and all values are expressed in ng/ml 
 
MTX 
sHLA-G SAMPLE IL-23 IL-8 IL-6 IL-18 IL-1B TNF-A 
HIGH 
BLANK 77 280 10 46 30 27 
LPS 98 1192 1971 54 80 34 
0.5 μM MTX 78 295 10 44 30 27 
LPS + 0.5 μM MTX 111 1166 1715 46 60 31 
1 μM MTX 79 263 10 45 30 27 
LPS + 1 μM MTX 91 1192 1314 45 45 29 
  
LOW 
BLANK 78 69 10 44 30 27 
LPS 98 1192 1732 52 52 36 
0.5 μM MTX 70 151 13 54 31 32 
LPS + 0.5 μM MTX 95 1192 1262 45 53 29 
1 μM MTX 81 142 11 47 30 27 
LPS + 1 μM MTX 88 1192 1737 54 59 37 
 
 
All data displayed is for 48 hour incubation. MTX (methotrexate), TNF-alpha (Tumour necrosis factor-alpha ), Interleukin 23 ( IL-23 ), Interleukin 










6.6   Discussion 
 
PBMCs were selected as the preferred cell type for study. It would have been ideal to study 
lamina propria mononuclear cells, but access to the cell population in normal individuals would 
be difficult. These two cellular populations are not identical and important differences between 
them can influence the outcomes of certain experiments.  
 
The role of the promoter region (5’UTR) of a gene in mediating transcription of functional 
mRNA is important and in conjunction with degradation and variations in stability of the 
translated protein influenced by 3’UTR region, they influence mRNA levels [455].  The HLA-G 
promoter region is variable and 29 SNPs have been described, some of which appear to correlate 
with asthma and adverse foetal outcomes. However, sHLA-G levels have not been found to be 
related to these outcomes and they have been inconsistent with contradicting results being found 
in different conditions such as eclampsia and multiple sclerosis [165]. The effects of genetic 
variation in this region are uncertain. A number of polymorphisms have been reported in this area 
some of which are associated with variant HLA-G expression. Many of these are in LD with the 
14bp ins/del polymorphism and include +3142G, +3187A and +3003C [456]. Quite at odds with 
a variety of functional correlations of variant genotypes, the HLA-G 14bp ins/del and it’s 
associations with foetal outcomes and immunosuppressive medication outcomes are very 
consistent. [457] 
 
A number of effects of HLA-G are seen on regulatory cells. Dendritic cells (DC) can be induced 
by the effect of HLA-G1 or HLA-G 5 through the inhibitory ILT receptors. The subsequent down 
regulation of co stimulatory CD80 and CD86 renders the DCs suppressive or tolerogenic [458]. 
Furthermore, suppressive CD4+ CD25- CTLA4+ T cells and CD 8+ CD 28- Tregs that produce IL-
10 are generated. HLA-G1+ APC stimulate and cause the differentiation of T cells into 
suppressor cells [162]. They cannot be defined phenotypically, and do not secrete HLA-G but 
instead mediate suppressive effects by the secretion of IL-10 [161]. In contrast, naturally 
occurring HLA-G+ Tregs do not produce IL-10 or TGF- β and are very distinct from Tr 1 / Th 3 
cells or induced HLA-G+ T cells[459].  
 
IL-10 production in PBMC cultures has previously been noted to be highest in individuals with 
the HLA-G 14bp ins/ins genotype [180] and serum IL-10 levels have been implicated in 
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modifying response to immunomodulators in RA [452]. HLA-G and IL-10 appear to be closely 
interrelated in their immunological influence [180].  Hence, it is possible that the HLA-G 14bp 
insertion destabilises mRNA and impairs sHLA-G production. When this is associated with an 
impaired IL-10 secretion, the response to immunomodulatory drug therapy may be diminished.  
Although limited by small numbers in sub group analysis, the genotyping data presented here 
appears to support this hypothesis. The results show that the combination of the favourable HLA-
G 14 bp deletion and the IL-10 GCC promoter haplotype favours a clinical response to AZA 
therapy in IBD patients. 
 
This offers an intriguing explanation for the considerable variability in studies on the association 
of polymorphisms in the IL-10 promoter and the susceptibility to IBD. The low producer -1082 
A/A genotype has been associated with steroid resistance in CD [460] and these experiments have 
shown that IL-10 expression is influenced by exposure to 6-MP and MTX. It is conceivable that 
the conflicting results may be due to the pharmacogenetic influence of IL-10 (steroids and 6-MP 
or MTX) on the disease phenotype. 
 
The functional data in this study demonstrate high levels of sHLA-G generation in mixed 
lymphocytic cell cultures incubated with 6-MP in individuals with the high sHLA-G producing 
genotype. This is associated with relatively increased levels of IL-10. However, there are 
apparent differences between cytokine levels after exposure to 6-MP and those after exposure to 
MTX in vitro. In the MTX group, there are lower levels of some pro inflammatory cytokines. In 
the 6-MP group, no such differences are seen. Overall, the differences do not amount to 
significance but are certainly suggestive. They would be consistent with increases in induced Tregs 
in the 6-MP group. Tregs are thought to express IL-10 and suppress colitis in mice but the role is 
less clear in humans. Tr 1 cells are present in higher levels in inflamed colonic mucosa in patients 
with UC and the administration of IL-10 did not suppress colitis in humans. It is possible that the 
levels of Tr 1 expression seen are not adequate for the induction of mucosal tolerance. [461] 
 
Hence, it may be that 6-MP, through the peripheral generation of Treg cells, can control and inhibit 
ongoing inflammation. It may induce IL-10 generating dendritic cells (DC-10) and up-regulate 
inhibitory ILT receptors on DC. These specifically induce Tr-1 cells that exert an anti 
inflammatory, suppressive or tolerogenic effect. There is some more support for this hypothesis 
from recent work in lamina propria Tregs and peripheral blood Tregs in IBD. Both are low in active 
disease with heightened levels of apoptosis. Anti TNF-α medication reverse these changes and are 
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most prominent in individuals with IBD who respond clinically to this medication [462]. Treg 
activity is clearly involved in the response to anti TNF-α and may well be relevant in other drugs 
such as AZA/6-MP. In this vein , a recent letter suggests that sHLA-G levels are higher in LPS 
stimulated PBMC cultures from blood in individuals with UC who are receiving treatment with 6-
MP when compared with those who are receiving mesalazine or steroids [463]. As mentioned 
earlier, the active inflammatory state may well be a confounding factor but taken with the report 
that MTX responsive RA patients have an induction of IL-10 producing Tregs from plasmacytoid 
DCs [464], the hypothesis certainly appears plausible. This work has also found that IL-10 levels 
are affected by MTX in vitro and are influenced by the IL-10 promoter haplotype. 
 
This work presented here has not evaluated lamina propria cells, but PBMC Treg populations 
appear to be good surrogates for examining these effects.  Potential influences are not easy to 
study as there are likely to be a number of redundant regulatory mechanisms in intestinal mucosa 
and as mentioned before, access to both inflammed and non inflammed intestinal tissue is limited 
[465]. The approach adopted in this work of identifying a genetic marker followed by an attempt 
at functional correlation in vitro sets the stage for a study in LPMCs. The lack of a definitive 
marker of Tregs cells is a limitation, but nevertheless , it would be illuminating to examine the 
effects of 6-MP, MTX and INFX in vitro on both lamina propria and peripheral blood Treg cell 



















The primary aim of the study was the detailed evaluation of the pharmacogenetics of MTX 
therapy in IBD. This thesis has examined clinically relevant polymorphisms in a number of folate 
pathway enzymes. An important aspect was the study of the pharmacogenetic effects of folate 
supplementation as well as of haplotypes and compound heterozygosity on clinical response rates 
and drug intolerance. Such information has been lacking in IBD studies.   
 
In this work, there are some small effects such as MTHFR 677 TT genotype which was found 
more often in clinical responders receiving oral folate and the MTHFR 677 T allele seen more 
frequently in the same group. The individuals affected by this polymorphism are small (n=19). 
The expected influence of compound heterozygosity was not seen and instead, the MTHFR 
677CT/1298AA haplotype was overrepresented in individuals who experienced all cause side 
effects. The number of affected individuals is once again small and an assessment of the influence 
of folate supplementation is difficult to make. The problems with assessing all cause side effects 
have been explained in a previous chapter. The small number of individuals with the 
polymorphism and the pooling of all side effects make it difficult to consider a mechanism for 
this effect. The effect of the 677TT/1298AA haplotype on response rates is completely influenced 
by the previously described 677 TT polymorphism and has no additional clinical significance.  
 
The TSER tandem repeats and the TS6bp ins/del polymorphisms did not influence clinical 
response rates or side effects. Folate supplementation had no influence either. The close 
relationship between MTHFR and TS was examined thoroughly. The interesting hypothesis that 
the MTHFR677TT mutation would impart reduced clinical efficacy on MTX therapy in 
individuals who possess the TS 2*R with the TS 6bp deletion was not proven and folate 
supplementation had no influence.  
 
The expectation of an increase in clinical response rates among those with the common ATIC 347 
GG genotype was fulfilled but once again, the influence was small. It was encouraging that the 
effect was consistent with recent GWAS results that have provided some clarity to yet another 
controversial area in pharmacogenetics [481]. Individuals with the wild type ATIC 347 G allele 
were more likely to be tolerant of MTX therapy. The putative influence of the ATIC enzyme on 
adenosine levels and subsequent anti inflammatory effects of MTX is not helpful in explaining 
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this observation. Folate supplementation did not have an effect and although this observation has 
been reported before, a hypothesis is lacking.  
 
No effects of the polymorphism in the drug transporter Reduced folate carrier and the 
extracellular oxidative enzyme Aldehyde oxidase were seen. Hence, at the end of the initial 
experiments, a marker for clinical response or drug intolerance similar to TPMT had not been 
found. This experience is not unique and TPMT remains the most successful clinical application 
of pharmacogenetics despite considerable effort. The relative weakness and the limitations in 
applying successful pharmacogenetic models from cancer chemotherapy to inflammatory diseases 
are easily evident.  
 
There are a number of reports of varying cytokines profiles and hence, an implied variability in 
adaptative immunity and the effects these have on response to MTX and 6-MP therapy. There 
have also been many attempts to find identify polymorphisms in the relevant genes that could 
predict such effects. However they have been less encouraging than the classical pharmacogenetic 
approach examining drug metabolism. In this setting, the reports on the role of the HLA-G 
complex in tolerance are very impressive. It has been extensively evaluated in foetal medicine, 
cancer cell biology and post organ-transplant immunosuppression. It builds well towards an 
application of a 14bp insertion/deletion polymorphism in predicting clinical response to 
immunonodulation. This polymorphism could be a marker of T cell regulatory activity and a 
pharmacogenetic marker of the influence of T regulatory activity in IBD is attractive.  Consistent 
with the results from Rheumatoid arthritis, we found a powerful influence of the 14 bp insertion 
polymorphism on impaired clinical response to methotrexate in a large group of IBD patients. As 
expected, the influence was not affected by folate supplementation. The number of individuals 
affected by UC was not large but there were no discernible difference in response rates between 
individuals with UC or CD.  
 
This brought up a number of important issues for consideration. The proposed mechanism of the 
effect of the polymorphism on immunomodulatory therapy was likely to be true for a number of 
drugs and this has been reported in renal and cardiac transplantation experience. However, our 
experiment showed that the 14 bp insertion was not over represented in individuals who arrived at 
MTX therapy after AZA/6-MP failure. It was possible that the influence would be greater in 
individuals with UC as intestinal epithelial cell HLA-G expression was higher in UC than in CD. 
The HLA region has a high level of LD and this region has known associations with CD 
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susceptibility and the 14bp polymorphism was associated with ileal disease in individuals with 
CD. The precise mechanism was unclear but there were reports of high IL-10 expression levels in 
those with the 14bp ins/ins genotype and it was likely that common IL-10 promoter 
polymorphisms had a secondary influence on the observed effects.  
 
Each of these was examined in turn. First, it is demonstrated that the 14 bp polymorphism had no 
influence on susceptibility to IBD (CD or UC) in a large cohort of patients when compared with 
normal controls. The DNA was obtained from a previously reported cohort. The results from that 
cohort have been validated in a number of publications. There was no association with disease 
location in CD or UC and it is likely that the polymorphism does not affect disease severity in 
CD. 
 
Next, the role of the HLA-G 14 bp ins/del polymorphism in clinical response to AZA in patients 
from a previously reported large multicenter trial [263] of the use of this drug in IBD was 
examined. The effect was very prominent on response rates and consistent with that seen in the 
MTX group. It was also demonstrable that there was a clear difference between the UC group and 
CD groups. The genotype was distributed equally between the UC and CD group, but when the 
groups were stratified for clinical response, the effect was more prominent in the CD group. This 
appears at odds with reports that HLA-G expression is greater in intestinal epithelium from 
individuals with UC and hints at a mechanistic influence that is currently unclear.  The influence 
of the TGN levels, TPMT genotype, concomitant medication, age and sex were examined. The 
TPMT genotype correlated with clinical response in the study group, but the effect was less 
prominent than that of the 14bp genotype.  
 
The effect of three common and well described polymorphisms of the IL-10 promoter gene on 
clinical response rates to AZA and on an additive influence with the HLA-G 14 bp polymorphism 
was investigated.  The favourable and anti inflammatory IL-10 promoter GCC haplotype was not 
associated with clinical response rates with either AZA or MTX therapy.  However, possession of 
both the favourable 14bp del/del genotype and the IL-10 GCC haplotype conferred a significant 
likelihood of clinical response compared to those who lacked this combination on AZA therapy. 
The numbers are small and a clear conclusion is difficult to make. In the larger MTX group , a 
conditional analysis on the influence these two polymorphisms may have on each other and on 
clinical response show that the haplotype of HLA-G14bp del and IL10 -1082G is strongly 
associated with clinical response but this is primarily from the HLA-G14bp del contribution. 
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However, an examination of the OR suggests that the favorable IL10-1082 G allele appears to 
reduce the risk of therapeutic failure on MTX therapy in those with the HLAG 14bp ins allele.  
 
The HLA-G 14bp ins/del polymorphism influences soluble HLA-G levels and higher sHLA-G 
levels correlate with greater tolerance. The effect of pharmacologically relevant concentrations of 
MTX and 6-MP on the levels of sHLA-G in monocyte cultures was examined. These changes 
were correlated with genotype and a clear influence was seen in both the 6-MP and the MTX 
cultures. The favorable HLA-G 14bp del/del genotype produced the highest levels of sHLA-G 
and the unfavorable HLA-G 14bp ins/ins genotype produced the lowest levels after 48 hours of 
incubation. A dose effect was seen and the changes were not evident at the lower doses studied. 
This appears to support the findings from the genetic experiments. An important observation is 
that normal volunteers were recruited for these experiments and PBMCs rather than LPMCs were 
examined. This was because of the large number of confounding variables that active systemic 
inflammation in individuals such as those with IBD would have introduced to these experiments. 
It would have been more difficult to procure LPMCs form normal individuals. A study of the 
effects in LPMCs from IBD patients would be a logical extension of these experiments and could 
be the focus of future work. 
 
As there appears to be an influence of IL-10 promoter haplotype on the effect of the HLA-G 14bp 
genotype on clinical response to MTX and perhaps to 6-MP, the interaction between IL-10 levels, 
HLA-G genotype and IL-10 promoter haplotypes were examined. None of the examined 
hypotheses reached significance, however interesting trends were seen. There was a dose effect of 
6-MP on IL-10 levels with an increase in IL-10 levels with increasing 6-MP concentrations in the 
culture medium. The high producer haplotypes produce more IL-10 on co incubation with both 6-
MP and MTX. The HLA-G 14bp ins/del genotypes did not influence IL-10 levels at baseline or 
on co incubation with varying concentrations of 6-MP or MTX. Hence although there appeared to 
be some moderating influence  of IL-10 promoter haplotypes on the pharmacogenetic effects of 
the 14bp genotype in MTX therapy, there were no such effects seen on sHLA-G levels. The study 
population may have been too small to reveal this effect. Alternatively, it may be that there was 
an influence, but that was modified by other cytokine level changes. 
 
Although significance is not achieved, there are suggestive differences in the levels of 
inflammatory cytokines between the high sHLA-G and low sHLA-G groups when the LPS 
stimulated PBMCs are exposed to MTX. The pro-inflammatory cytokines appear to be 
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suppressed. Similar effects are not seen with 6-MP suggesting an alternative mechanism perhaps 
more predisposed towards expression of the anti inflammatory IL-10.  
 
There is scope for further work in this field. The functional studies could be expanded and 
Lamina propria monocytes could be used. This would be a closer approximation of the 
mechanisms at work in vivo. The cytokine profiles could be refined further and may identify 
those individuals who are more likely to respond to other medication namely Infliximab. Once 
such influences are clearly defined, the next step would be the application of the pharmacogenetic 
marker to a prospectively recruited group of individuals with IBD. They would then be exposed 
to defined therapeutic algorithms and their clinical response would be correlated both to genotype 
and serum sHLA-G levels. The levels could be examined sequentially over time and correlations 
made with drug response as well as the subsequent loss of response to therapy. Attempts would 
be made to identify those predisposed to therapeutic failure and suited to early anti TNF therapy 
or even surgery to minimise drug induced complications.   
 
The work presented in this thesis makes an interesting case for the application of a 
pharmacogenetic marker of response to immunomodulatory therapy in patients with IBD that 
departs from the traditional approach. This marker for tolerance of an inflammatory state appears 
to identify those predisposed to respond to immunosuppressive medication. It is recognized that 
the response to medication is not usually predicted by single genetic loci. Instead, a polygenic 
approach that includes multiple loci and the interaction between these is proposed as a viable 
alternative. Nevertheless, the clinical application of such pharmacogenetic panels or indices has 
been disappointingly unimpressive. Clearly there are other influences at work. There are many 
possibilities and they include variations in metabolizing enzymes, drug transporters, receptors, 
drug targets, absorption mechanisms, excretory mechanisms, confounding interactions between 
drugs etc. Even the impressive advances in high throughput genotyping with micro array based 
and sequencing technology is not adequate to cover all of the mechanisms that are of interest. The 
inclusion of markers of hitherto unexplored influences on drug response may help achieve the 
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(version dated May.2008) about this project and have had the 
 opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free 
 to withdraw at any time, without giving any reason, without my  
medical care or legal rights being affected. 
 
3.  I understand that sections of any of my medical notes may be 
 looked at by medically qualified staff from Guy’s and St Thomas’ 
 Hospitals. 
 I give permission for these individuals to have access to my records. 
 
4.  I understand that my GP will be contacted to inform them that I am  
participating in this study.  
 




___________________  _________________________ ____________ 
Name of patient   Signature    Date 
 
___________________  _________________________ ____________ 
Name of researcher   Signature    Date 
 
1 copy for patient, 1 copy for researcher, 1 copy for notes. 






Appendix 2: GP Information Sheet 
 
 
GP information Sheet 





We are writing to let you know that your patient:______________________________ 
has agreed to take part in our research study as a subject who does not have inflammatory bowel 
disease and is not any immunomodulatory treatment. 
 
The aim of this study is to find out why it is that some people respond so well to 
immunomodulatory treatment, whilst others have no response or experience adverse events.   
 
Our study simply involves taking a blood sample from your patient for an in-vitro experiment. 
The relevant WBCs will be extracted and incubated with methotrexate and 6-mercaptopurine. The 
samples will then be studied for the cytokine expression profiles and correlation will be made 
with genotypes of certain genes influencing cytokine function.  
 
As well as testing patients currently taking these medications we are also interested in those 
patients who have had them in the past, but had to stop them due to adverse events or because 
they were ineffective.   
 
Your patient’s co-operation with our trial will not affect their ongoing treatment at GSTT in any 
way and should not have any impact on their care in General Practice. 
 






Dr Jeremy Sanderson 
 
 









 Appendix 3 :Patient Information Sheet 
 
 
Patient information Sheet 
Pharmacogenetics of immunomodulatory treatment in Inflammatory Bowel Disease 
 
You are being invited to take part in a research study.  Before you decide whether or not you wish 
to be involved it is important for you to understand why the research is being done and what it 
will involve for you.  If you have any questions please ask. You can take your time to decide if 
you want to take part and talk to others about it if you wish. 
 
What is the purpose of this study? 
 
Inflammatory bowel disease is a condition that affects many people, young and old. It contributes 
to considerable ill health to those affected and can sometimes be fatal. Many people require 
operations to get better. Whilst we know that immunomodulatory medications (such as 
azathioprine (AZA), 6-mercaptopurine (6MP), methotrexate, cyclosporin and infliximab) are 
effective treatments for IBD but they don’t work for everyone and can cause side effects.  This 
may be due to differences in the way that people’s bodies break down these drugs which is 
controlled genetically.  By analysing blood samples from people who do not have these diseases 
and who are not on these medicines , we can tell how the normal human body is metabolising 
them and look directly at differences in the genes responsible for this process. 
 
Why have I been chosen? 
 
You are being chosen for this study because you do not suffer from these diseases and you are not 
on the medicines whose effects we are trying to study. After the sample has been taken, your  
blood cells can be analysed for their response to these medicines and that response can be 
correlated to your genetic makeup 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part and whatever you decide your treatment 
will be unaffected.  You are free to withdraw from the study at any time.   
 
What will happen to me if I take part? 
 
You will need to sign a consent form and then be asked to provide approximately 18mls of blood 
(4 teaspoons) in addition to that taken for your normal clinic tests.  In order for us to relate the 
blood results to how you are responding to your treatment you will also be asked to answer a few 
quick questions about your treatment and how active your IBD is at present.  No change will be 
made to your treatment and you will not need to make any extra trips to the clinic. 
 
What are the risks of taking part? 
 
There is no risk to your health or safety from taking part in this study.  The type of genetic 
information that we will get from testing your blood would not affect your insurance status or 
have implications for your future health or that of your family.  The results of any genetic tests 





What are the benefits of taking part? 
 
We cannot promise that the study will help you directly but the information we get might help 
improve the treatment of people with Crohn’s and UC in the future. 
 
What happens when the study stops? 
 
All remaining blood samples will be destroyed.  We will let all participants know the results of 
our study. 
 
Will my taking part in the study be kept confidential? 
 
Yes, except that it is considered good practice for us to alert your GP that you have volunteered to 
help us and to send them a similar sheet to this, explaining what we are doing.  Authorised 
researchers will need to look at your medical records to collect information about treatments that 
you have taken and how you have responded to them.  Nothing that could reveal your identity 
will ever be published or released from the study.  Our procedures for handling, processing, 
storage and destruction of patient information are compliant with the Data Protection Act 1998.   
 
What will happen to the results of the research study? 
 
We hope that the study will provide interesting results that improve treatment for people with 
Crohn’s and UC.  We plan to publish the study’s results in medical journals.  In any publication 
of the study’s results you will not be identifiable unless your consent has been specifically sought 
for this. 
 
Who is organising and funding the research?   
 
This research is being organised and funded by Guys and St Thomas’ Hospital Trust.  We have 
also applied to the National Association for Crohn’s and Colitis (NACC) for financial support.  
There is no other outside sponsorship or incentive payment to researchers for including you in the 
study.  This study has been approved by the Bexley and Greenwich Local Research Ethics 
Committee 
 
What if there is a problem? 
 
Any complaint about the way in which you have been treated during the study will be addressed.  
Researchers are all members of Trust Staff and are covered for negligent harm via the usual 
arrangements. 
 
You will be given a copy of this sheet and your consent form.  Thank you for taking the time 
to read this information sheet and for considering taking part in our study. 
 
Contact Details: 
If you have any additional questions about our study please feel free to contact us on this number: 
02071882497 
 
Version Two May 2008 
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You have been offered an appointment to attend at Guy’s and St Thomas’ Hospital for an 
appointment. We are a teaching hospital and are involved in the research of a number of disease 
conditions. We would like to invite you take part in one of these studies.  
 
Before you decide whether or not you wish to be involved it is important for you to understand 
why the research is being done and what it will involve for you.  If you have any questions please 
ask. You can take your time to decide if you want to take part and talk to others about it if you 
wish. 
 
What is the purpose of this study? 
 
Inflammatory bowel disease is a condition that affects many people, young and old. It contributes 
to considerable ill health to those affected and can sometimes be fatal. Many people require 
operations to get better. Whilst we know that some medicines are effective treatments for IBD ,  
they don’t work for everyone and can cause side effects.  This may be due to differences in the 
way that people’s bodies break down these drugs which is controlled genetically.  By analysing 
blood samples from people who do not have these diseases and who are not on these medicines, 
we can tell how the normal human body is metabolising them and look directly at differences in 
the genes responsible for this process. 
 
Why have I been chosen? 
 
You are being chosen for this study because you do not suffer from these diseases and you are not 
on the medicines whose effects we are trying to study. After the sample has been taken, your  
blood cells can be analysed for their response to these medicines and that response can be 
correlated to your genetic makeup 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part and whatever you decide your treatment 
will be unaffected.  You are free to withdraw from the study at any time.   
 
What will happen to me if I take part? 
 
You will need to sign a consent form and then be asked to provide approximately 18mls of blood 
(4 teaspoons) in addition to that taken for your normal clinic tests.   
 
No change will be made to your treatment and you will not need to make any extra trips to the 
clinic. 
 
What are the risks of taking part? 
 
There is no risk to your health or safety from taking part in this study.  The type of genetic 
information that we will get from testing your blood would not affect your insurance status or 
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have implications for your future health or that of your family.  The results of any genetic tests 
will also be anonymous in order to further protect you. 
What are the benefits of taking part? 
 
We cannot promise that the study will help you directly but the information we get might help 
improve the treatment of people with Inflammatory Bowel Disease in the future. 
Will my taking part in the study be kept confidential? 
 
Yes, except that it is considered good practice for us to alert your GP that you have volunteered to 
help us and to send them a similar sheet to this, explaining what we are doing.  Authorised 
researchers will need to look at your medical records to collect information about treatments that 
you have taken and how you have responded to them.  Nothing that could reveal your identity 
will ever be published or released from the study.  Our procedures for handling, processing, 
storage and destruction of patient information are compliant with the Data Protection Act 1998.   
What will happen to the results of the research study? 
 
We hope that the study will provide interesting results that improve treatment for people with 
Inflammatory Bowel Disase.  We plan to publish the study’s results in medical journals.  In any 
publication of the study’s results you will not be identifiable unless your consent has been 
specifically sought for this. 
Who is organising and funding the research?   
 
This research is being organised and funded by Guys and St Thomas’ Hospital Trust.  There is no 
other outside sponsorship or incentive payment to researchers for including you in the study.  
This study has been approved by the Bexley and Greenwich Local Research Ethics Committee 
What if there is a problem? 
 
Any complaint about the way in which you have been treated during the study will be addressed.  
Researchers are all members of Trust Staff and are covered for negligent harm via the usual 
arrangements. 
You will be given a copy of this sheet and your consent form.  Thank you for taking the time 









Dr Jeremy Sanderson 




NOTICE OF SUBSTANTIAL AMENDMENT 
 
 
For use in the case of all research other than clinical trials of investigational medicinal products 
(CTIMPs).  For substantial amendments to CTIMPs, please use the EU-approved notice of 
amendment form (Annex 2 to ENTR/CT1) at http://eudract.emea.eu.int/document.html#guidance. 
 
To be completed in typescript by the Chief Investigator in language comprehensible to a lay 
person and submitted to the Research Ethics Committee that gave a favourable opinion of the 
research (“the main REC”).  In the case of multi-site studies, there is no need to send copies to 
other RECs unless specifically required by the main REC. 
 
 









Dept of Gastroenterology, 
First floor, College House, South Wing, 
St Thomas’ Hospital,  
Lambeth Palace Road, 
LONDON, 
SE1 7EH 






Full title of study: 
 
Pharmacogenetics of immunomodulatory treatment in 






Name of main REC: 
 
 
Bexley & Greenwich Local Research Ethics Committee 
 
 










Protocol reference (if applicable), 
current version and date: 
 
 






Type of amendment (indicate all that apply in bold) 
 
(a) Amendment to information previously given on the NRES Application Form 
 
No            
 
If yes, please refer to relevant sections of the REC application in the “summary of 
changes” below. 
 
(b) Amendment to the protocol 
 
Yes     
 
If yes, please submit either the revised protocol with a new version number and 
date, highlighting changes in bold, or a document listing the changes and giving 
both the previous and revised text. 
 
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other 
supporting documentation for the study 
 
YES            
 
If yes, please submit all revised documents with new version numbers and dates, 




Is this a modified version of an amendment previously notified to the REC and given an 
unfavourable opinion? 
 





Summary of changes 
We will recruit patients with inflammatory bowel disease and controls (patients without IBD, cancer, 
Inflammatory joint diseases, skin diseases, SLE, who are not pregnant or have not had a transplanted 
organ. They will not be on any immuno modulatory medication). In addition to the blood sample for 
genotyping(which we already have permission to collect), we would also like to collect blood 
samples to study the effects of azathioprine , 6-mercaptopurine, methotrexate, Infliximab, 6 
thioguanine and ciclosporin on cytokine expression by white blood cells in vitro.  This will allow us 
to look in more detail at the effects of the immunomodulatory drugs on the immune system in health 
and contrast these with patients with IBD. It is important to study normal patients as many of the 
diseases and the medications themselves influence cytokine expression and can make results 
impossible to interpret. We will also study the same samples for the levels of by products of drug 
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metabolism, giving functional information (to complement the genetic data we are already 
collecting).   This will strengthen the conclusions that we are able to draw from our results.   
As anticipated when we submitted our original application, additional target genetic loci have 
become relevant since our initial protocol was drawn up and we would also like to test our blood 










Any other relevant information 
 
 
We do not anticipate any additional ethical issues to arise.  As with our original protocol, we are not 
altering the patient’s care or medication in any way, simply collecting data and samples during a 














• I confirm that the information in this form is accurate to the best of my knowledge and I take full 
responsibility for it. 
 
• I consider that it would be reasonable for the proposed amendment to be implemented. 
 
 
Signature of Chief Investigator:      …….……………………………… 
 
 
Print name:                               Dr Jeremy Sanderson 
 





Differences in Cytokine levels between low producer and high sHLA-G producer individuals after exposure in vitro to 6-mercaptopurine 
(data used for calculation of significance).  
All cytokine levels displayed are the difference between the LPS stimulated sample and the named study sample. All data displayed is for 48 hour 
incubation. 6-MP (6-mercaptopurine), TNF-alpha (Tumour necrosis factor-alpha), Interleukin 23 (IL-23), Interleukin 6 (IL-6), Interleukin 8 (IL-8), 





High Producer  
s-HLAG 
Samples TNF-α IL-23 IL-8 IL-6 IL-18 IL-1β 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
No Drug (LPS 
- no LPS) 6.6 9.07 21.3 23 911 450 1960 428 8 19 50 46 
Blank - 0.5 
μM 6-MP -0.6 0.5 -8 3.6 -135 222 0 0 0 2 0 0 
LPS- 0.5 μM 
6-MP + LPS 
4 7.8 -2 18.7 102 109 -23 39 9 17 6 6 
Change after 6-
MP + LPS 4 8 6 17 238 239 -23 40 9 20 6 6 
Blank - 1 μM 
6-MP 
0.3 0.5 0.6 1.15 41 79 0 0 1 2.6 0 0 
LPS - 1 μM 6-
MP + LPS 
-12 25.5 16.6 18.7 0.3 0.5 -50 87 -8 35 6.6 33.8 
Change after 6-
MP + LPS -13 26 16 18 -41 80 -50 87 -9 37 7 34 
 
Low producer  
s-HLAG 
Samples TNF-α IL-23 IL-8 IL-6 IL-18 IL-1β 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
No Drug (LPS 
- no LPS) 9 6.5 20 27.8 1123 44 1722 841 8 14 22.6 8 
Blank - 0.5 
μM 6-MP -4.6 8.9 4.3 4.5 -92 114 -2.3 4.04 -12.3 20.5 -1 1.7 
LPS- 0.5 μM 
6-MP + LPS 
13 18.08 18.3 89 397 688 825 1213 19.3 25.9 21.3 33.6 
Change after 6-
MP + LPS 18 26 14 90 489 711 828 1217 32 43 22 35 
Blank - 1 μM 
6-MP 
0.6 0.5 3 12.5 -57 93 -0.3 0.5 -0.3 2.8 0 0 
LPS - 1 μM 6-
MP + LPS 
5 8.8 -3.6 9.4 0 0 123 214 8.6 15.14 -2.6 9.2 
Change after 6-
MP + LPS 4 9 -6 22 58 93 124 214 9 12 -3 9 
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Cytokine levels between low producer and high sHLA-G producer individuals after exposure in vitro to methotrexate (data used for 
calculation of significance).  
Cytokine levels are expressed as the difference in either stimulated or un-stimulated samples. Comparison is made between samples with or 
without study medication. All data displayed is for 48 hour incubation. MTX, methotrexate, TNF-alpha (Tumour necrosis factor-alpha), 
Interleukin 23 (IL-23), Interleukin 6 (IL-6), Interleukin 8 (IL-8), Interleukin 18 (IL-18), Interleukin 1 -beta (IL-1B) 
 
High Producer  
s-HLAG 
Samples TNF-α IL-23 IL-8 IL-6 IL-18 IL-1β 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
No Drug (LPS - no 
LPS) 6.6 9.07 21.3 23 911 450 1960 428 8 19 50 46 
Blank -0.5 μM 
MTX 
0.5 0.7 -2 2.8 114 173 0 0 2 1.4 0 0 
LPS - 0.5 μM MTX 
+ LPS 
3.3 10.6 -13 15.7 26 45 255 442 8.3 16.65 20.6 41.6 
Change after MTX + 
LPS 3 11 -12 15 -50 95 255 442 7 18 21 42 
Blank- 1 μM MTX 1 0 -2.3 10.2 17 28 0 0 1 1 0 0 
LPS - 1 μM MTX + 
LPS 
4.6 9.8 7.3 13.5 0 0 657 578 9.3 19.7 35 41 
Change after MTX + 
LPS 4 10 10 15 -17 29 657 578 9 19 35 41 
 
Low producer  
s-HLAG 
Samples TNF-α IL-23 IL-8 IL-6 IL-18 IL-1β 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
No Drug (LPS - no 
LPS) 9 6.5 20 27.8 1123 44 1722 841 8 14 22.6 8 
Blank -0.5 μM 
MTX 
-4.3 9.2 7.3 20.5 -82 164 -2 4.3 9.3 18.7 -0.6 1.1 
LPS - 0.5 μM MTX 
+ LPS 
7.3 8.5 2 16 0 0 227 227 10 13 -0.6 9.5 
Change after MTX + 
LPS 12 12 -5 31 82 164 229 227 19 23 0 9 
Blank- 1 μM MTX -0.3 0.5 -3 15 -73 144 -0.6 1.15 -2.3 2.08 0 0 
LPS - 1 μM MTX + 
LPS 
-0.6 20 9 33 0 0 -4.3 7.5 -2 27 -7 27 
Change after MTX + 
LPS -1 21 12 35 73 145 -4 8 0 29 -7 27 
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